var title_f16_38_16992="Contents: Pediatric pulmonology";
var content_f16_38_16992=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric pulmonology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric pulmonology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asthma epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10713\">",
"           Genetics of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20682\">",
"           Risk factors for asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31014\">",
"           Delivery of inhaled medication in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36760\">",
"           The use of inhaler devices in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44184\">",
"           Trigger control to enhance asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30376\">",
"           Use of medication nebulizers in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma triggers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34472\">",
"           Nocturnal asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29144\">",
"           Bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29114\">",
"           Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25207\">",
"           Pectus carinatum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18071\">",
"           Pectus excavatum: Etiology and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21704\">",
"           Pectus excavatum: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Control of breathing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/13/43223\">",
"           Management of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/4/12360\">",
"           Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/22/41322\">",
"           Cystic fibrosis: Antibiotic therapy for lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/49/28442\">",
"           Cystic fibrosis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27351\">",
"           Cystic fibrosis: Clinical manifestations of pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/11/39095\">",
"           Cystic fibrosis: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/26/32167\">",
"           Cystic fibrosis: Investigational therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/15/19706\">",
"           Cystic fibrosis: Overview of gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39274\">",
"           Cystic fibrosis: Overview of the treatment of lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22503\">",
"           Cystic fibrosis: Prenatal genetic screening",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Interstitial lung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26985\">",
"           Approach to the infant and child with interstitial lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18775\">",
"           Classification of interstitial lung disease in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21914\">",
"           Clinical manifestations and diagnosis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/33/43545\">",
"           Genetic disorders of surfactant dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12089\">",
"           Idiopathic pulmonary hemosiderosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7335\">",
"           Lymphocytic interstitial pneumonitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/360\">",
"           Pulmonary alveolar proteinosis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36951\">",
"           Diaphragmatic paralysis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15753\">",
"           Management of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25398\">",
"           Outcome of infants with bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31511\">",
"           Overview of neonatal respiratory distress: Disorders of transition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18793\">",
"           Pathogenesis and clinical features of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19656\">",
"           Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/37/27225\">",
"           Persistent pulmonary hypertension of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27880\">",
"           Prevention of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4631\">",
"           Pulmonary air leak in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/40/17034\">",
"           Pulmonary outcomes of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32804\">",
"           Transient tachypnea of the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7193\">",
"           Assessment of the pediatric patient for potential organ donation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34903\">",
"           Atelectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16057\">",
"           Causes of bronchiectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44662\">",
"           Clinical manifestations and evaluation of bronchiectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41895\">",
"           Control of secondhand smoke exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/0/37896\">",
"           Hemoptysis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/0/6150\">",
"           Management of bronchiectasis in children without cystic fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41497\">",
"           Management of smoking cessation in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/18/24874\">",
"           Management of the potential pediatric organ donor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/31/43513\">",
"           Overview of aerobic exercise testing in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42534\">",
"           Pulmonary manifestations of systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/4/5194\">",
"           Secondhand smoke exposure: Effects in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/34999\">",
"           Spontaneous pneumomediastinum in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40793\">",
"           Spontaneous pneumothorax in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16810\">",
"           The acute chest syndrome in children and adolescents with sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary function tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16074\">",
"           Bronchiolitis in infants and children: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/19/27962\">",
"           Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38970\">",
"           Clinical features and diagnosis of community-acquired pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2938\">",
"           Epidemiology, pathogenesis, and etiology of pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/34/9770\">",
"           Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/48/25354\">",
"           Inpatient treatment of pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27882\">",
"           Management and prognosis of parapneumonic effusion and empyema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21512\">",
"           Neonatal pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/46/27369\">",
"           Outpatient treatment of community-acquired pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/35001\">",
"           Pneumococcal pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33062\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Resuscitation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/50/5929\">",
"           Assessment of sleep disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36806\">",
"           Behavioral sleep problems in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/38/44649\">",
"           Evaluation of suspected obstructive sleep apnea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40217\">",
"           Management of obstructive sleep apnea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/36/9801\">",
"           Mechanisms and predisposing factors for sleep related breathing disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15320\">",
"           Medical disorders resulting in problem sleeplessness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32282\">",
"           Restless legs syndrome and periodic limb movement disorder in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/53/11092\">",
"           Sleep physiology in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28473\">",
"           Sleepwalking and other parasomnias in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sudden infant death syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37194\">",
"           Sudden infant death syndrome: Risk factors and risk reduction strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36872\">",
"           Sudden unexpected infant death including SIDS: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21414\">",
"           Use of home cardiorespiratory monitors in infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27640\">",
"           Initial evaluation and stabilization of children with thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29285\">",
"           Pulmonary contusion in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma and injury to the respiratory system",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/46/38632\">",
"           Aspiration due to swallowing dysfunction in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37081\">",
"           Prevention of smoking initiation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wheezing and cough",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2585\">",
"           Airway foreign bodies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/9/17561\">",
"           Approach to chronic cough in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/61/21464\">",
"           Assessment of stridor in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28088\">",
"           Causes of chronic cough in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10201\">",
"           Emergent evaluation of acute upper airway obstruction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-ECC2651446-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_38_16992=[""].join("\n");
var outline_f16_38_16992=null;
var title_f16_38_16993="Contents: Red cell disorders";
var content_f16_38_16993=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Red cell disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Red cell disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Aplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/1/17433\">",
"           Acquired pure red cell aplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/586\">",
"           Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29930\">",
"           Aplastic anemia: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/50/18217\">",
"           Hematopoietic cell transplantation in aplastic anemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Erythrocytosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24777\">",
"           Diagnostic approach to the patient with polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10857\">",
"           Erythrocytosis following renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Erythropoiesis and red cell function",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37224\">",
"           Control of red blood cell hydration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17046\">",
"           Red blood cell mechanics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13352\">",
"           Red blood cell membrane dynamics and organization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20650\">",
"           Regulation of erythropoiesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General aspects of anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22538\">",
"           Anemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9434\">",
"           Anemia of chronic disease (anemia of chronic inflammation)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38213\">",
"           Anemias due to decreased red cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29418\">",
"           Approach to the adult patient with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34346\">",
"           Approach to the adult patient with splenomegaly and other splenic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18489\">",
"           Approach to the diagnosis of hemolytic anemia in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23914\">",
"           Hematologic consequences of malignancy: Anemia and bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/42/1705\">",
"           Impact of anemia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21767\">",
"           Macrocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36326\">",
"           Red blood cell survival: Normal values and measurement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38138\">",
"           Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9305\">",
"           Spiculated cells (echinocytes and acanthocytes) and target cells",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemoglobins",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8729\">",
"           Clinical features, diagnosis, and treatment of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42055\">",
"           Genetic disorders of hemoglobin oxygen affinity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/46/4841\">",
"           Genetics and pathogenesis of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16984\">",
"           Introduction to hemoglobin mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/968\">",
"           Laboratory diagnosis of the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24585\">",
"           Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/29/23001\">",
"           Structure and function of normal human hemoglobins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/616\">",
"           Unstable hemoglobin variants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemolytic anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/18/19754\">",
"           Anemia in malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18489\">",
"           Approach to the diagnosis of hemolytic anemia in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/29/8665\">",
"           Autoimmune complications following purine analog therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19256\">",
"           Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/56/33672\">",
"           Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4505\">",
"           Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39719\">",
"           Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/46/43753\">",
"           Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9194\">",
"           Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6697\">",
"           Extrinsic nonimmune hemolytic anemia due to systemic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/62/13289\">",
"           Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/16/15623\">",
"           Hereditary elliptocytosis: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/56/43911\">",
"           Hereditary elliptocytosis: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20506\">",
"           Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8841\">",
"           Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5464\">",
"           Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32982\">",
"           Overview of Rhesus (Rh) alloimmunization in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16422\">",
"           Paroxysmal cold hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30535\">",
"           Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/2/20521\">",
"           Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40648\">",
"           Prevention of Rh(D) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/58/27559\">",
"           Pyruvate kinase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36326\">",
"           Red blood cell survival: Normal values and measurement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5399\">",
"           Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3513\">",
"           Significance of minor red blood cell antibodies during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42200\">",
"           Stomatocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/62/14313\">",
"           Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14583\">",
"           Xerocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Iron deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26234\">",
"           Causes and diagnosis of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21082\">",
"           Regulation of iron balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25578\">",
"           Treatment of anemia due to iron deficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Iron overload syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/49/25370\">",
"           Chelation therapy for iron overload states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/60/28617\">",
"           Clinical manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2266\">",
"           Genetics of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33748\">",
"           Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38856\">",
"           Iron overload syndromes other than hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/19/35129\">",
"           Pathophysiology and diagnosis of iron overload syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21082\">",
"           Regulation of iron balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2265\">",
"           Rheumatic manifestations of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12535\">",
"           Screening for hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18952\">",
"           Treatment of hereditary hemochromatosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laboratory measurement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/54/35690\">",
"           Automated hematology instrumentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/45/35543\">",
"           Mean corpuscular volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36326\">",
"           Red blood cell survival: Normal values and measurement",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Megaloblastic anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5130\">",
"           Diagnosis and treatment of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11786\">",
"           Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4710\">",
"           Alcohol abuse and hematologic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/3/15412\">",
"           Erythropoietin: Subcutaneous administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3098\">",
"           Hematologic manifestations of HIV infection: Anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12680\">",
"           Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paroxysmal nocturnal hemoglobinuria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/50/14121\">",
"           Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17082\">",
"           Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42392\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/17/13593\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/33/5656\">",
"           ALA dehydratase porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/12/10439\">",
"           Clinical manifestations and diagnosis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40198\">",
"           Etiology and pathogenesis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41687\">",
"           Hereditary coproporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3398\">",
"           Management of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28458\">",
"           Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/51/825\">",
"           Variegate porphyria",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5464\">",
"           Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32982\">",
"           Overview of Rhesus (Rh) alloimmunization in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40648\">",
"           Prevention of Rh(D) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3513\">",
"           Significance of minor red blood cell antibodies during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sickle cell anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30104\">",
"           Sickle hemoglobin polymer: Structure and functional properties",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sickle cell disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9066\">",
"           Acute chest syndrome in adults with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/45/17114\">",
"           Acute pain management in adults with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18506\">",
"           Bone and joint complications in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39434\">",
"           Clinical variability in sickle cell anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23017\">",
"           Diagnosis and management of priapism in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/49/2842\">",
"           Hepatic manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/1/39961\">",
"           Management of fever in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42170\">",
"           Overview of the clinical manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/62/20458\">",
"           Pregnancy in women with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27082\">",
"           Pulmonary complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13960\">",
"           Sickle cell trait",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30104\">",
"           Sickle hemoglobin polymer: Structure and functional properties",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/33/34330\">",
"           Specific therapies for sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16810\">",
"           The acute chest syndrome in children and adolescents with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/5/5209\">",
"           Variant sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14330\">",
"           Vasoocclusion in sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sideroblastic anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36441\">",
"           Causes of congenital and acquired sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6138\">",
"           Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41882\">",
"           Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25450\">",
"           Management of the complications of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35750\">",
"           Pathophysiology of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34425\">",
"           Prognosis of the myelodysplastic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/53/9049\">",
"           Treatment of high or very high risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31210\">",
"           Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thalassemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38106\">",
"           Clinical manifestations and diagnosis of the thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41783\">",
"           Community public health issues and the thalassemic syndromes: Lessons from other countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5529\">",
"           Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43591\">",
"           Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/58/9129\">",
"           Molecular pathology of the thalassemic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25880\">",
"           Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7802\">",
"           Treatment of beta thalassemia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-88F0BD4B50-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_38_16993=[""].join("\n");
var outline_f16_38_16993=null;
var title_f16_38_16994="Posterior shoulder dislocation radiograph";
var content_f16_38_16994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior shoulder dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 425px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGpAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwC6dmY/Mep71Vy394/nVyZRlz7mqwXn2oAT5sdTj6007j/EfzqUimYxQAzc2SNxB+tL8394/nSOuRkdaRJOzUAPy237xoBb+8fzp42sBinBOKAIizf3j+dN3NnqfzqZlFM280AN3Mf4j+dGW9T+dO20mOaAG5fP3j+dKWb+8fzoxS0AMy2PvH86Xc3PJ/OgDrS4oAZlv7x/Oky2fvH86fjimHIoAQlv7x/OkJbpuP506koAaS394/nSbm/vH86dikxj6UANJb+8fzppLHufzp5GKQ9aAIyXH8R/Ok3N/eP51JgZ96Tb3oAjLMepP5005/vH86mwPSm7c9qAICG/vH86YQ3cn86slcDNNK0AVSH/vN+dNJcd2/OrRFNKigCtvb+8fzo3t/eP51MyCmGPmgBm9v7x/Oje394/nQVIppoAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86N7f3j+dNooAdvb+8fzo3t/eP502igB29v7x/Oje394/nTaKAHb2/vH86VHbevzHr60ynJ99frQB2EiAuwA7mqzLjOM1dmGHbHXJqGRQehoAq0hGeKlI7dKacDtQBEy4qJlHWrLdO1Qvz2oAjUY6Gp0ZwPao1X5hipskLigBDIO4oBUnrUeeOlKBk80APx700rS7OOCaTDetAAFx0pCOKXB/8A1UHNACAd6bT+cUmaAG4pu2nHrRQA3GDTSDUlIRQBHikxUlJjIoAYRmm7akxRigBmKQjFPI5pCKAGEUmKewpuaAEI9aaQKcT60wsMUANI5J4pMcU4sMUzcO1ADSvFMwc1Lg98UbT6igCHHtRtBqVkx6UwqRQBEYh2ppjPap8+tLwelAFQqR2pKtkeopjID0oAr0VKYuOKYVIoAbRRRQAUUUUAFFFFABRRRQAUUUUAFOT76/Wm05Pvr9aAO4uBtkf0JqoTtJ9KuXg+/jqGqp99T6igCIA5oYd8Uqqc4FBHegCGQc1Ygty0IlIyD7VHGm+QD1rd014vLNrL8qEEKwHf3oAyGhQg7RhqrPwcNnit2fTngIYjKZ6is+6gDHCHJ7UAZpGG9qcKYSckMORTlNADhS8GmgjtSj2oAUgUgHFFAPBoABSDqaUUUANI603FSEcUygBox3pCKdzSUAJikpaMUAIcj0pM9aG9qiY0AOJGe1JuHqKbtLH5QTT1tGIy7bR7UARsw9aYXAzUwt4wcFi1OCIjYCgn3oAqEs/3VY/QVJFZ3U7hY4XLHplTWzZ2VzMVKjywehAFdHFp7WUAmnnkz0oA5uHwtd+WJLuWKFT2Lc09dGtxna0zKD97bx+dbc0rS7ikbPEv8R6mqMl3PJHsCeUCfuA8UAQxadp8alpklJ7YYU0W1qWAWEkehwKs3CpHEVCs0ueCBkGnmF/KUyoy5HVetAFVbOFv+Xc8ddozimmwhclfJkB91xWu6RWtuFaWVN4ySBgmoog9wm0M7R5yJN3I/CgDKbRrSUHDOCDjAxn8qq3XhueJv3cgZT0J/wD1V0zQDYPLyWH8eADmrbWkoVN6jBGcu/J+goA8+m0y9gGTA7L6qpNVGGDhlZT7jFd/bf2hJM8diryBTyM4FLeW/wAxS+0qIv6gc/pQB56aTI712r6JpU69ZLab+71FZt34WuljaS1Hmxj0IzQBzZQGo2jx0q1NA8EmyVCjehpm00AVSCKSrLLnrUTx46UAR0UUUAFFFFABRRRQAU5Pvr9abTk++v1oA7m6JaRgemTVHJViD+FaV0jxyMJFIGeD61RnQHkdRQAmRwQKYxySaaPl6HOasQx7cM/WgBtvEQS7cDtVgHDCo2bGcdulLGrMM+tAGja6g8RIYB0PBB9Kdc26SxGe2+ZD1HcGqbRMBgrz1/CrFqDEQytgjqKAMi9gy2GG1wOKokFThhiusnijulJkARjwDWNfae6bjt+UfrQBmgjFODVHIGjbDDB7e9IGzQBKaUVGG9KXdQBIKO9M3fjR8zHgUAPPem5p3lOetSR2mcFmoArEikJ44rQW2jU9KkEaL90fWgDKCu3RTTxbSnkgAVpA9s4pA4BOW4+lAFBbPIJZuKeIETGM1cZhjDfdqBpRu+QY96AIyhAHQCo3AU4OaV3GSTmrNhYPetubhPT1oAq29tJdTBIVyT79K6LSNDIky3LLyc1t6XoDpbiUR7IVPLHvVy6KwxskTDDjbx2oArNHbadGXeQyXX8KY4A+tVH868imklUFjyFzgCob0LvRVBdgOWPGDTpLlkt0hQne5+Y0ARQwylFVT845Yk8CkEGICY4lfB5dmwfyqygknQxQsQOhOOlOtrRN20Z3ZxyeKAKFyw8hFGPOJ+4tRajLLKY4WCxkAfdbPFLeWsgv38hCCf0qrDFMzyPEpPPJoAfq9yJWSEKh8tBk7uc1HaTtEpQIoUrg/NVW4tJ55S4Q5B5NKmnySOxlYr2GaAHC7VGYRW247sffPJ9a1pr4gbZWIlYYVSMhfxp2meGNUnwbK2acdimP8a6eL4O+PryE3Fv4fklc9A9xFFj/AL6YZoA46fUpbOJEiuGHGGwO9Pt/Ek0cQwisgPzEkkkVq3/wj+I0EoW48K3shHXyZIpAfxViKy5vh740inWGTwxqUbNwqFBk/rQAh1m2u9yyx7XPKsoJwaig1OezkGznByc8cVbX4deNRIAPDWpYA5+Qf41H/wAIr4hVN1zpdxCm7ZlwBhvTrQBuandaTr2hQRahCsN0rErNGTnkdx9TXE6p4aurNDNEDLbHpIMY/GrM+mXkUhSVTG6nvWlo+rXmnh7V5RJbOfniIGDQBxWzscgj1pjRHtXW+JrSxmH2iwXymHBXk5rm9uRnFAGa8eahIxWnJFVSaPGfWgCtRQRiigAooooAKcn31+tNpyffX60AenXCuZHDL8mTWRdxhCdp+WvX3uoI3byYYjzjayjIpsl3ZBitzZW7HHI2gUAeJxsvmDkYFWHIJyTwa9IvrLQWjaZdMyp67ZOlZEmmeG51/dC4ic+jggUAcdHkMOfl71ehYBgcDbiuhl8JWrxqbLUVGf8Anqf8Ky7/AMP6lYHPlfaYv78ALCgBqOGO5h06U+GJfMDA5B6is1Lgq2x1KEHowwa0LcqzbkODQBqRQxlcPlT2pzo0a7kRXQevNNsUJIPVs966Cy02a62m1hds9AFJoA5iXQLPUoG+yzKkueY3/pXKavoN/pb/AL6FtnY165d+A/E88Qls9Bvnz6QkVjXuk67pX7vVIpYB/wA8p42DfqKAPJlfJxnmpkQsa72507SLsfvoJLef++pABP0rPuvCtxCvmWcqXcf92Plh+FAHOJF7ZqcIFAA696tvZXEJ2TQyQnP8akU77JJjqBQBSGNvJwKUHA4Bx61ca3WPlnUtTAyKMYJoAhBBNKI9vJ7etOM+0naAD6mqzS7uuKAJXKjnOajaTbkggntUJYc55qNmx0oAlds9857VEzD8fSiJZJnCxqWY9gK6zw54aeV1lmUk+mOlAGfoOhvdOr3Iwg5ArvdN0q2sLVri8VY0A/dg/wAVWlig010yu5+w9Kzb67e4usfebPfoKAHX+ob4xGDtiI4xxisOSR5YiijYinOe9aEkEs52KpWEd8dTWnpnh6e4Q+aPLUn5QQcmgDmktpZ5Iwg56D3qUabunZic7PuqDXpFn4UWVhGFYygDI6cVrPodvYxEy7EUrjHfFAHltlpby27GVgFPQKfmrodM0ay0t459Ql2xt/B1NbN3Jp0cSx28qx7OHDEVyV9e2Dtt84YXjLPmgBblNJ33Eswl3OdqlfT8qr250skx2wnH4f8A1qjk1vTYQDsZ9vQkjFYOp+MYFLrbQAsehGKAOoj0mwiQSS3O9WOSo6gflWbc+JNF0ousFuJXBIBIz/MVwF9q91eSbpCQv91eKrrcsBxGp9yM0AdlJ8TNZi3x6WsUETHsnPtzUf8AwtvxzbTo8HiC7j2MG2K52kg5wRnBHsetcj57kEFB+AqAJk8igD1VP2h/iOf+YnZf+AUf+FWo/wBoXx+25Zb+05GOLNBXkOwjpT1PZxx6igD0/VfjL4o1NV+1XrNkFSEGz+Rrm7jxtrE5bfM21uuST/WuZ2jqpyPSpI0JHJ/OgC/Lqs9zIS5y54zUTO2Cdo68mosDHTmkJ2qQxzz60ATeezxFWH0FUAPmYVM0yqCFO5j0PpUYAzQBGwx9KimQFMgcirLDihBlWB60AZE8YIyKrVpzR7DkDg1Tmj7igCCiiigApyffX602nJ99frQB9DmO0kdne5ZW39EIpJbbMm9yPLOQGbrW62k6XFI4e7iySeVZaqS29mrFFvoyo55YUAZdva2sQk3SSzRei4O2sbV9Hht2E1lOHgb16j24rqbOyt5Ji0VzFsP3vnFWpNFQuY0aAqeq7hg0AeYyTT27YcNt7elWbPUriJt0csm3uCTWz4h8P3mlSmaJGktieD97FZeEktyLqHyjnIeMcn2NAGzbRaTrpSPUxHET0nUBSP8AOag1fwZJpH+kaZJJqlm3IaL52X2OKxzDKkRNuRInUYPIq/o3iW/0xiq5Kn+Bs4/KgA0rUbGy3PPES6HhJuOa6eLxe9ukaae9rAzdPI5YVlTWul+LTk4sr4DgrhVasXVtIu/DkiidEJccTL8wH0P40Aen6X8T9daYIdXO2PrkZA+vNdZb/EfQ9dRrXxZYWc6n5fOVBvXI6jNfO3nLAu+3cs8nr0q7FdNBCPmUsTjJ/pQB7bqvw88I6/YvN4Y1V5bnBYWrSoXJ7BQBmvLtVsL3wrcvGbK4SRGyBKh/Pj6VS0zX7i2uVlt3aJ05yhKnNdfB8RlmgWDXbS3vom+U+Ym5gPXJPXrQBz//AAmMGpwraazp1ooHBnjTEg/OsnU9AjuVe50a5FzH12KwJX2IFdc+jeFPEUkh0i6axvX+fy5yqR/QfpXNap4b1XRZGlhyYgeJLZtyt78UAcNeJNbHE0bIf9oEVXMhYZXAHtXaNrEcyiHXrBHTtNGnz/jmq9z4UtruFptEulkXGSjOAR+FAHFs7c5HWmVoXmmXdo+2eFwR3wap+U2cEY+tAEWOafBA9xKI4lLMT2GcVbsNPmvpvKgUk9z2Fej+GfC6W6plN0hxliPpQBm+FvDJ2qzIdx6kjmusvZ4NIgWO38tpcfNnt+VSapeQ6fC0MBHmHjK9K52K2mvbjMhJXqTQBHdTtK/mO5JNWtL0+4naRzG5yPlwvatnSNBWS4V/mfHO1hxXe2NjDYWoeRBuPVSBx9KAMbRfCyrbpLelgucqhABb6+1b8a2qyKpjVQnAxjAqlcXjOxZ5OfQH5QK5TxN4i+yxNDayqzHt3zQB1Gt+JrPRp02PANwwW3c15V4m8aXt9eTRW33S3D85xj61lX7XN1MJb1mIzlRzT1t1H7x1A4oAzxLcujmaVyWOeT1qnLtjUszfUmrt5IFBx+Fcxf3jTsUQ/J7UARXt207FI+E9R3qosPPSpVXAqVV4oAhEdOEYwamxnpSgYB4oAhCUeWKkpOaAG+WMZppSpUSSThEY/hUiWVwwztx9aAKuMdDily3941c/s6fGcpz71G9nMnYH6GgCsdx/iNG3PBJp7qyHDKRTc80AMZMc1KoyKRuTSqcH2oAVulMHyyDPepDzTG60AMlTeCMVRddpIxxWi+Qc1BcICNw79aAMmZNrcdKjq7Iucqapuu1iDQAlOT76/Wm05Pvr9aAPUzMzO2HI5POagluZQ3MjN/WpdP01gd15OBGT/DzXVWmnaWItxtw46hz3oA5OG+aNsgMATzitiO6mmKvaSzK46gVqTTaeuBHZRAL/ABY5NatlexQzRyRWsSg8HA60AZOn+I9Sjha3uQ08H91x0z+FZt5f2ok+dDEG7YyM1313PZnDJZxc9QB1qGS30C9g8u506MMw6qDwaAOHjiilUSWki5AycVVZCHdp08wE9T1FdFPoOn2Fzi2lkhQjKnHB9q0LTRtPvkCtd+XL0yy8GgDjordvOWSzdgf7p4Nbmn6+2HsdXgF9avwd/Ve/FbreBb5F860mjnUdGHH9a5/UNIurUOt1Bhgf9YpBoAj1jwfGIPtnh6T7XEvLQkbSmfTJ+tca8juFDghlPQ12Njql7o06y20mFP3hnhvr+daWq6do/iWETWO2x1MclFX5XPbmgDgC8xKtu29sVJPGZGwh3cdfSnahZXGm3BhvI9rA8HOQagRx0FAE0aNER5THzOhatjS/EOraRzBcOYzxsJBB/SsUSgNnHSpRMGGMnFAHWR67omoqRqumpbufvPHk5py+G7G4l87QdTjDnlYypU5+pNcg5QgAmnxSTJJ+6coR0KmgDq9Qh1a0ZYtZshNwNsm4HI7dKbY+FrXxDdJFDGYXJ+YkdKr6NrutXMi2zzNMqnkuQcCvdPAd7pttaolxptu8hPLEc9etAHH6V8Mhp8Sm1Ac8A5Hf86j1xJ9HiaLytp5BKnNe2truiLEIYY1Qt12LyKwb3w/peru7JdMrejpmgD5+Fu15IXJwwOAprpfDuitPKAckL95vSvTH+GfmKGszBMCfv427f1qO90G60YmCKFYYlGWlBzvNAGFBax2kjzRINqr95ug+lZ95ftM7bJcleeegqtql805eGK4bYTggdBXPapqtvEyWlqN8q/6wjIz9aAG6rqF00RFu5VcncxPWubFi08vmyEu+eprda1a7uwjFQdoLKOgFXP7JeJS8JVlHO0UAULbT/PtlFxGDsbA9xVfUNH+UsoIHtXa6NYlLbfNGCM9KfqsVsLGYlEXaMhh1AoA8O8R28kEhijJ3sfyrm2gki+8h/nXqUemxXd4ZZSGjkJI3D7orVi0zSo4xILCNip64+99aAPGooJZThI2Y/TFSGyugMtCQK9c1M2lxCPJ0y2swvV4h96sKUoYS4QOg4yRigDz8W8ucbefrUbZUkHg9DXcS6db3LZtgPMI5QDvVO+8P/YL6IXIBkdA+z+77GgDm7exll+ZhtT19a1YNMiVc+WGPYtWsbVUXke+BT1ABAAwCOR60AZ/kAKMDAHXimGI5ynINaLRuVBB+WnvbxhQyAK3PSgDHMZ3DI4HX2pLxEDjyjkYzWnPauQPlK5GSeuaZBpctwVEKEnGfTNAHP3MRI+6SDzWdNEVJK9O49K7tdONuxE7p06dce1ObSdOv4cxhYbjpkDhj6UAee5p/HetXW9BuNPdsxFGHVD6eoNYytmgCVTxSN600GnH9KAB8kCmEZGDUjjoPaozxQBUnj9eoqnKuQfUVqSLuG786ozrg5FAFGnJ99frRIMHjpQn31+tAHaTjZIzB+9S2eqOmVdmI44qS5Wxgc7pA+DzzWbcahbhv3KAL9aAOys3NxCrqTmumsobjyV/d5PYZry3TvEklpKqogZc11TeJ7mSEGKPZ9DQB3cH2tbfD2xYHpg81UnnuomwLdlA/2c81wi+MNYs2HkzBMHPIB/pWpb/FDxAgAkkjdeuNi/4UAbc2pNMjRTo209MjofXpWXHqC72ikPIOAc9anj+Jdxc4F3aRSD+6cDP5CmXnibw5qkA+06W9ncofvpKSCO/FAGt4f8T32kykREvbnqmRXUC8g1eEz2jFX6vExya4fTI9GvOLLVIlJ6I+f61pnQNWsXW6sE+0IOS8WDQBpzW9tO7R3UO5O/Y1i614antIze6ZIZbdeWT+JcVq298bgbLlGil77hVmBp7KUPG3TnjoRQByiX0d9aC01FGkjPyg9ChrndZ0eTSpQwbzbd+UcDoD2NenXlnY6v8AMQIb0nC47msifT7jTla3vYTNZyfeI7Z70Aec4yAaeBitjWdFbTz9pgJlsJG+RwPu57GsxkyM9qAIw233q/pUEuoXCxxnC55OM4p2l6NcahKCFZYvXHWvStA0VLOEYXaB60AX/DWhQQQKqhQRyWq/qeopDEbS0+Vx1k9azr3UPLXyYeF/nWfEC8pJyMdRQBMkcobfHIQzHkn1rqPD4vGkCiXzF6uAOlZ+iaU12+5+I/756Cun+3Qaba+TbEKB156mgDqrDXEsxGgZjGByAcZqO58Rm+eXBVYM42MRXlWueLTCzENG7jonf+VcvLrsepSk3Un2bPVR0NAHY+OWsNRvHg0oCzdFz5mdyk4FcTZ+G7q2jyziV5jw6jFb+mm0igjmDfaACTtHFbOk+bqWow3O1kiTJ47DpQBj2OkmeHZFE0UZOHZs5Y1fl0UhrdEcqNw4wa9x8K/Zb/SPLkRJPLbIXvVPU5bS31Jlns1T5QFO7ge9AHBQ6ZK8KRyAhVxlvWuX8dWzWWnHb93IXPrXsslxp16gjj6qP4W4rlvEmkaXeQMl0zEZwBk56UAeG2k7RxZG1hjp3qw90wViFAU9UHetjVdAt9PkaW1LPArYO48iqA03+0JSljG/2kchhyMfSgCnDai9VxbktJt4VQctWdqMOIxCzYVRlkxzmvVNA0lvD1vPdTXMM18RmFFXBQ8/41xs+mXOqapGYY3aSSTDrxk96AOj+E/hqK+ka9dQAit5YYemOa47x5Ei+JLhiMMZWGD25r2hdmkaGpj+UmELn+7kdK8a8XM322V3UNlid3qKAOeaEFcc9c496SS2dgr5BK8nAoDggFm2kHKn1FTo8iv5g+6W5IoAou3mK5HCE857VJDEpDRhge/TrU00Ye5ds7EY5bNRcwEM5GOgQdh60ANuJXtIY9i5ZiQcelRXWoytaiOMlAeCBU11GtxmRcnK/KPcVSu0VYYkeTvlsD9KAM26m2usaEkkDn3p5l+ytGyqTIy+vSrPlrHbSzeYPmygGO1ZJCpIm5woXmgDtNA8SxNaNaavCLi2ZSME4IPbBrL1Xwppmr+ZLoc5t7kfMsMuW8z2BzweDXKTMu8urZHZalt7hlkGCVbqpoAxZEkhleKZSkinBBpwOa6XWZG1y3WSXDXsQxuHVh7/AJVy8Z+bBoAkboPamuO/rT26Uh5HFAEY6VWnTkirPtTJVyue4oAynXtUSffX61cmXB46VVxiRfqKANebcXbJPU0wgL161ZkUGRs9cmq8g560ANRcyriuh0ybcm09RWDbrmTNXraUxy5zjNAGndx71DDg+lVMFG5H1q8HBXJwcVXn5YFuKAIt2zqOKk3qDuwMYqF3+YqcdOKjZv3fJNADJJ1ik3IGA9jW/wCHvE97ZSqLe9ljHTbuOK5x1DLUQXuOMUAe26Z4x81V+2WMc6jqUwD/ACruLGPRddtFWxvFinY4EbZzn0r5s0/VJ7VwdxxXeaFrsc7LvOxsjDJxg0AeiapoN9pj7ngZkByJBjH1otLxXUxzAE4wQ3cVJoPia7tF8qZ0ubZsZDjdgfjXRJolp4oG7Th9nn/i3HAP0x9aAORn0NZhI1n++ilGHgx93Pce9c5/whN1YaiGvI3Fs+THkfoea9q0TwtLo06NcKWcfxnkH9K6qaysNRtjBdopY9CuAQaAPGbTTI7aME4QD2pl7e7/AN3CMKO3rWl4ksrvS7w2t4PlH3JAOGrJS3PUD5z2oAqRRGRjkZb+Vb2l6UT88vCDk570tnZBMSSjavf1pms63DaQuFYIqjpxQBf1PVIrW3CIQqrxxxXnXiDxQzu0Vs25skE56dax9d1241CVljYrHnr61iruB5P1oAuxyvK5aRyWPOTV1ArY4y1ZsA5zjpWhbnAz+lAF6CWW3TKSkDuPSt7QfEjafbSL5mWbuT0rnk5VyTwRwKcLc+RlV/DvQB7L4X8RCCK3mSTdJGdzAEjd7GvQmu9H8Xae0Mkqw3GOucMp+vGa+dNF+1eVtjz1wM12FrqawmOxiDGbbl5M9z0xQB2OqeFNW063EenXHnRlwQw6kfnXO3VrrEuq/Z5mCRKMYbuada+NLzT5nSVxPYxnyDxlsn05qW6v4LoFrRjIGPytnkH0NAEF3ocI2nUp9g746GpYNOgsiq6YySFRncOGrGvLqVrhlAbnja54FVI7hWUmRsTL02nGaADWnlEyR3UVxFMOrE5B/KtfwBFu1ZbkxK/lscMR14rGk1OTcwDs/ljLBuRXQeB7+MoW27GMh4bt9KANfx6AumpEqsmW8wgHpwf0ryXXovNj3IS5VckV674veO8kCFgu6EAc9DzXkuswKkkkWXYglfk6UAcdjJOQwcNxmpy0q53YJY9qc8REkiLzz0NTQWlwLgbAoU45fpQAwbjbzNGm4ggZ+tEMRaDLxhiBhjWvDpAIP2i7jEUjfMqHB+tSW0Fvp1wVtgk8annzDuBHegC14Gs/tcqoYVeFiVy+MCsPULWGxvLlYXS5dXcbWHTk8c1Z1HUriaRntF+zFCMYG0L74qhqMhuHWRjGWKZY46n1oAyMq7M0oVe+COAfSsy6HmExLsViSS2K11haRshlC9T6VnTqgkljKnBGd3qfagDBJB3YBwvGR60sYxIhyd1S3IRZGwpUZHBpkbhW8zbnaflA6UAWrd8T5UEetZmpwiO4WRBhXq5GxXJTp3NT6/GptLdlBBHWgDF7Ui9SKBnbSd/SgBpHNJT3HNMbmgCpOnUVTYfOv1rTlGRkdqouuJVHuKANaYqCx75qu+D0Bro5rW0hkbbH5mCfvYNUpZ40yRDGPQAUAZ9lBNIxMcTMPTFXjp1x5ih1EYP96p9OvZEOduAfQVJPcmebLMSR0GaAL8OkuAAJ4h9TUV1pEwfHnREfjT4ZjhcZ46nNLcS5jzvYEH1oApXWj3cJVtodT0IqpNaXQBJgfHstaLXssm1fMfavTmpYtQmjiIDbl9DQBzx3Jw4P5VBvGSK6hL2KRcTW0J5/u1A402Wdg0Gz/dAoAwgQQKuWFxLBKphBbnoK6LTfCUGoPlJ2iXrhq6S28Cy2yb4AJh645/lQBv8Aw9gXWdgmcB0wTHnBIr2nR9PW1RZICI2TtnrXgWn3E3h69jnjjZZEYErggHHY161oPiZdTtkmjdcnhkDfdNAHpVvr1rcxi2vI9rgY3kDBqlfWFxHJ51i4aM8kck4rnFdLghZG2ehFb2iX0tvIsNy5MA4DMenpQBBd2Vv4jtBBfIEljzsc8Y+v5Vxt1obaRN/pIyB0c9D/AJzXql3p0T/v4z5bnkKOA1cV4q1W3MX2e/Cq0gwM9VPHrQB554l1uK0jJZwvooIrzXU9Tl1OYsciPPT1rR8UWF9b6m4vdzRnGwnOMVi+X5Unyg4oAaYfakMfPQ1bX5h0ApSoHNAEKJs74qaJsDPvTCMklulA+9gdKANCJwMZ6elW4WZyxz26VQhGRzzWnaDC5I4oA1NPuWtHCzLnIyAKtQ3+28lnKYZxtGR0qhHDIzkqSW7VJPb3RKKVPze1AF2VNqRRqQd7eY564alsZmsbxhvIUtk56ZqG3t5fN5ZiehX096fPmaWQshEYHAx3oA22uVupnkdERj90diazpRbpbFYlYuT94npzVFLp3hIUZdD8gHpUPm7SCu4g9eeKAJ2CvJLIsnyjqAefrXQeEZogfkwWEh79RXJDPU5Abr71teE5Vin2RANljg47+lAHR6/fbtTfC7VUAL71yfiWAlo54jt3j5go6GtXW2I1Qse+CKjnVp9NmbbudRwcdaAOAuEKzZx82c1ZizKmX3fUGo5kL3LkuRip4ioTy4xjHr2NAFSeaXlF8wgjNOXCRwAMdu4sTnmrdzEVGMfMPv8A/wBamGCPh0zg/cXsT3FACam8C28csZMjS5BAPpWHfyAMCq/w7Tjt9a2Jki89UaRDt52/3ay7mIIZY+Du5BoAzllKquG3AHAAqnOPMnI8wDHr0FTTj92RgqR6dapzluCRjAx9aAIprZimH+dhzkd6oFCrhCDgHJArRdxwTkM3YVGzrIdxQDPXFAEMePnXHB7CrGoYewYE8heKWONCTj7wGRS3yeVaSMwx8vFAGCo+SkIpyD5TQRigBuMqDzxUZ71Mh4I9ajK80AQnr9aqyriRfrVxx0qCQZK/WgDoXkZnYkgY/WqMjxs5Zunoau4SPzBI68kkc1UkktAQX6+1AE1tIudq9O1Ptoi0zNjIFFlf6fGxJiYsO/8Ak1qWmrWCxbVtWJ6k/wCTQBApaMKWVRk80lwPMUlACKsXOvWqkqlh24z/APrqimsxKXYWoJ+lADY4XYNhSBjFNSJ+Rgmrdtqt3cNiOzVUOOStdVod1HbOHuNNSdj3KmgDlbDSrq4Xd5bKmeuDWzpGiLHM0ki7j6MK7638S6THbH7ZprAk/wAP/wCusW88S6HcSFLeJ7fB6sP/AK5oALdre2P7wnPYDirh16bASBsID0BNUY4NOvmJt76Hee0jBaY+iXdqDN8sq9/Lbd/KgDVXUjcjZPDE4PXI5NbXh62g87fbM1u2eVHCnpXJQyYZPMicEHgkGur8NiU3HzYKHn2HSgD0m0sJxZxypiQYB+XnFasdxFHGFk5JHO7jBrK0jU4tKjz5uFK4YEjArJ8QatHrO+OzbyyTzJ70Ab1z4wS0kS3yZMHBPXb+tZWv6cusWsjGQG4IzFJnjj1/KuQt4pLUmK6DFvU963fDupJaXa216N1vIflJ7UAZEIg1S1fT9XUrMv3HI5B+p7Vwmt6VNpd41vcL05VuzD616d4isNt/JGT1AeNx6HtVFoItc0xrG9AF7FkxE8c9qAPMY4wOopjKCav3du1pdS28ylZY2K8jHQ1XdFBz+NAFcKCDmlSMFvapsDFOSMKQfWgCxbQ85AFbNnBmMgrwe9Z8H3gK1YGYRhVb8KAJbAMCeD0xmrEMk4uOfnHbPakfiMbOM9amMUkcaMzZU9DmgB8rOgby8qzclu/0qnK0rxZk4J6Y71dR0YAbWbio0i3ck7UAyCaAMedWhljYZyvpVuWEvGJFAVG5Oa0jp4SVD/rg4zhecfWq0FvLC/8ApP7xD/AOeaAKFxAUXuAecHoKNHums7hJVG1FbOz1rSjhR932punRAeazJIVS4DbTn+FT6UAb+tBTcrLuba6AiovtDrbFYCGXyyGJ7cU5Sl5YxuWzJGMBRVCZWBxkqG4wO9AHMXmwSBSWDk5PvzT7VP3v7xDgkFak1GIyXjKBhh0H41aSKQS7pFYBCPlx1oAtSQx3MRdflcdR3qlCDuU7VyjZ24rQR1WRiw2B+ee9OuLcyFru1GwBdrqKAOdljxdvIEXLcisyScNJhgDgnJxzW1dja4cqQucfWsi5jzI8uDt6dKAMucq8jJ2J5NV5bf5yu7K9qvyQgDeAVDcdKivoxDGrLyzCgDJu9u8HAI+6KqIGy6HjB7VflQ4AbGDzxQsQLJkct1oAZp9tLNJiJWZscAAnNQ+LwbS7SyD7nUBn57kdK73wOiwT3N8yYFum4Oei9RXlN5cNeahNcOctI5JP40ANU44xQSKB0NBFAAOCDQ45+tMb2pxbKjPpQBER14qNl+cemamYfrTR94fUUARSF2kbcx5NRNHkn1qV2O9go709bOeTkJx9aAG2aYkx6da1raNmAESFjWj4c8OPcPuk5Ge1d1a6PHbRIsaAEk84oA4KLR7m6y0i7FHTkVs2Xh2OGAuY97Hue1dZFbW1u6rO3APJA6VDNqYgSaOFAQ+Rk+lAGbb2McMamTAX+VXWuLeKMLakl8YLVlyTvtCdQ56ntTgr7mXocdfWgCvfToYyCCT61jJCGyTxWzeRHaSXA454qnFEow7cH3oAqTWoYghAo9c1oabeapaSJ9kuHQZ+4CKt22nPOQ0XK/xM3atCWTTtHg8yaXLng8Hj6UAdDo+vqqL/AG1p0Uq95F4b68Vcvdc0TcDoF8PtJ62jIV5/3j+AryPW/E8t2THa5SMZG7ua54EmZZQ58zcDn3oA9nm1O/ubgrfFoFzynatzSJwpGX47H1rznRPGE8FslnqiC4twMbz95RXdaRBBfwrcaRcedGB80ZG1k/PrQB2dpNbXShLkZx/FRqOlNDHmL95H2b0rGtJTsCMMEcH2ro9PvGh+RuYiKAI7e6ivrSOK5yZl+UN7DpWfqFtLHOrxAC4jG5T/AHh6Vf1nTHeyN9pnzENlk6Y/OpoCmqaak0Z/er29CKAMDxDo48Q6SuoWCAX8GFmQcZwMnrXnrwsuVfIYHBHoa9QtLmTRtSF4qlojlZU/Hk1hePdF8iePVbM7rK7+Yn+6xycUAcUBjjPHY1KgG7k0SxMVyRxT7ZM49aALlsBuBxWraY8xW2ZK9ar2sIIBUZ9avwxlVyo5Y80APQl3wBwTxViSORVCMOnIFXDCiAGIYwvNWbaB5Spxx6+1AEVjYO1uZmUdcYpJokVj9oXGOPLTov41uNbn7MFU4C9azbhyZGRFyPXNAGW07R5MAMTdMA9RTUU+YXjlJB6LjgGppYQ8gaQ52n86rySGNsjBAoAYUVJPNUHzB94jtUNysk5kKAFmHU9akcyTSAK4Qnpg8UyW5itV2zuuVG7cOaAItPuXtZvKmjARupz0q3fxRoY7gyZQrkfX2rndQ8QpMSsUeFxjJ71kyaxPHkINyt1B7UAbNg4vJLgvlnRjswO1X7JpJLh45XYnHy7qj8Gahp8l40chMM8iFVUgkN+NaNzpc9pfRJKhUNnDZB4oAo3MLvAycEx/xH+H6VqeGUabT9SZV3lY8hSehqO7j8jzFC7oyOW71d8FMjCVU48z5HJ7DPFAHL63A8aIs4xuJK85rOmRfsWxX/eA5+tdL4whWKQQj+J8KfXpXKSSeWGQAE4KGgCjcKUt2A+Zjzz2rOn+eMYbOMDb/WtN4nZGUH5QuaoyQeWoYDJYZx6CgDOeMK6g9M8ii7KpMpi5Aq55IXEjc7Rg1AkLSl0X77dKAOt1Ef2P8L9QmJKTXjosXuMjP868egFe0/HMDTvC3h3Tej7GZx/3ya8ajHJoAcB8ppp/OpSPlprDigCI9KQAbTTj2pFwG+tAEWcc0q4Lj60MOcUxSQ6/UUAdda6VFES0gXFXLyOzjRfmBPTArAma+uHYhHIJ61o6To15cksRhQe9AHQ6Pqa2iqsceMe9XZb6e6nO6QhQKx49JlW5KvKqqOny9a6KHTEdViW6XbjP3aAMu6lbYVLAY7etVfPO5Qoy3QVdn0qFJl2sxXPzNRBpNvM+R5hTONw4oAz5nZp9rdPb1q9bL+4PmtgHgVvWnhe1unBAkUqR1zx7+9bI8OaNp6NcahqsSlBkB0IA/WgDgrmA4RYF5J+8al8i2s4jLeOGK9zxmqXi3xKpnMGjzJdoBxIo2j8jXB38t9dSF7ve34cUAdNqni1m3R6dGU7bzjH5Vy0sktxJvmkLt70yPjGQR9alTHXNACMuBSxLiRfrT9uRkHn0pUAWVTnoaANNY+c+tammz3NhdLPZStHIO4rOByAOgNWlBUgA84oA9d8LeK9P1xlt9aiMF2MBZgflYn2H4V193p0+nuFlIeIj5XUcGvn2MFtowf8ACvSvA/jyfSoxp2rA3OntgDJA2dT6etAHeWd69qDsOUbqtSWsAtrhpbX/AFMo+ZfQ96TUNJ32ov8AS5BPaSAHco+79aq6JdS29z5cuSud31oAdqMWyUOv+rf7w/nUmkRx3FvcaNdjNtOC0RP8LEYFdHeadHf2Xn2WOeSvv3rmWgcNtIKyRtuU+47UAcJqGmPp+oTWMwy8TbQfUVWW1xICBXp3ijThrWkw6rCP9JtxsmA75PWuThs9ybiOoyKAKtrbnII6Vq2dobmNpD9xPapbGxdwFztQctxWzBaGYhVBWBO1AFGzs3lciM/LjnitqC3S3iA6n1q0DHbxmODGcc1Gx2r5gIL/AMqAK0obaxGQT6+lY15sib5TuIPWrV/qRAIZhntXN310G+YsMUALeXBbdzg54x0FY0krEN82Khv9QBOFB/OsmSeRmwOAaALNxcLswM5PcmsueQupXqD1p8m5wSxyajxgEdqAICvbt1puN7hTzT2O047VNaKGck/WgA2EeWQcEEYNegeHNWfVrf7DeSfPEflZuc5rhWU4I9TU1lObS8hnXJwRuweozQB6NaxLJq0ccwzFnaV9eKna2gttUeOIbY4znHqK0tIiF7JDdwj5HUguOlZd8q293K7ks+Ng5oAofEmDy7uxZCPnXIwMdq4uK3VeZQW+bhh6mu9+JkgE2muVJ3RAYHbiuJndkkBA/dsMUAZdyo81kPTP61UmBVljIzn9K0rrG37nftVSSMSOD6Dg+lAEM0YZTsXC5BNW/CmmDUPE+n2rYCu5BP4E04wNnc3Urx711PwotBL4rtpmXIjBJ9uDQBzP7Rd59o8R2UKk4iRgPwC/4V5VGOK7X4xTm48ZSjP3Cw/lXGoBjigB2Mr700jmnn7uKYR3FAET4HFMP8qmbHJqI0ANmHzVGPvqfepW5UetRgfOvrmgDrnuJLiQR7Qqg/wjBrbsZ3to9kabt3HNNs9HfDSgFpGPAA6VvaRoN/LKqpbSA4zllIH50AUoEiEzs7sGIwM960LJZTAEjX58nkjoK1f+EW1We5j3wbZOxKkBf8a6jT7XT9GtzJrEsSTN2Lgc/SgDmbDQGuHVSJJW6qF4Gff1rWnsNP0O2a6v7hFYfwMcDOPT8KwfFfxAnt2a00KFMHjzSg7+nNeY6rJqeoSmS+aRpCc4OcflQB3PiT4gGSIppQjBXjO2uCvrm8voJbi6laR2OcZ4/KiaCRYYg8LD324qnqMxEaxjOMdKAM6OFs7hVmDzs438HsahVjjHAJ7VLF0zzQBOkpX+FD65XNBt7eRvmUxnuQeKAN2PT2qTb1wdwPWgCrJp8y7nh+dKqgFHAYYOe9aoLR4AyB3qa2jW5mVJlBUck4oAZjKRj6VcgXJ9WHepn09JMm0bJXnBNVzHJGdsqspz1oAux5x71ejUeSfbvVOLHAPSrsXyxNxQB1/gXxrd+G7wI5WWxfh0cEgfrXrF9ZW+q2aatobCSM/M6qeFx1r55UYTIPOe9dl8M/Fs3h/VRBOwawmO1gwztyetAHr/AIYuzFceW+AGGce/FWfE2lASrd2wOD94dh3qWSxiuIU1DTSHV8PtU5688YresR59splXcMbSPQ4oA5bQsRXBQgGC4GHB6ZxWXq+lCw1KWMKdhO6PPpXXXWjvHOGjz5LHOR2NWNXsY5tMjumXdNB8uB3GaAONttP2D94CA3XmrZURoREOcVNKzyM20fT2qYLbWNsZblsuexNAFIRpGhkm+VeuT3rmdf16C3Ro1ZdxzgCs/wAS+JJbyVobYgIMgnHFcs8ZfLOdxPegBmoX9xcu5UhR+tUlZzgOxIx61adMDpzVeQdcigCNuhyB7GoWwRjvT5GIG3tUbEFTg80AMI6kVHLlRUsTAgg1HKD0waAKbRkEk9DUloTuIJAx3pZM4wT06CkQKDuORxQBbRg0uG5zShAWYjLD24pYoXC7uCrDIapYFdvlTG0/rQB6R8F9VjOoto122Y5zlAevAJ4rc8baGNM14QQK5tZSpRnOecc815Ppl/Lomr2l/HxJA+T9OlfRviEx+IfDttfwYcp+8G3070AeQ/ERllvrVFfKxoB+OK424bZhH78V03icrNeybvvJjAz0rk7hi9woGRigBv3lZAflHNRFfn4NT8g7Suc9xTX27wp79DQBLFny1bHTgV6B8J7dUvL5yCGWIEfXmuAhDBSuBtJzXpfw3jWO2u5Pm3MgBx9TQB8//EgmTxheMf7xrnQnye9dF8QR/wAVXd46bzWCBgUAMYfKPXFRnrVhsHAqJ1544oAhbrUbe1SODzUTUAIoyp4qMffX608H5vrSbf3i/WgD3q1vVjVmW2RVdsglfy+lV7jxsNLnZZpskgnAGcV5tqnibULlnELGKLJ24JFc/wCZJLI0lxI8jHuxzQB2+t/FPW7htunzvEo6Pkg/zrm5NW1TUHMl9ezzP/tuTWNJhTlcYq1Ax9xQAtxcXJmBM8nB/vUC7ullIFxIQO7Nmh49wDA5HqaYqZfB6UAXptRvFRGM29QOh5qjLqEs7MSEz7rTbmTjYnSqyKBnI60AWobkdZYkJ9qmS8gB/eRlAeu0ZrPj78cUoXI6/nQBqobeRv3U7KT03cVK6PAvQN3yvIrH246cn+VSNPPE+A7cds8UAX4mLPlz8vuau6cQZ3IPy4xishb0EjzEBHfFa2l7JVLREA+hOKANWB9vCAD1rTi8uRcTRK47ZFZtumSu5SAea0oFYscZKgUAJJpxVQ9v8wHLK3Wod5LYUY9q1ELDyyTtJqaWxjny8KhZR26A0AZLqM4PAxk1LZxBsbjT2jZGKuvzD1q9aW25lxjPf2oA9S+FXiOWMf2dclmQDKM3oMDFezWFopgMsRyjc4PavmvTJWtlRoNysP4uhNe8fDzXRf2y28jZcIO/sKAOkYxIuxlzkd6zY4W+0PC/Mcg+UVpX0Deauz7pByfSpFSMQYIBZRkN3NAHCXQh01JPO5kHHIrzvxJq0l3M8cbtjsQeK6j4kXMr6hlCVSYYwpxjAFcHNHgZzk0AUDHjsCe9IYsg9hVp1B59KZjjrxQBRlj4wf0qpIg28rWrIOMH9KqSqNp9KAMq4XjIHSqbDHIPI7VoXCflWe8ZxxmgCND87djTyzLzxjtUYXPNNLENg5xQA92Zuqr0qI85B6U8HrzQw4GDQBY05xseOVyFPT2q8jKmQOMDtWNkqSKt2tzuGH6juaAHXEpnXD/TPrXvPwQ1ldR8I/Y7n5pIi6Nn+6W4rwmSMEkKRz712/wd1X+zdZuLVmI+0KNo7ZBzQA7xtZ/YvEN9EBhQQwz7iuKmyspP4g16t8ULTfexXgH+uG0n3AFeWzYEnzc4OMUARbt2ckg4oY70HH3eM96mnG2MttHA7VArBkOeD2xQBOpZSuT0/lXp3w+Y/Zbhcg/ID+przKDepAYAivUPh6FNpOcAFY8fqaAPAPiQgj8WXGRwWJ/lXOAc4rsPi1b+V4lU/wB8Mf5Vx6549aAEf71MbuKeTyc00gd6AIWFMZM1O6j6mopM49KAK5HPFDDEg+op5GBSE5Zc+tAFy/k2tj3qGHG7kA5p2oAebwevaoQwTvQBHcZEhGOantZNq7WqpPIwcZ796khdTkmgDSgQyW0kqjITqKrqxjUseGY4p9o+FfB+THI7Gqs8plmyBwOgoAc+3oBzUbqN2d3ams2DluKRWVjkdaAJ0QZqdIlA3HpVeIZcANnNaaR7lEa49+aAKUmM8DntURB6nr3NTyMokIHXpUZcAHHPagCBlJYDHU8VqQgRogxzVS2BaTJ6L0q6nJLfgBQBsW2phVSApvQdycGul0uNLlWNq+WxnYRzXEooQhm4NaVlLOhE0LbGHGQaAOujjWVcsuCO1alhGruo2BevOaztK1O0vYwmot5Ew4WRRkP9fStqS3ls0TzEHzf6sjo9ABeWMWoIGJEcy8AgZ3YrPjtTFP5RQqw5J9a1LBJFm/fNjd09BWxcWaXEWIztkH8XrQBjRNxt+8wH5V2XgG7e01KHB2ksMc+pFclb2pSdlbh16g/zrpdIjEQF5IfLhhYHPqRg4oA+gW2yw8/dIzXKajqbw3ZjHReF57Umm+KY9Rt7fygBHIuOD0/SodWtC0rFRlj8wNAGD47sPtGkrexj/VN82PfArzt4y6ZH/wCuvX7VVv8ATLuzk+YSJj6c15ZewPYX01rIOUP50AZKjjBB602ZcHjirTqFfI6GopV3DgYFAFUjjOM5qpIvzEfpV5s9McVDKARQBlTRgniqMsL5GK2JoxgnOPTiqjLzzmgDKkj29aryDcM9MVoTxfOcc1TlA38daAKm3D56ipFbPWh1JPFNB6g9RQAH6U0gg5FG7BoagBftDIw44q7o+ptD4n0+RDwsgB5rNwd5qmWMVzFKOCrBqAPpHXk/tLwmHxuki+ZfbNeN6nAyTksec5xXr3g26/tDwz5eMmSLA+uTXmuvwLHduh+8GIP5mgChD++iCle1Qyx7GweuPzq5GmyIFRVeUljluDQAsS7lBHB7V6N8N+IJw4/g5+uTXnkZKIo4wK9A+Gx33AXJG4cj86APJ/jXBs1e0kGejg/pXn8YPU1658dbYKttL/EHYfXkV5IDw30oAaetMfrTsc01uO9ADH9jzUbHs1PLnb0/GoyM80ARsePSmqPmH1pzjmo14ce5oA7+40TRnkLSRyL7mQ8H0qi2naTErBrdmYA4/eGnO5eHdIWORk81mSyKzZ3sVoArSQ2ZYf6I6kermpoba3kYKlvx3+aoxOA/zpuXHStCxmWJBtjy1AFqVYLKIRiDhhyay52i8wsgCrjge9SXE0ku8uCfaqZzIfuHGeT6UATRsETc8IIPHNTRJaMSzWp57BjTd/7rbvXbT7OVQWyyqBxg96AJbWDT1JM9uw4P8ZFZ08VpLIWt3dR2HWpLifcHDcqOmDVBZmAwowPSgB81hJgPHIjk9u9VX3o4SRGTtyKlMz7s8kexrX0llYtJPGskePukZoApRokcYAPBqWKRUyFXNWru0guGzbP5J/unpUH2C7gTMkbMnZh0oAVZMtyOKuRfOFC/dA5qlGVzg84rUtEjcgnKoOaALkIBxkfKOtdR4d8QC2nFtqIM+nj+DoV+h+tcy7AIEjwSeSfSrlsiuo29PWgD02S2URLd2BFzYMOJV5APcH6UtmJPPAB4Pc1yvhfXZdDlVWzNaSE74Ccj64r0u1063vbQX2lN5ti/32H/ACxPfNACw6VFfQ5kPllOrk4zXnvjTxC7XH9n24McER2465IJGa3PFXiIQqNOsZDtQ4Z1PUjIrj7uz+3xbgf9JXnPcigD0n4d3udLSNj8yEEGvUbeUX1kGHMkZ6ivE/AskkHliVSvGCD64r1jwtcYuSpJ2t27cCgC3DiDUEdPusen4VynjOzE6teRj54z8xHccCu0uYSt0VwPVTWHIqSX93aS42yYGGoA8wZsMfemyR5UkH6Cr95aNbzywum1lY4H8qqBSp5HXtQBTfgcjFRMpxxWhKgxnHbNUX4z6UAVJskg56VUb5W5NXGG7ntUEqDGcigChcDcCMc+lZUxw5PT2rWmcdazLiPJz60AVgSSetNKHIOKm+VcAYzTDyTk9KAIm4yAOtNDf3uRTz1pNmKAGHJzjoO1Ubkbsn14q65woqrIpJzxgUAexfCC/LWUKswwvH6mo/Hdn5WqSYHDHf8AmTXOfCu88uYwFuhzj6mu/wDH0XnW8Fwq5yu3cPoaAOBiUtbn2NUrhCeDySeK1IUAt3XqxzUESZB3LkjgUAV1jC43YxXa/Duf/iZxopwQc/Xg1xMrBnBycA4xXR+DJTbaxbyA7Rnp+BoAi+OlsX0dpCOUcn9RXg6kbc+tfS/xcsxc6HdIoySAc/iK+ZI/uY9OKAH5pjDk0+kPSgCI8Com4/Gp2HH0qF+aAI80wH94v1p2KZ/y0X60Ad+lggst1zMiv3XPIrC8u0DlWmOM1Wiv55ll858sW6k1mT7llyWJ5oA6q0sdPYF3uowo7MwqldLCXPk3EfljjAbmsEuzOSx2r6VXQszlhnB7CgDofsJdC32iPHpv60kNpKMhSvPA5rFTPUsR6c02WZxwrvn1zQBr3FtdJxs3f7vNUpDJG3IYN3HaqyXV1bsHjuJAT71ZttUlEhaaKOUer0AKI5CQNwGe+eKkgSBWImy2P7tLJfpKx/cqg9u1DCApvR8E/wAPHNADdyuQkCknPetAZCBUwoXsPWq1onkrv4LntTgXYlgCD6UAWo3Kk56+taFpdSk/I3A455FZkSsPmJyD1Bq9bFQihCF5waANb7PYXEY+1DZKeA0eBz7059Imt4i0BE0Z5GOSKS0tkbliOK1YLglNkZAC/KNtAGBCrTNuYeXn+E8VpqwA8pBn6dq1ZbWHUFVJYRBIvBdB1qjd6c9i/UtGT/rB3oAs2UTXTLBbpmUnitqbxhL4M/4llk4kacYuFPzKA3XHPBrK+3Q+HtNa83Br2T5VXONo9f0rgZJ5byaSe4YtI5yWY5oA9Fu7VZ1W9tJPMhmG9hnJVjziktJGjlCH73b3rn/COrnT7jyLnDWzjGGPHauyuLFBNDcQfNA5BDY6Z5xQB1trbAWEFxAMSDBYetdPod3iaMsSCTnFYGjzYRVzkDsK2ZoBC0VxH9xuT7GgD0C8BlghmTAIrmNcHk6yJVPDj8uK6LSXFxpoGcso5/OsDXkLXjLxlfX6UAc74vtgtxDdp9yVcH61zLLtYnrmu71e3W80KU/xQ5cD8K4iTmLPQgUAR8MCDWdMqq2O1XQwLYyRkc1UnwxI7UAUnxtOOneqkz9eOBVqUbD14rPu3wpwMmgCq4359qqzKdmeuKsK+YyO5qpKx2nnigClK2D+NJnrg06QYz0NRJ174oAfQeRRSgc0ARSKcD2qpICBxV5+elVJhye1AGv4Hufs+tgZxvHFe5aiEvPDJ4LOoyPb5a+d9On+zanbyDs2K+hfDkguNHEbnd5kfH5CgDz3ytgb+8ahVSIyOM55rYv4DFevG3BXOOPSsa6OHOBwTQBSkHzEdz3FX9KnMN7HIQeDkCqTLhs7qktCRcR5PTrQB6r4siN1pwwobzEGPyFfJNzGbe8libqrEfrX11KwudEtyGycY3DtXyz40tvsvia7jAwCQelAGSaDQD+lBoAY9RNU38RqJupoAiPAqP8AjX61K3pTB94fWgCVZMTsg9TQY9rZakVQbjeeBu/rVq7dEY4XAFAFF1JZuflFIuEUheppySqy/cPPX3qOJd+45oAGyuM9fShIy2S3C4pQoVfm60wyNjHQUATbVaPBxkVFJtACoc00KS1SkCKIEjk9KAIgrMp2nFOt4wWHmn5VoJL8A9acgXIUcAdTQBpROikMWJz0FWI7yNf9od+KxnBZ8HtU0KnJYUAbUU8LOM5GelattaxyKpUg5P3R2PrXPRx72X5QMda0re4a3DNG+CO3rQBui3kh43ZVuM1o2caKoROWHLH0rL0zVUdAbxNwHAOelbEaxyR+ZAwfdyADQBMkkm0rG+4nt6Vo6bLGq75UWaNTzE/IrAhaWBs/dJP5U2+vjFE5gYB34AFAFHxci6lqDyWJxEoA2dge9c9HhWKMCGHY1uwEnrwx6mn3dlHcjPSTs3rQBkHBC9zXonw11VLi4GmX2GjP3SecHgV54Izbyss4OV6e9bfhxjFcC5jOCpGP0oA9qa1On3uw42Ana3rXTab5d3aNC5xk9R2NYGhXcWtaOglA84dG9/StDSneK48uTIZDg5oA67wWzCWW1lzu9D171S18bdZmz0GOPwq/pH7rV4rleFfg/lVPxEd19I+Mlj/hQBU05t8txbsCVkQqM+9cJdwGC5uInzkE9frXbQP5d3C4bnIrA8ZRbNbeRekkamgDlj97HeoHyDkcg1YYbZGBPXnFQSnAx2oAo3hwMkVlSMS3zVp3ZPlhQayHY5INAELnaW4qDh0Y1PN8sWetVkzk8/hQBVkGFNQIwHGealuOC2apq3NAFgNjPXrTkbvmouq570RlcN6UASk5INVpfvGpGYYpkowf60AU5W2FWHY5r3P4f3/n6fbeoVR+grw2f07V6X8Kr0GFY2PzBsfyoA67xrbC31ISD+NB2+tcVdKfNJzkV6V4zgM1lbyckrkZ/OvOr1NsjF+aAKEoBRSO3FERAIOBk07oAKjxggUAepeFZjd6HOpUEoVwK8F+Ldp5GvJOAdsgxXsvw9lLJcQ5+UqDj161598Z7LOnQzgfNE7E+wxQB5Kuec0vbmmqcgH2px6UANI4PNRNUrHp71GfSgCI9KaB86/WnN3pq/6xfrQBda2uDJ8sRwDkHNVrnz5ZTvRhzzXRPcRs4jjG0luattZRgoI5tzZzxQByNxH5MQ2oVJFVYSSx65rvdRMrWoUOoA67lGaz7W1VJQ8vlsvegDlSXY4UcnvTAPm+c5rvLxLSMOIQhxzkCsAGOR2Hlgc46UAZjSIIwIxnjmqMkjSyYHbgV05t0a0kWIbW5yMZ4qnbWEAz5iEnGcigDLiUoPenxocfdznrW1BpMTxGRXIYetRf2XclMrMhX6fyoApqF4JHPerEBQklVqOa2nQjzYn2+qjinL0BBA9AaALMcrDORwar7nmuAi8DPSo5DJL8kZB9cdqmsomjBYj5hQBbaVlPlI+OOeKsWl9JZSZhk+YdxWUzuznGMZpZMIm5sk/WgDsYdXsr4AajJ5M3ZwCQT+FZtwLgXG6QbUzxjkGuTaZ2YfNx6Vs6XqL2h8uYebbt1HcfQ0AbMbruAJI96uwhs9cr6+lNeyiNstxYyrcoeWVOWX601ZlSPYA3P6UAWbqAXcQ3rkjgN6VLBay6fEkUqY34YH1FN00NLdKo5wMk9q6wxQ3qCGXAUDAPoaAL/gO9Mc5tmbCucqfTivQ5lDIsyf61MBvevJY7efTLpfmyAcqw716d4fvRcWcbjOVHz570Adj4dnEwZD0A+U+lGtxHgEfMOtYttcmyeIr90vnHtXWeI4g9tbXKdGXnFAHIsSApUfcO7NUPGC74LS4JyTla0DxK3PUYqr4mjL6HGTgmOX+lAHGTL8447ZqncsByfvDrVm9bZgnI9KzbyX5x70AV7sgp7msSYnzRitGd8gnPNZdz1G2gAnb92oI4JqoGAkBPanyPkA1AW75oAgvsgnjpVEHAGTwatak3TrzVJmyBQBYjcYPPFOOCg/Wqqkg1NuywHSgB/wDkUxycYOaQtgnmkZ85+lAEUpG3nr6V1Hw2u/I1ho2bAI3D8xXKOc9as6LdNZ6zaSg4DMFP50AfS92gvvDc4x8y5cfgK801aIAYI/hzXo/heUXdpLEed8ZUe/FcN4gjWOaWNwdyNtAHfmgDmAdsfXJ9ab5hOO3an3SFGYgHaMYqFjlU9KAOu8EXH2fV4l4AYFf0NRfFCyF1ot8gGWMbY/CsfRrk295BKG+6a7jxbAJoJUwCHjOfxFAHywhxle6nFSc8U/VITa6tdwEY2yNj8zUXcY9KAFPU8VGevvTy3WmN0oAjNMX76n3p79/SmL/rB9aAOkt7JlkLtyc4ro9M0wuAc7WPPPaq0VxYx3lxDIxYK5+6RyR6Vbstb0qOOVpzcLjspFAFPxDGbIMgkjcsOcdq4+QzMCUkx6itDWfEFvNcsYkLRMep5NVJ9W054VDQyK3qmBQBNFdM0KI5+Y8FqlheOH5WXJPOTUFq1hcRq4uGRs4wccVeewheHMN3GSemTQAguUjTbEy7j1NV2LswIYL9RTfsU1sA52sueSOaScOrALkqeSSKALtuzyIY24QckjvVk3MPkxqsbAj3zmslBI67YGwR1BParMMZXa+enbNAF6LURDuQopyf4hkVDepbXyYEQgkbjeDwPwqKd1jPCAsajtmQSD5iF/2vWgBh0O5sYnmjlS4THRAc1myXjn5GHlnocitma6beVDsB6Ch44JwBcRqE/vADdQBixSKWOTSM29zuyEHTNTXmnkZaxYvGD0brVB3cELINpXgigCyGtR2LHvzSiRd/ydPeqwIA+7zT1Ubl9aANXS9VudLmEsBGDwynkEV1MTQ6lG11YAbsfPATlhXEEbAN/NWtKuJ4L5JbdigiO488EehoA9A0SMRKXYbZG7N2rfto280EjHQ57GqWlXFr4khD2+IL6NQGXgK/0/Or1j5qFkmyGU4waAN8Wq3cIin4OOG9Ku+EpPsWoSWVx0YkqTxkYqjZvjAck5FaHkeYYmjP+kIflPtQB0Wony3hi5yhJIr0URi78LooHzBePzrzG4n+1Sx3B6H5SPpxXp+hSf8AEsiU88AEH60AcKfll2N1HH40msYbQLlWHIy2fTirmrwCHU5VHC9QfxqtqYVtJvCR0hJxQB51eMSADzxWTdc45BxWpduAEIGcjrWVcnIyKAKTdCWIrOlB3EH8K0ZxuORwf0rPulYAnmgCjK2DjPNQFuQM9adcOFwRzVN3IYEdOv0oANSf5Y8HjNUieRUl/LyAfrVV2O1WFAFlT8wqTI3k1XibLZ9qeG+bBoAkc5Jpm7nrQx61HIflIHWgAkbIGKhlkMbxOP4GBpN3XPUVFckkA98UAfRfw11L7Rp9vIDnoD+Qpnj23Ed+7rgb/mH51yXwW1DdZNC5yVfp+Veh+PIUewt5wMlkwT6c0AeaXIO1d3T0qgQxZgADir98cBRnkcVW8sKM56igCJTjGD0r07UWW60yK4U8NHj64FeVFWDsQcDvzXoGh3JuvDyqf+WZIx7UAeG/EWy+y66JVGFlGSfU5rmi3SvRPivb7raKdR/qnOT7V5yjZGfagBxx3ptOoJHUUAREZ4poPzrj1pzkk4pgP7xfqKAOh023ZJwlwPmLcsf8azPEJVL+WOBwUBI+U8Grt7dMsZiZiHJyCOtYBkTeWkOSP1oArj5YzuXj3FRpGZGIANaVtEL6XbkJCvU1OIoYZCIP3gHcjFAGcsbQ43KcnrkVZ8pyAd7KMZ4NTXbq5Lkj04qukpHA5HoaAL+mS3EEyskm9QfuyHINa1zri3bj7TbwgoMYhXArnDdKuVYspPYU3zE42kr6nHWgDoY7+zLbVQJnuRzUmpeTCFFnKrkjqTmuXac4OUyexzSRzygDBoA0nedHXzgQaVZmL5xgetVorh35mYtjpmpjIlwuCuxh/doAtxzIAdxBYdPeoZZJXYHkr6Ckit227kXIHepSAjjvxn8aAJImdCrYYEirgjguIyJo+pyWxzVUXUhwrIPL/lThKu4r5jYzx7UAV7vTWQ7rMiRe4PJFUMsOGXaw7EVvIfIJYHIbvQY4L1GWaPY+OJB1oAwmYyDDbt3atG1iMceCOW601LCe3PnyDdCDgHNSwOWctk0AaelXEthcLLbMVcds8V6bpV7Fr9srRsqX0YG5em/j/GvLYgd+WGcjrWrpF7LYXcc0bHAIz+dAHp8LOAA4CuOCD2rTjmEaeYvVRjmqFpOurWgu7ba0wH7xemfekkuOVj/OgDqtNUXFuroD833h6V6JpD7LJV7gdK878FTq+pJatzHL/wDXr0WOE2100DDGBxQBR8TQb/KnxweCR2rDvd39l3YI6xMM11d8n2jS5FAztz/KuTuyTp9wAePLYGgDzW4yVOByDWZMPn9s1rXTgMyj1rHnf58D7uaAIplwF3Y/Cs6/b5K0ZiCtZF8w280AZF2cA4zVINk84qxdOSCTwKobuevFAEV5J86jrUTPjHcGorl/9Ixniml+DmgC3Cfkbmnoctk1Xhf5ce2acjfNz0oAtBuvtUcjcikZwCMVHKwNADGPJNRSnIXNOduMVA56UAd18JL7yNZlgLYD4I/MV77rMZvPCz4GWRlP4V8v+Crv7H4otGP3WZV/8eFfUmkv9p0qeIfxIdv5UAeRauqmTaAQeKq34C26gnnocVr6rbkT5I5HWufvnxuGc4PFAEKNuj5611XhC5yDB0LDpXIxNnH8q1tFujb30bocbWGfzoAq/EaDztNvU28hSR9c141C2Mg9uK9/8bWoktZnVfvIW+ua+f7hTFeTJ6OR+tAEy/Wl9qjU8Zp26gBj+1NXl1+tPPIpsYzID2B5oA0L3572TuBkAmsgWbyzYXkk1v38c63TrsyuTyKTShLDN5qRNweOKAMzYbMyRE4buaiM+0bUJ5q1r+43jSMpBfmsvcS2elAFl1JYKg575pmwhjntQrtw3Q05XAyMZHWgBBHk5xk0jcdF4pRKVYEdKJJRI2QMUARM5YYIwaSMHNWYYlkb5mwPpVsNCv7oIDn+LPSgDPDNmrUMihuR9adckD5QAfpVXYAcDqaANSC9aIOUPyddp6Gp4tQhn+WZFQ9iBWQ25AA2CKRZE2kFeRQBuTW77Q8ZJTqPcVCpAJJGGHFUra9mjKqjfJ6f0rUi8m4I2sFfuPegBgdiu3GfQVds0d1OOI/4j6VSNtMJdoPFadi5t4zGrZx1GOtAGrbPE2YJIleEc4aqmo6OYF+0WYDwHkrnlamt5gXIlYAHoav2ZaJmO7DenUGgDl0mOTt9cYq6CBjB5I6VqX2kJOhubQhJycsmM596w1JRiJAQ4bBoA63wbrj6ZeiN2Jhb1+nSu4uE87N3bj5H5Zem0144ZS7jYcBTnNeleB9WNzYmGX5lHyOCevoaAOo8KXJg1i0yTw2f0Ne36hEZooLpOpHze9eG6NAYdbCn7q9D7Yr3Tw1IL3R1z3GP1NAFS3JkWeNscqeK5S9jENveRt2jYiurtFMV5tPUttP0zXO+Lx5ct5j7rQnAoA8jvMrM+c4yazJxlgR0rU1Qnzj9KyJXx24oAJ2Aj5PSsC7ctnrir+oz4jCjoOtZincrZ4oAyrh+DWdKzIc9q1Z4d7EkbaxbwOm4AZFAFSd8zj86TfnkVUEp85844FPifJwfrQBoQuN3XpUgYHmqUR7e9Thu1AE4bvmkZwTURfjH50xnwpJ9KAFLZJzUcnQEUgPy0xzlRQBJZTGDULWYHGyVSfzr6s8A3y3VvbFuRInf3FfJDtzx1HNfRnwfvxNoVmx5K4U/kKAJvGtr9i1GWNTwec1wOoIfMYA/rXrnxStgJ4rlhgOo/ma8iviHZsDkHpQBUQlTkHFSxXBRtw6gg1WJ24z+NRKT8/OBj86APRNVButEgkIzuTB9+BXgHiy1+ya5KoACv83HuTXuejXpuvDqoTzE2Me2K8q+JtoEninA/i2/zoA5BG4qUHKiqqH1qZG4oAdnA9qPulB3Y0RrvcAUhYNOpxxmgD0s6TM8kuF2gMck9qla7FoojkPyEY9MVbjMsscgicFmOTnvWRPZz3cjbiCqn8qAIb02NzA4niBX+Ek1gx6bpN1clUZogB1ySM1pXun+WWDBzH7GqTWSrGZITsXsGOTQBn32m26DZDdBiD/d6VWbTZVTghyenGK0pVWNWwVY4yTiqsEzbid2cc/SgDPm02dAC6kE+1MSMxD50JFazX0vZhjPcZpxkjdPukHv70AYBmY8Yx7VIiqi7yeT2rcWzt7wYOVfsR0qvdaHcJloSJFHcUAZRY7sHoaCWUe1OZZIWxIhU+4pUjZm5cEUAIrGQgYOaQoFbDnB9Knk2KQBkmnCWErgp8wFAFYNsJKikhV5X2pwTT2fcQq9CamGFwoHzdzQBs6detbxiKRPNQHnnFbCWf2jdcWR8yNfvjutcpFv25QZA61oaZcyQsJrdysinOD0P1HegDWhi2tiThc5BxWpHuLqOSBVrSntdeUlAIr1RzGT8p9xUMs0sNw0UiBQowMigCQbjLhM/L3qvrll58PnRsBMq5Ix1FPa6VYNpPzdRimRMzkOG4PUGgDmY5ARgrgDrW/4U1BbDU0Dn91LwfyqDV7BQpuol24++KzEkXAK5z1zQB9B6FGtwDKp+aIZDeor1X4ezbrOWLOSmD9Mk14/8MZxfeGVnbJnXII9txr074eO0epXcLcZUED86AOi1WIRX6yA/K2M/WuV+IrIlqJFHDJt/HFdvrUe+zZgPmTmuG+I/Phu3cdd/J/A0AePaq+64U9AR0rGu92DtbArYv1+QE8nrmsrUIysW71FAGJNkls96ZDhkO7qKWRivHWq6Nhjg8H1oAdcANGSvBHUVj3gBDBuuKvtIVkz2rPuyAsjflQBzdzHhmcetLDjYTU1yMx4FMhGIwp70AIrnOcdKtA5UEiohGA4qwyHYMdKAGg+nWobl9qj3NWggVCe9Z143+kBfQUASoeBRJxHz1zUURz9KlAyDQBCRhSfavW/gfqB+zT25P8AqpRgfUV5JI3UV1/wjvjb+JTb5wsqsx/AUAfSvj6Fr7wvFcKeYmVT7814XdNi4bd0Y19AW6DUPBd5Ewzj5xg+grwHVVKXrL02nvQBn3A547VWMmWA7HirF25xxxxWbuIYDvQB1vg+U+Xew98ZXn3rJ+J1nv01mK4ZQH/nS+ELgjUpU7lcCt3xPCL3RZGcE5jIP4A0AeE4yAe+KcppSNjuh7EimsuGGOhoAsIdkTN3bgUxP9Yv1olPIUdBSR58xfrQB7XZaasEZW+lWFs42k4IFVY73R9PuysheU567uK4q91G68sGWeQnoWZzk1ivJJNuImbK88t1oA9N1DXdPupygCKm3Ctxx9a5DVYpGO6CaGcHtGcn8q5qK4Lsg3MCevNah0+ZIBN5rxg/d5xQBlzPMJNrqVYdsUKJFbchAY+op8urPBJsuYI5SO5HNSJfWNyMH90/p2oAUIx+eVlHpip12vFt3KG9TSfZI5/uXC8Dja2c1UNvMkjKcgDpnvQBZmlfydiYBB6qKktp5kUhH4PVTUKnyseZjPpU0l5BGRtRSx6mgCylyJf+PpAyDqMc1BcWFlKxMUnlMemTxVSWUOud+KrBpOAGJNADbuyu7cbnQvF2ZRkVVR1Y4PXpWvBcyIQHY7e4bkGpn0+2v1LW+IrnrgcBqAMuONVyQcmp0yR8wwPWm/Yrm2nK3MbRgdyODUwKZO4/L6UACPj5Iwcdz61IkJY5U4A60xcZ+QYz6VLtYNkNjHagCQ3flABCUYH7wOK67Rtfh1W0FrqpRZU+5KMLn0z61xc0fJlJG3pVEyYf92zDHTBoA7e/tXtrolxkNypHQj2qS3U5CvkE8iqnh7U49Vtk06+kCSJzHKevHGM1feCeyuRFc9/uuehHrQBYjbko+GQ8EVjarp4tphLDkwyHP0PpW0q7TlRu7Va0+NbqYW1wAY2PIx0NAHVfCa8+zXZszlVkXjP4mva/BwP9v44+VT+PBr530ppNG8QR7icI/X1XFfRHhIiXV7O4i+5JGdx9eDQB3VwBIkkXdlNefeOUJ0CSJuTFuYivQmwsynHJGK4zxxCDDqIxwYcgfhQB4vdRgxn1IrCuRuQDrxnFdNdR5TA9K52YbXZfQUAc5KvzHPSqe5dp9RWhdkKHAHINZFx8rZBoAidssKo6k2IpFY/N2qWV8OvrmqurtlOeGx1oAy5CdwHaiNhu569qY7fMMmolz5xyeM8UAXslmDEY4qZCdoCjiq8bfMB1qwBjpQA5jhck8CsNpN8zvnvWnqUvl2zHoax4QWwO5oAtxZYgA8d6sSMAuBUYAiQY61GxJyTQA1jnOKv+FLo2XiSzl6AtsP41mknFNjkMU8cgOCrA0Afa/gNxcWU8BI+dWAAPtXiXjaE2us3KNx8+P0FelfCrUPNit2Vssyk5zXIfGO1EHie8+XapYFeP9kUAeeXbnywT2rPL4YH0q9dAm3BPSs1vmz6UAavhxmTVNyDMjD5a7EOZ7GSLgqFJrhtLlaDVIGQ87gK7W0x9pKL90x7WHvQB4x4ig+za7epjAMhYfSqkS7ufSug+IcHla0JAMb81gIdsRoAgJy31p8f31+tNZeKI/vD6igDevmE8Y2nJPNZAWXJCg471p5WMtGowzEkE1WmYxYJ59aACysme4Unt1Faup3LW9mIGYsSeCD0qta3cQIZD8zdRnpTJnUyt5uGX60AZskKkb5dzN71RlgBO6M8E810MrQPEuwAkVm3ERUblB29+KAKsIeM5RmB9QatC+nxg/N9e9V4nGTyKmWQNnCg8dqAH/aBNKA2VPTmrxtGjGTtfP3G6isqRxwduTSi8kXHzHaOi56UAWZIWB2ll596kB5AjXkHBquk/m4yBn1q9HhBwM5FACx28jtwoLfoKvCxms2jkJUE8jmq1pNKzgAbQeOe9aLszhTKeQBjce1AFy0l370v1SWEqR83JB9qyr7RGVPOsCXiz91vvCnPKiSgE7vTB6VZhuZd+2Nym3vnrQBz6SbGwVYH07irCzAje6kD+dbt1b2N0oef91J13L3rm79JlbBB8sfdIFAD2nDAgqMelQhQuCFBqurZzkmplYkcdqAJFcowaIFXHcV3fh2/h1mx+w3zMtyozFIfXGACT2zXCxtkZ71LazPbzrJG/zA880Ad2Y5LWUwz/AOtXg46GtPw8oa5aQjOMjn6Vn2VwNW04PuH2lAMHOSR3rodHjSG0QMMO3LDHegCW/tBe2zFRi4h5Ukfe/GvZvhNOb7SNNmOQ8ZKt+ZFeVRglQPTqRXpvwcYrLMigiPjjsOtAHqF22woxOAKwfE8Ql0e7nIBLRMufbFbWrMBb47niqF8vm+GL5WGSIX7f7NAHh9zF8nArmbyJluJGwMEV10i/um788VgXqDlj1zg0AcfqCHcTjisG8OG46V0+rqY3IHfpXLX3+tI74oAzjIC+Dg88VU1p9u33FPf7455zVbXDgxigCqQW54IqNT++GRwKdA+Q2egpG++KALVvhnyKuAbhx1qrYr154q2cIjNjgDNAGNrMu6RYgenWo7cBV9zVZn825kkPc8VYHHHc0ATbs9T06ClIGw+tRqMECpiMLQBBj5eagk6VO3NRP0NAHvPwO1YyWsAdjlGK9fYV1Xxxt911Z3AHyTKTu7nGK8l+CV2Y7qWInhW3Dn2Fe6/Ey1S/8E2tzj95EdvHPUigDwK4fdbSDH3elZkR/dkHOa1uGZ1xwe1ZQQpMV7CgCSFmjaNs/MrAiu90fDXkyE53p5i5rz/lmXnrx9K6/TZnWSzkz90CLNAHMfEi0L/vSPmjJ5rhM/Ko/OvXPHFuJrOcnHKk5x7V48D8xoAsDmoh8sg+tSLSEfOPqKALGpmSK5ZWBDAmqxldlAkOQa6PxH/x/wD4H+dYs3VaAGhFVVCHlv0qzDBvXg0kPVfrWrbf6pqAMWOJopGLfdq9GqmM7wSh60/Uf9Uv1qW1/wBQPpQBh31p5DCWIExE02IgDeBx6VuXH/HmfxrNj/ioArNIoQ9M1DhTy3FWl6mnr1FAEMRQYBGB61oxsqtxznuaYvSpDQBciuoUALRqzryKWe7F4yhFAAAG0VUT7oq1p/8Ax9D6UAWYoEVfnjHTrRcELFmMDGal/wCWxqGfqKAKbtJKwyMKOwqWOQBGjcblPrVpe9En3W/CgDJn0xny9sCR3WqsZUBw3DDiuzs/9Qfqa5rVf+PugDOBLtgHFSJiNvXirFt98/Q1J3NAGj4QuXj1WOPOEJyOenBr1R1R9t3EflIw4H8JryjRv+Po/X+les+Hf+QJL9aALFudxCr3r0z4TOseptEcguucfQGvNrb/AJZ16P8ADn/kYof90/8AoJoA9K1viKI5xgmooh5mmXkTHduiYfmDUuu/6mL/AH6Sy/1U3+5QB4nMMPOnZXYfrWFqCZ3AfU11Fz/x+Xf/AF0f+dYl5/HQBxOrL8xzXG3rZkOeo713er/d/GuMvOp+tAHP3J+YEcVU1p9wiPTitS7+9VPVv9VHQBnovAYDANNGWkJHar//ACwH+7TIvvUATWCZTHfNN8QXH2eFUXqwIrTsPuH8KyfEn+vi+hoAxIV2oMVYj5NSr0FTx0AQjrUhPyGrC9aevQ0AZx5FRSelaP8AFUUnU0Abvwtuja+JlTOFdW4/Cvqi7j/tD4e3gUZKKr/+PV8oeC/+Rntvoa+uvDv/ACJ93/1xH/oRoA+aLlSl0AOhJzWbN/rMgd8Vvar/AMfq/wC8386zLj/WtQBnBiJBjpmut0mMy6dZsrdLkBh3xiucPWuq8PfcT/eP8qALPiZFk06eQD5dpCfTFeHzoY7uZOysa9717/kX4foa8T1T/kJXH+8aAKaGnqBvH1qwnWnj76/WgD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the \"light bulb\" appearance of the humeral head on the AP view and the greater than normal overlap between the anterior glenoid rim and medial aspect of the humeral head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16994=[""].join("\n");
var outline_f16_38_16994=null;
var title_f16_38_16995="Myomectomy tourniquet and clamps";
var content_f16_38_16995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Abdominal myomectomy: Use of a uterine artery tourniquet and ovarian artery clamps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myomectomy, controlling blood flow. The blood supply to the uterus is controlled by the use of a rubber tourniquet and by Statinsky vascular clamps which are applied to the ovarian vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16995=[""].join("\n");
var outline_f16_38_16995=null;
var title_f16_38_16996="Calcium lactate: Drug information";
var content_f16_38_16996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium lactate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16020?source=see_link\">",
"    see \"Calcium lactate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12405?source=see_link\">",
"    see \"Calcium lactate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-70 years, males: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12405?source=see_link\">",
"      see \"Calcium lactate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: RDA: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage in terms of elemental calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males &gt;70 years: 1200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 648 mg [equivalent to elemental calcium 84 mg], 650 mg [DSC] [equivalent to elemental calcium 84 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of calcium depletion",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Constipation, dizziness, dry mouth, headache, hypercalcemia, hypercalciuria, hypomagnesemia, hypophosphatemia, mental confusion, milk-alkali syndrome, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Achlorhydria: Calcium absorption is impaired in achlorhydria; common in elderly, use an alternate salt (eg, citrate) and administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D: It is recommended to concomitantly administer vitamin D for optimal calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Taking calcium (&le;500 mg) with food improves absorption.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F144713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes.  Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13333871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Lactate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $6.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325 mg (150): $2.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     648 mg (100): $3.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (100): $2.41",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12873982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium: 8.5-10.5 mg/dL. Monitor plasma calcium levels if using calcium salts as electrolyte supplements for deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corrected total calcium = total serum calcium + 0.8 (4.0 - measured serum albumin)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biocalcium (PL);",
"     </li>",
"     <li>",
"      Calcium natural (PL);",
"     </li>",
"     <li>",
"      Lakalsik (ID);",
"     </li>",
"     <li>",
"      Pro Kalk (ID);",
"     </li>",
"     <li>",
"      United Home Calactate (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As dietary supplement, used to prevent or treat negative calcium balance; in osteoporosis, it helps to prevent or decrease the rate of bone loss. The calcium in calcium salts moderates nerve and muscle performance and allows normal cardiac function.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Requires vitamin D",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8831 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16996=[""].join("\n");
var outline_f16_38_16996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144726\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144716\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144723\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144717\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144706\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144693\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144725\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144697\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298942\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144701\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144713\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333870\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333871\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323035\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12873982\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038548\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144696\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144709\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/41/16020?source=related_link\">",
"      Calcium lactate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12405?source=related_link\">",
"      Calcium lactate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_16997="Tolmetin: Patient drug information";
var content_f16_38_16997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tolmetin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=see_link\">",
"     see \"Tolmetin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/3/13367?source=see_link\">",
"     see \"Tolmetin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tolmetin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11103 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16997=[""].join("\n");
var outline_f16_38_16997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030122\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030124\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030123\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030128\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030129\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030131\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030126\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030127\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030132\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030133\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=related_link\">",
"      Tolmetin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/3/13367?source=related_link\">",
"      Tolmetin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_16998="Primary amyloid bone marrow";
var content_f16_38_16998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monoclonal plasma cells in primary amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 295px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEnAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ZgjWR9ryCNcZzjNXI9KuGkRSjAMMqQucj1qlDnzBhSxPYDrXsfhfw7LdaLpz6wSJ1H7mFv7mSQG/wrKpKaaUep2YeNGSbqdDnLD4a/a7NZ/7ZhUkAhBFuJ/JvY9cVT1TwC9hKU+3GTAByIlUDIyAcvnpX0F4a0a42xsscNmhOGZIgWdcZ71rr4Q0c3b3F3btczyDDmRyQeOhAxn8ayc6kdLjToX1ifL3hzwJfa7PcpBJsSDILmMkE9hx61oTfDi4tiwu7qeLAPS0JBPHGSw65r6l0/SrDTFaOws7e1jfqsSBc/WpWgikAYxgj0IpxrSW6uZSdNv3VY+cNP8Ag/HeWxkGv+W4UMUaz5XPr+84qW/+DcdjZRTza+xMxxEi2WS4xkn/AFnA/wAa9+u/DljcytOiyW07Lh2hbbvHoR0IrA1rR5o7eOO8A1C3iOEjZcFV9FP9DQqvvK70Gowlsjx22+DbTxh/7aZQV3f8eg6ev+s96ZefBuZI2FlrCTzKcbWg2L0yfm3noCOxr0/VJ/sRFxZ3DwRsrRNA0eduMc89OvTpXN3fjOF7W5gub0WkgZo0m+4xK45GeAeo69u1aOM2lNS0ZcacW3G2pw9j8LGm1gaZcaoY5zMId6W+5CSCepYHoD2rnr3wgtrpM182oIBCNjxOmH80HlByR68+3SvZ9CtYI7ZtTubh7h7QGRXZ8s7EHDbhnsTzn1rGfwd4f8WXE80TzWdwpMj/AGeTejknliCPlbke3NS3PWUbuK66f1qXyU17slqeX+GPCTa3Zz3XnukcUgT5It5YkZIHPXpxXSaR8Lv7Rt1MeoO9wfm8mOHLKmep5r1jw7pGg6No8ekwMyo8nmedja0j9N248E9sdPStnwHpKRXUt3C2bb5oYVPZVY5P5jFO7ScpX8jN8qVlFadTz+w+AEE1uJLnXJ42J+4LdeBnud1XR+z5pmRnXb3GP+eC/wCNe3Ny33R6k0pGDjH4dqw5pPqZcz7L7keJL+z7pPVtbv8AHtElA/Z+0jJ/4nGon/tmle3AZ6H2IobnGFyPelzS7hzvy+5Hh6fAPRQwEur6jjHZUHP5VZ/4Z+0LII1bU8fSP/CvX7vA2H37DNS27FlGeo9ad5dxt/1ZHjR+AXh/eVXVNXbHB2+WcfX5fce9PHwA8OuAU1XVSPXMf/xNey5AIUAgsTyP50qx7XDDgn7w67vf/wCv/wDWpc0u5Nzxo/s++H88apqoH+9Gf/ZPrTl/Z/8ADmdp1PV9wGT88X/xFezEfT05pqR7WLbs9fQdevQUc0u4HjY/Z+8OD72paufo8Y/9kpJfgD4cVSRqOrj6yR//ABFezFTnknFQzLlWxkE9xRzS7gfLfxk+HGmeB9P0y40y6vZzdTSRsLhkIAVVIxtUeprlvAmj6LqzXo1ya+jMfliFbUqN2d27JYH0FenftQ3Exm0m3d28lSzomeMkDJ/lXL/BGyF02st5cLNEISDIOmS/SurDzi4809UKcHzWNL/hXPhlI5HkudXxkeXmWNc/+OGr2h/CHRb65cXN5qEcW0FAkqFs+52Y6V2Wp6OLmIrds7YHAChCT14HYdOayYRqGmzwf2fA8sIHCr82D74OfyroUY1I+47P+u43Hl8zN8R/BnQtM0t7mC91NnBAAeWPHP8AwCsyT4T6ShtEF3fvLPGJMK6cA/8AAfWvVbTXNO1/SzaXgEF1jD28vByO6k8H9D7VEl/bWjrG9stysKlUlTO9V9PpUxpzj7rjqr/1chOLWh5+nwZ0Y43XmpD1/eR//EUv/CnNBzg3uqZ/30/+IrvZdZV5CFtZIewabOG9xWPca3LHd+VL8hHdh19KqFCctAbSOaHwb0E/8vuqf9/I/wD4in/8KZ0H/n+1M/SSP/4iuot9cmVmEqxkDpkADFOh8VWvnGKUjdnJ2jgA1bwtTori5kcqPg1oHe91XGM/6yP/AOIpw+DPh/A/07VBn/ppH/8AEV6BBqUFxD5kUgK9mJ7dqsJPG7EblOcY5FYShJbj0PNl+DGgkfNe6pn/AK6R/wDxFKPgvoJ/5ftUH/bSP/4ivS9/Oc5HXPrT1I79frU2YHmI+C2h973Uyf8ArpH/APEUp+C+g4/4/NVB/wCukeP/AECvTi43Yxx13A8U7d6cCnZgeW/8KX0IgYvdU6f89I//AIik/wCFL6Jn/j91T/vuP/4ivUV3eY3z5UgcelSMSRjuaLMDyn/hTOhDre6p/wB/I/8A4ioz8GdGZxsv9RC9wzIT+e2vVsnbg8mg8dh04pCueVH4OaHwBd6oe3+sj/8AiKVPg3oJQ7r/AFLzB2Ekf/xFeqrjCkcnvSeWolzgAnqc800hXPK/+FOaETgXmp/9/Y//AIiqWpfCLS7cxPbT6lNGHxLGHTftPAKnbjg8kHqO4r2GSJfY885FQvGu0kHjNOwXPLm+EGgg4+16t06748f+gUn/AAp/Qu19qR/7aR//ABFensrbeQC3seaikQmJsKMj+HsakZ5hJ8JNCVWYX2pYU4P7yP8A+Irzn4j+HLXwxrkFlZSzyRvbLMTMQTksw7AcfKK+iltfKUL5khjH3UCgKOvpzj8a8R+Ouf8AhLrTJ/5cUx/38kqY3uN7EfwP0uDVvF88Nym4R2bSqcA7WDoM/qa+kdN8P2tpIkqoXcEEbhwPpXgH7OI3eOrvIyP7Pk/9GR19Lwg7AD2HtzWdR2k7FKT5bE6YxkcAflSALgAcDPGBgU1dxH3cfj+tPOSvv6ZrOwkRcrNIsqsY2UBTyR6EEDp256VNxjapwAMDA6UyRgu1jn04Unn8KVJAW2qcMOSDwcdjikNjxk9CfbmkljWSI7lDcfnQoJ46470/BAxigDzTxTZWsN+326QpbShiQF6MB+fI4rzbxVoH9s20dpZWaWiQSsyXMpwCGwOT6Hrz6fWvWfFsUj6rbzR4LRyhQrHCnPXJ9KtweHYCWkg2F2O+Nedo/wBn3HGRQpN79Dv5owgvM4HwzDc2nhyKzvHgmji/dfumyrYyOo7/AONaVrNBBHcNaRyF5Qofy8Atu7DjqPf0ro5fCZlaRNrLLKuSd3BP+PFeeSQzWviCKyewk8+BEBaHK8fMAzMc9ecjvjtU+2dNuPRm0KcK+vVHH3/xBng1pXhtkuIbeQKPMZlD7eh25IXnnjvX0b4CiWPwppksUwmWeETbxkAl8ucfixr5TOizz2N68siwz28pVo5eM9MYPpzX0t8F33fDfRxksFV1B/4Ga6ak3OF5PscdeHJtsdvk5HXOOaRAEAVQeM4Gaf0/GlzXOcoDgd80oOOP0zSDaTjPPWlxznHNMAYAriqy7Y5Mj73erKKFXjP481S1ORoQoU/NIdqgdScZ/DjvSRa1L6NkAj8Kfz14zUVqP9Hj5zlc5z1p7/KMltoBBJ/GgQpOASeB6mkz2HJ607Nc34u8WQ+HtJuLpbc3U8a5EasFH4nsKTaRUIObtE6CeZIEMkzKkSgkuzYAridV8faQhMUN/AhJCpLkyBm7KQOmfU8V4xbeOdR8TeKDDqm65spwS0IOEi78DuAPWu+uY9C07zbm1tFmlVUBjMYRSWOQM7emMHrVqlJySXU6lRhBNy1scd+0FfXep6Vol1c2UMUfmyIlwjHMhwMjBHQevOc1gfBK6+zz6wgKbpEiwrHqAWycd8Zrp/j7qdvq/g/w/dwQNbE3UqmEkFUwoB247ZFZf7O1kt3ea0zdIlgPTJ6v/hXRFewi1JbdDklJTnc9esYJbwGSWPYvQBVGSK1LTSYlO4kgf3QcfqK0Y41RAAMfhUg6E4rNzk9xNroZsujWErBntoiy9CV6VMNOiKbOqEEYx04q0qtt+dgTzyF28Z4GKcSAvepDmZmQ6Skdv5U4WcIfkYjkCuO1zTlh1Dz2CrEQFKldyr+HWvQ2YbeuBWPqyR+RJ54VlI71vRnJS9RX7nMW1lYTDE+2IHASdGyjf1B+oqA+Awbszw3bbH5BUA8e1a1pp9rcq/8AZ9wlx5f+sUHDD8Rwam3Lp6xpJM8buxUKZNpbp05wT+ArqdapF8sW0/T/AD/4YlcrXNoZc2hy2w2RyO4UfMCQKpRG4hmMZBYA8Z4rqGkhmJBDFzwd2QT7VGYbUNvwQ44Ix6D0qfbO1mNb6mJJqFxEhDB8Ke/pVm01cTqAjOZMcqQTWyVtXysyHBGQQuafbwaXG2UkiRsfxfLUqq2rclxy5Vu7FIX3Yjg88g0xtTiV1DuBn0I//XWnd6Qt0MRSABv7pxmspvCrCQuXY46UlOna8hJXJ4dRheNJHKpuUHHpmpY7mOXIWRcZ7NnFU28PFU5Ln61lSeH71Jd1vLtx60RlSe7sPk7HShwpwGp+7J5PFYb2Gp+UrLt81eSA2ARVG6mv7Ql5I3HQFlbrj6U7Qe0kLkb6HXK2F7fTNNZv9kMR09RXIQa/MD+8yBno3er9vrbSrkICmcFsdD+dX7N9GS4NdDf8zIyc49ximsccYyDWVFrEbllKjCjqDirEVykxLbmB7AelJ05R3RJdBGM8ccHimLjdzkgg96YjA5GQT1pC3B3AgHuDWQwkUorq2OfbtXgXx3GPF9p72Kc/9tJK98kO9SQeleCfHjnxhadMfYUxj/rpJUJWkU9i9+zhj/hOrzOP+QfJjP8A10jr6aj2gc9D+lfM37NwB8d3meg06Qn/AL+R19MLwMnnHoKxqfENbEuWGzg+9KRtXGQB9aUZ9aQnr3qAQmPmzTIz5mHXBTqD3P8A9b+dPwCMEcGnEEfT60hhjnr+NOOD3PSkAzz3rO1O5nEsdnYlPtUo3Fn58tM4Jx3Pp+JppAlcoXkP265XYP8AVzhGPv1reSNYwAihR+dR2NrHZ20cEWSqDJYnlmPJY+pJyasE8VLt0KcmxAOwNcH48ijWxvWjwLdyDKRj72fTqeldjf3f2eMBQDI3QE/59a4bxBbSyXPDyeW55IQHBwf0/wAmp2aZ0YeOupx2r+D5NS8LpbyGM3Eo+0IT1jBK49+QCcdOa9F+FOmQ6V4VitredpY9xbDD7ue1ZtpL9qiK3AfzEVdhBHzqAMHjpUnh6/trDW3WMbbeX5GKn5Q3UZB6Hnjsa6Ze8ubuKSk1ydj0E4xSEA7ckj0pqOHXcjKw7EHIp2fX61icw7GDnil460zd/wDWqC+vbaxgM17cRQRDqZWC59h6n8zSBJvYtgYAJNedfF/xHHoWii6jc/agfLiAPVjzj9Mn6Umr/EeB72Gx0OBrq4l/iYYVRjgt6D64rxz4g3Wp3Xie1bW2gkt1YnYuSOnPyn8h1zUyTujvw9Bp8z/q/c6Twj8Yphbi31YSxgEZkiG7jHoTxz/Wuh0j41xTSzC4sZmtg+2KTb/DjqxHTntivFrFdOt4b+S6t5niYgxRqcY54XJ/WvSPB2pWtxYLZ+HdKVZvle43jzQoOerHp09K0nPd8p0vDrlTlY9Ev/F13PaefHGkUROBySTnpxXnPivU7SabyL3VEgvXUiNGB2j69gevU10Fza283lm71IxXyEbYI3KREDqucfyrx/x3rs+r6jJaJbFIoXO3cvz8cfl3/GotKb5GrCiqdGLmtzrPCHg25+3XF1ahGnaELbq0nyEtgZz/ABDkcfnXZeEdDfwzdzDWp4rm+nbayI29BnsxxyenFcZ8HbLUNNu3vpVIVkAiSY4Ubs+oPJwePxr2fSmsr66eV1fMshVt4B2uDggEdsj+VdaouD5p6qxy1cRzRcYaJnl/7Q8Wzw9pBwiL9qfaiD5RlM/h06VX/ZkIE/iPkD5Lfr/vPUn7SzXaSWFs21dPif8AdKuB823ksOufr2qn+zbN5Nz4gOOqQc/8CapjrT0OKfxH0AOtInIAIwe4z0qKGdZBjjPsalyM5zxUNCQ7OAAaQnr6VE0hxjqKeh+Uk0WsA1trDlsEenNY3iIKlm5LHIBJxx2q7NOHl2oc0s9stxFhhmtYe402Lc8o8C3k8HiuF5XUCQNCyRvuBHcntkHFbHi23u/7anlXEkUwUAldy4wMggcg8HvjmuusvDFpazmWCJEc9Tz/ACq7Jpr5LLIhz/eBP9a9CeYRdX2kV0sZqlZWZzunwmHSBhMKik7TyQoOQM1h2l/eT6ojmbCtLgKpPOcdc9Mc+tdvJEbi0dEwJIyUbaMAmudkktrCcrKFSY5+6vf61NGqpKT5btjkttdCM6xZyO6tET82dxIJye361D5CtcMfLVw2cELgn0+lYniCWw0Z5POll+0yrvj2D5UBJAOCfY1vfD+wvEtD/aciyyA5Q4z8pHX8RiprUOSn7Wm7fqaU62vLJXNa0026CKFkIjwfl3sQPfrWmLS9RP8Aj5lUY4ArWiACDHWnMTnGK4fazb1YNrsZMb30R/1yyYPSRfbPr71IdQlH+sgTp/Cx/litAofMJ6g9QfXjmobiJCDuAo5r7oSsVhqkGfnUrz2WlZ7K5G5mwPpVG8hUDG3viuP1vWbuw1AQ2zRgou5S4++cHCgZA9K3pYb27skEpKOp3X9k2VxExAQoeCdo/qKij0G1VWELbS3GV2nH4Yqh4e1ZdZ0vdJCI7hMpMq8oTgHg+mD/ADqWRIYdp+1hFJ6eZk/gKh0fZzcdb/ePnlJbhd+HYnJ8rDHHPOM//X4FZM2h3Noj/Z7g7if4hgVt286M3+j3BkPPIfP16VNNePvAeMEdeOpq41akHZP7xNX3Rx0kV/A6s6Epnkg5zVuO7kQcllBB+8OldEHt5lB+VH7huMflTxbQn5WU8j61UsS38UQ5UjlE1xHUxvw46EDrXjvxsuUuvFVrJGcj7Eg/8iSV79c6FaXB3GFQR0LDGfyrwL422EWneLLWGFcIbJGwWz/HIP6VDqU5v3U0xtWRqfs4MV8dXpAGf7Ok6/8AXSOvppWxj5uO+K+Y/wBnNd3ji846adIfp+8jr6XjIAKrxnkn3rnqfEC2LRb060wsOnekAXAxjAP5UuONo57jArMaHA56dM+lKDuHII9qavrg8cUy5uYreNnldVA9aAtcdPMlvFJLK2yNFLMxPAFcPomu/bNauroOFWR9ijgnbxjmr2pzLrs0NvdNLDp5kXKIMGXnjcT/AA+oHPvXC/EjWYvDfh+K4gQNqGohokY/w4xliM+mMD/ChpqyOujCNmpbnslvcRXJcxOG2nDYz8v1qO91CCziLzNkDjC88+leXfDHU7/X9HjvprJlihU26yfaT5bYxuwnY9PWt6bRJLt7g3ep+TGz4KcuwQgD5TkY7nnP60JK9mRKkovch1vVSrrqMCR3UcbC4TD7S6HGEB7Hkj8BVbXrWTUWSW0vZrV1cGQO3yIMZyWPQ9vSs3xTa2OnX7Wlpdw6baW8awTXMrNI7uB8rAfdGOMnn6cVVuYJvE/hLSP7O1C2klhY+bDJ8qXDrk8kfmARzxV0I3lq7Lub1PdgmlqdCsdzaWizPNA0TRjZJG24MOvXp0zWLaXtlFqcAlledSPKLbcqwBzjPsRx9M96ydOXUtN8P34vwLSa6u2ljikYBEHfaM8A+mBWFo13c2SlbllukkcsuV5Zj05zwOM4qp1FRlKlF3Xculh3XgqrPSEvm0fUo9Q0zz44ZVIvbWQ5VwB8sq9cEZ59uSO9V7/x7qi6OdQV444ZHKKTZO1uo/uuzAMxPqAFGe9ed3HjCSz1Z01BJtRlIG6FH8uNBjHOMk4544r0Oy1288U+Ho7i9tUlsZYzH5SjaVAJBAHrxx+ea525OPMXOjGLXMr9zzrxN8U/GKXX2SCdLKNPlUQWoTcPUZLcemDXJt4r1JrsXF9cfaZX482VRIwB643ZxX0DN8MtP1C0tZbi7nkvYfmjm+7yOBuHfGPxqa/+GXhZ1gm1CKBJkO4ys5RWPpyRx7VaqW0aMva01fkf4HEaXqmn6bo1jdauXieaAS4YcBscYUfhxT/FOueG9RtdPuGmmaSPP2f7GuJw2AcYAwcdTn1qj8VNG8PN5Uen6m09/EP+PW0jMwJI4y2ePbNef2dpd69eDT1n+y3NshNurDacBeUJHOcA8/X1pNuqveX9eR0RhCPvx3JfFMsuqzMguDceWpf/AEggTbBjHyrwODnnNdl8G2isfC2vXawPLMHIkQHLOoQkYH1JB+tbfwo8CWNnpg1DUfIu5bkgRMnzCMoclSexzj8q63W9CtrWFriNktJApx9nAUNxyCBwTihtU04JaGcqntZJy+I8lu/FTXKzS3VssCqFGVBIPP4ZNd/4Rg8PeKtZhHkkzwQmSSTySgIxnnsRz0rD8TeE7jWBbfYLiN5wMvGMqTjByc9DkmtDwFomqaLeXIvJFhhaJl2SRk/N/v8Apx0pyxCqu6VrXsW6EYU7c2pv6/pyPqcbaZPLEZTiSBZQgcZPQ46/MR9D7Vu6FpFxZ3JuZFht9MQOI7UjLLIduGDZ6Yzxj3z1rNj0t1v7dZZoQxAkEsYO2Pv1PU5P61Y8aWeptNaS6dfusCIGPmdWCnJPT+VdEainGNNysu7/AK+R5s42bZ5h+0fPdtJbwls6as4NuFI2nKcn1znOc1V/ZvhEtx4hzwRFBg/8Capv2g3nurHTLua2MIMm0uRy52k/41m/AXVodGh8TXcw3FYYdiDqx3NxTpRlOKhFa7f1+ZlVai7nv0ca26/dyc89vxp7XKEgblX/AIEOKyfDviS0163kkSKSFo/vo/UcZ6VyXibxbcLqQhECRxoD8rtx97HY9ela08JUnNwejRHOrXR6Isyk8HOO/aoX1KFpWiLY461xXh3xBPe6a7sqjH3iMque3atiGL7TKGhmilT+IxyBgM9QcHrRKgqban0He+xvWkcYIIbK/TOK0AFxnuaitxhASPmqYc1ySd3cYe/T60n88Ucmg5KkGgkbIpZcKSOea5PxZoUF/LFIsq+ev8Ltjd9CK61ydpx1rLv9O+1sPMJXbyDW9Cp7OXNewmrqxwnjCwgnFs91ZLLLCAIw7lB+Y/Gt/wAH3huYsyoElwAVC7QMDjj6fyrH8dm++028FvbrNbMCsgZcgr3zXU+HNK+yRRyOFUhRvGS3O0Dr6V2VZJYeKl12/roSl71zajkBPPTrUm7HcYrKmuki3pGwZlJx+dS290rKvmNgnpXD7N2uVcvk4BYHg+xNUtRn+y2rStnYo5qRpUHCMAD17mq92I7iF4mbAI9aIxs1fYOhnaXcx3WnRsvBCDOTk/8A66wNf0FNckiaFkEsR/jPStiLS203S7oRTFiVZkGeh61yHhUyvrQ3KzAs3zspA4xtJPof64r0aMEuepSla2xDb0TR0yy6Z4U8PCG8u44dwOS55kY4zgcnoKhvppbqOGayaOWFv4vVDzkEd+lWdb0Sz12NY9RthJGpLjJIIbp1BH5e1Wbawt7aBIoMJGu1VUnAUDA6VhGrBLm1ctb7WKcX8iPw5aO93O8ysocA/LgFSM88eue9aV99lsoA91Isa98nA+uadZiS1iYLkr1IHP8AnvXNeJGkv7a7jk2owULmQfKMEc59/wClSkq1T3tEDuldGv59vfRE2U8cwBwwz8y/WiOSWFAAd6g7gG5H51wWkx2/hzTZtSkmE879EjbjrnJJ75/+tWuuvajqGimbTo9j+f5JCoCV4B3jPABz1xVVcJyu8H7t7alQqX0e51seoWxdY5XMchBK7wAPwNeC/tB4/wCEzstuMf2enT/rpJXrlnbXckDHUJop8fwnll/HvXiHxiijh8S2iRK6j7GuVY9D5klcsYxUtC5xaJ/ghrdvoPiy6u7tHeFrF0IQjP30PAPX7vSvpjTPEGlajbpLb39uNw5SVxG49irYNfG2g2V3fagkVgpaUDcSCBgZAz+or0O/vdf8PtDBNOtppoBJuIoxPu9cqfrjmoqWcrHRRoRnT5nofSV3qenWUaPe3tvAkn3C8gG/6etZTeMtECAWtw1xISFVEidcnOOSwAHPevnT4f61rGs+I300ypLDdowYuiKI8AlXJA4AP8663VrO8tLgxw2jxbCsbRpKGJwc9ckjNNRgm1NihSU17mp6zeeILi4BhsoDFuIBlHzkDvjtn8/pVVmbKhp7iVwMeZKNxP5AD8gK5Kx1eWMeVPJ9oZmGEChMZ6+/fHXmtS41b5IirtJwxLMmQv19Pp7VNH94+WJrVoukrvYj8XasNN04XB8z5XVS0ak4yRk+3APWuV8c6O3iy90yOG/hitLWyVzIV3ZkkJIGAeuFHTOK9Ds5Df6bOzKN8aEtwCDjPY9K5TxSsUennUEtJ0lg2207xHLspfMbDnszFT/vCk4NStIulNWtE0/h3/xJvAuj2c1qTcNI13IOg+f7mf8AgPP5VkePdcvbLw5rL2J3SxsgXYufKVhgkEdwuOfzqfxb4kis45LG2dzeQQhFhEbDBUDIbjK4XHtio7Lxc9joukS/2etzPqAZbhGbARwceXgryxBH4Y60oRlWaUP66g17Fc0z5/S484yNK+ZXIJdufxr3H4daSttaQ2i3wt5Js3KRNH7YwSfTG4gY5Jra1/w/4d0yGXxFNosct6kiHy1IUIxxywxjjrnHpU08lpNo41zTNMm/ti5QiKF23LuP3m29D1raMPaR5pKy26b/AORm6zVorc6C+06NtHmtrrZqUkyMzpcIAHO3pwOBnAHevEV099N0KW/urW6k1HY0fly7gFfccFVxyMd89jXqeg6/LbLaadrcbrqc4BBji2r833Qec5PtV7wnoOr6RcXFxcagXtJiSIgzEc9yD0IHpU1MLy3cnbt5+gUsXyaLU8o8I6Rajw+NU19WjkuWaKKFYfmbawZnYk9OQAK7u7hsvDlnYz6bPNJJcNHIEDdUI5bBPGPwFXrvTIYtaWzVRIs7mRrefDJ83AcZOQw43AdQO9WtQe20+9063nltpte1CfZFIY/lhiXBO1WHXjAPq2e1ReFotLX+v6/rS3OpJtXuv61Nvw7qep6jo0F5PGlpvQrhyWeQg43EH7uQM456/n4t8a4NYuPEqW9rDqV3GEyJxucSZ6qABgAY6Dr1r3PSY47aFYJFATa5AxnLHHJPc5yfxFQX26a4dYvOZZMpiMKcA9s7uB17Umve5kYwny3PmLwx4y1PR4p7O0tbe5luDjdJDulBAwAD6D0x1rp9N0i/v5JNR1/VBpF8YiLcswXylK/x91BGRg+pr0vxDJp/h+3+2HTopbmchQ3l/dG3nJxzzXnPxKE1zcaNcW9nhpVFybdwQxxxtPr04oqOTs5Kyel/l/kdVDW6Tu97HqvgK107Q/DFvZNIL7DPMZbZsxuT1BIyMY7/AJ1wXxd1e81G8ubSGaWAIQIreIlRJHgH5h69eR6VhNrGqaY895HpVxpDfKXnizGEBIBJCkBhg4wRXP8AiKMMkF8Nca+1FyFjXqx6cY7Dk1m17SSs7/5msafsm5yPVvhBd3d14Svp7qW4mvILgw9csFAUgEEc5zxmug8RXt1bWgmbzIGU/OkrbWcY7DPT8fasz4e+GtR8JQao1zPHcXM/lOSoGEwDgDPfk/lXmfxn1e81HW/Lne4FvEqhfMY4Y45OKpyvNcn9aGKineUnsepaH4p0XXp4NE1JJVupWzaTAkxbh1TPrxXQ3N5dedDFJ5qyR4BYjcFx3Vh6+1eW/DnRWA07WdUnEUMCsbe36bWPG4HpnnOPfrXrCazpdzFCkVgt5Mp3u7Ao2N3XnrWk3ZpL5/1+ZjKC1aR5X+0LbzzaHpuoy3L+R9oEEFuRgAbGLOf9okflXK/BbTxqB1yPJDLFEykDP8Zrtf2jb3z/AA3p8L7YpFvFbyQmNqmN8HPeue/Z0Ki/15nHAgi5xnHzn8fyrWjNwSlE5Ki960j1jwtpi6bBKYkKseSWHzNXnsfhu+k1yeeQbUebzHduGXByOe/pXqyTR+YHjl3AnClRu/LHWm3kVu1tNLeEmNR84xz+NdFPFVKcpW3kTyxe/Q43W7Zv7HNuoVY3cnKHH1yO3OKd4AtZrS8bcSVwc8dR/nH5VqW+tWMtk+IQ6xvykoBB/H15qfRdQs7i6mW3hELqMFc578fhzWk5VVScJRsHut3OxjACDHQ84pwHY1Xt5VIwGFWM56V5lrAGQDz3pDyOOtRiJw8jNLvDMCq7QNgwBgevIJ59aeM4GRiqEDcLx1pBnGTz6ilwMevvTd3zDHbtTAhkih8tjJhhjOetYuoanBcWDDTZkm2kA4GQuf4iPT3x71rXCBrcwOMxlNp+mMVy3hnwmmjX11cGZZDMuAAMDqCT9ciumh7NRc5v3laxEuZuy2Gafdpf7thIkRfmIXGDV7UntoJRFLeRQ3A/hPp/n1rVi09YZd6Qoxzle3NcnrtnMJ7hmIQyE5fcQ3PAAHQ/jW9Fxq1L7BK8VZGlC8iv5jXSOrYA2kbR+P8A9esjxHq11bXCrbM6xBd2R1+lR6PYC0tirSkxMeS3y5Y9Tz05/lXTadpCT2qPcH8wCPw/KtHKFGXM9UK3MrMztHvJ7u1jaRyS59Pu89RmtW4/szS5la9uILdn6BiF3H+vWkS90e3uBD9riMgfGD656elcR8SvD2o63rME+l3atC48tgz7RGfX6d+PWs4QVSr+9vCIOTStDU0tU8Wavb+LIbKy0xLqwlZFExBwFbqdw4/Oul1jQm1G4t7iK6e38s5IPQY9fas/QdJXRtJtra4uvOZVIB34BAOTwa2Jbw3CbIlIiztaLIDOMds/hWcqtpJ0lZLS9tyuRJb3MfxhrV5pOiST6ZEZZ42SMqYyTgj72PSsXWLe48QeEPJvZPsFzeRxGQspGGyeo6gEYrbvNRtILuKG4uWjmKkIH6/TNLq+nQ3doizMWVcEkdW7Dp+FaQkoKKcba3vbUmyd9TG8L+Dre38Lw6dfSpdSLM0gfbu6nGBnt1qbRb/RYp5tNsJA8yOxJVcAnvj1/wAKil8Qx2Wtx6THA+1eN5PHTpVTQl8Ptr00lhbyJeJuO4sdpzwxH/16uUJOMpVbu+q2/EaeqSdjbv1McbGKX94wOecceuO1eEfF0sfElsXOSbRe+f43r3e+0qG4vxeJIxJHIGRke/avFPjjbfZfFdmmCM2KNz/10kriUo25UayTOV8IyvDq25J4YP3bbmlBKkcHHAPUge1e4eHNDe/t5P7TMn2QoMpLtYtx936V4b4TjM2twQJcfZpJv3aTbchSSOo9Oo/GvozQdPi0yzWJtU3u5V3CxnBJ7A4wOwzx7Vz1JWlY7aLfsVZmlZ+HdE8OWoks7eK3mlUGXaAqsuf4sDsapw2FlLftK0vnbgZsNwqn0GOT175qtqOtW/k/Y44xdXjE/JvIVBu5Zse5ry2w+IeqaN4luIr5IWtg7I3lphlHYqankv5suF4q7drnrlxo9ncKWaBCV4DoACB25rK1KP7PbjyLy3um5HkXTYLqTzhhjJ6nBBpY77VJPFVvcQS7tLliQ7FQYKFeWzjt1rzz4h2K2XiuO5+1lotoujAzfKmOOAPoKpr2bTi99TSlepeMlse42Kx22lQNG8VtN5Q8yF3GMEdAe46/XNYsNlDqFzejUJlsdGRg0jrwbhg4yitnJXIHOPTk9a8a0z4hX+6Kx2RTW8kgH+k/MRk8AYxgAmvZfEOiJd6VYzG8EDhhcyzRYjQxpyU9gePyrOfNfUiCjH4X9xgeJPidoHhs3Nh4Ys4JbgDy3u5Yt5Bzyc9+Cevf9dzwxqOlaposOoO6LLfJHcSuk7geYq7XBXPB3LjjBxjHSvJfF3h77VIraXEs01wXLeVgKzEk4zn9TXWeEvCt3pHhAsfmv1IdoHYfIXx/DnB+n41pGlqoy3f9fdcKjivh27/5lrUdA16TU1n8O6ldXGnmXE0NxcLIsJJ5AMhORjn7pIxjnrXpi20rJbo2+MpgmVAFAUDkADpnjiq/hCzktPDtsdSiUXDFgI2UKR1PbvWlLMUeMI4BY8qHxim4uD5N7M5p1faalUppS6rbrMEN0qkwyMoMi9fu9wOvNaU90RGILWJBGvylpThcfTuOK5jXNJTV7xBpt+seoxoBJtYFwo5BA/nVNYdbh1axil1NpUxtkDfLz/udCD9K1cIyive1tszFLXY5fVfGOnaZ45hD3X2u6EZtjHFbK0ULP1G5jksCB19TUl/olzc+OdL1i4luRDbJu+zvGchhngY9yM4/Cp9U8L348WfbF0m3az4K3XlKC3Aww7lsj+faum8S3UdvZloneFwP3cm3nI52rnrkknvxXNKDp2knqegqsZvlS30Lul6/b3Lyi4Z4diqpSTO4P/eIxnHHHfk1qaVcIbdnt1huJuNyKdvr19TjjAr5ov8A4leJZtU85rlWhQgGExKMgdVOOf1r1Pw/8S9G1HTN9zLDpd0CP3ZY4Hbg46f54qmna7RjKjraOp6JbRNJdCW/sTBbxqVRHKsNxIwcfgev0rgvH3hrX9b1ctp5jltFXEKZChMA9up/+tXSjVZJ9OgmhkW4VyqhkO5Xzn0z6fpVDVIdQnjtk0u/NpJHITMI2KuqkfKePvEEHjvTjFPR2s776/MmLlSlzLdHh+sWniRGvtMnsLrMJ/e7YSVKcHcx59Qfxqp4ItLCLxVbXepXEcWn258ySaUECNgPl47ndjivSfjFr2t6XploY4I7W3nPkeazCSVsAHcRyEzx0z0PSvJk1Rbi5sY9ZPm2aOWmVBgtnucYz2rOgpJ+7ZL+tTvqVI1YXqav+v69D6JsvE9rrUF8mlXELkhR9oMo2xk9M+mDjtms+bw/a39lHc+J1TUmQmJmS33EsAeF6H3zx71B8I/CcN39s1qGO4sLGcILe2BAWQryJCCD68Zr1DU4bEPCshaJ3O5PKzkccnHI6dfoKU6fI7Lf8jjdaN7JHKeF9AtbOFCHdxklIivOMjqD07celdLLpy3KKYXQPuUFCMYIOeCPzx71Zt7KxRWKTySMzHa+dpBOCQMADoBUGs3X2GJVt4cqRuO0ZI/DqSeOad9jGU3N3PFf2hYAfDOn3DRkSre+U0hYHeQr54/DrXn/AMKtTk0671IQuFeWJBjGSQH6Adz9K7z4/wB47+HbSGbyw0t6Jgq9eEcEn8TXLfAuzS61XVmLBJI7dSrlQcfOM9TxXbh5KDUpLQwqK7tc9whura40MT3HlxGMjPO35uPT/PFck+uTXOozLFcRyQeYUMSAEMD1Oe56Zz68Vo+IrK4jsYIbZnaEkvI204JzzxVLw5p62MU+pNbn5ICNjDAZh6E8ke44rsoezhFyWrey+ZEot77Dv7KaCESZdopsEgc7T6e4rT0TT4LDEisTKzeYyjoPX35JJ9Kxotf1OS4cxW4kgBwuI/lJ/ujvXRahOtpaj92ElkGECjk574qq3tNKcne/Z/mEbbpWNS3kla5DIfk6fT/PP6VuROGXG7pXGR6pFomlw3GuXBtxK5RAELsxx2Arc0+/inSOW1kEsUgyrZxn8Pz4NcFam97ad+g126mzuIPBP1pS4wASMmqF5fRWaBpX2knAGMkHp0rDvNXe0cvJcQxK/wB0zHGT7DvSp0ZT2Jk7bnVswXqRgnFMxz0rEtLmTUGhdJQ6ZwSo4P0reAxgd+lZzjyu3UpEZTf97AHPANORI07CnHHfpUSks7HjbSESZUge9VdSto5YjvhWTkDBGfxqyOOtO65zTTs7gcB4z8IR+KILWz+3T2axSb/kXcrZHcZH4H3q74U8N/8ACJ6TeWj6nJdLOd2WXaE4xnGTye5+ldb5SBw+BlRXB+OVu3OI/MmTOXjX+Ljiu2hOda1JztEmSSV0tTJj0Wf+0BvBKDIMhcHHPXHX3+tdgYWRQzlg2eBgZyFIAx75P5Vz3gyPU44Ea4tpbeIBdsTnO3OcgZ7dPxrsU8xgGlIUk/KpPUDt71WMrNz5bp27DhGyu9Dm9Y1GWxkjj8lmaTBDhgu0Hr+uenrVyC4llKyxKsYYBjufJJz6dcdPeq2uX9pBqCW92bfG/eBIrYB4/SqviSe7t/D9xd6DHFeXEbI2Y0z9TjrkcYHpU8t1FWtfrrYe3mO1nTbG91OD7RO0c6YJAIw341Fba/v12TSjaFFC7gztwQvfPbH9K5bStdu541vNZ05BeA7NsjFN/AwcdvT8K1ha6le33n3MYhUJ5Z4wzA9c/wCea63CMVy1HdW016+X/BIs3qtCK28R2Go+LDYNp4eWNnVZx94kAk/1p+pf2T4cnlvIbYiWY4WFW6sTyfbpn+Vb9rZaVbaioEaR3JXaZMKGcY5PrzXOeJNKFzqEYlMckauGwxwQR9OfSlTlCU0rNK213qFnayep3ejv9osI5mRkBGQG614V+0HgeM7LHT+z0x/38kr3zTAo0yARoFTbwo6CvA/2g/8Akc7P/sHp/wCjJK8hfxXY1exz3wshjm8ZWhlUN5QMi7jwGGMH3+lfQlvq8byG0gzMkn35S4bY+e4xx9K+ePh7aXFzf6lPZI0lzZWTXSIDjdtkjDD/AL5LV3/ws1qy1PWtSt9wsXuVYpFJIWMjA5CqcAZ780SjG7lI6qWsElucR4muNTh8T3YmnkhMkjmOTOAU3Hpz0yP0qk+hxWt0P7QvERZT8skJDBSe59BXrfxF8Mya9pcXllGvxl4TJhCRxlfxz+Yrx7SvDWrao+y1t38rLAyP8qjb159qhdr2OqU0/ecebtrt5HXwLqemxpG2seRa28xt/JjOQzLjJXtz1z71U+ImuzT3ZsbdRHFFxJMOZZCf4S/90DHHrmvVtM0NJNJtnRrUsiqiSoFcnb79jkHJrlo9B0S/1tbeVp3u9jzu+7cpVOTv4/Hr0rnvaSutjrTjOMrOxnfB7wy98095crDiNVkjL434ycgHtkGtDXJtWi8X6hcRX6KHQtFp83zQzRBec84ycdua63Q7DfoM8PhlI8n5FlcbHHrw3f0PT6Ves/CxuLDGt2kMk6JIgklQN85HGPp7V0KLXvS32t1ON1Ip8q2OG+HWoW3iKfUtM/s37FOYxulVg2D90AEj5euevauw/wCEYt9V1MRXU1z9rmQC4COoRWXgnJyTkjjj0qTwl4dj8NJLFcGKKS8IUspz8mc89Dkevuazn1q4b4nLFYSuksOfIQRBln4wdwOABxnNaurKnVbhL5mPIqsHpod9d6lBo2jRboj9jhVYgQ2XAyByPXNc5/wmtu/i6HS7SzYIMq03R0YDOQO4x1rVurtoI411KGHay7p90iv5WDuOxepByM9SKxtY1aOGzuH0mBLu7dSyTgKUXoMZ6ngnj1FFKUH8au359zF05Je6JJocVj4on1OzvSt26NM1u43MAcZIx1GOxqSz1O6E/lboX03aSsrALJnsMEZz6/WsvwrpGp3OvJrGoXCR3SwsksS5ySRgDGMdOuPpXRXmmDCtcBJ1HzorMU6dA30/WtajjGdpPm0S9PT9BRbcdCEtqF/rUN3bKWt1j2hHcA7hweKyfidZyfYbS61GOHako+ziHcDyMkP1H4jr7V1mii4nhaUNFEGIOwccgY/Udag8RXV7bWqJpGy61GQqyo+HOATnAbjOayhK84+X9bjd1ex4D8UPD66TqNtqMFtLbWeowiVYpSCUlH304+qnkD71Z3g6bSY/OudZiDwxEeYrD74OdoHB719C6pYRa5ocdr4k05ftj8zIzACJuQGVucEj/Jrg734YQ6V9oWx3X9rOu2eGRwJUO042kADgnOO+BXPP3bx+70/rqd9CqpWbe+/+f3mD8OPFOi6DqmqS37vDpMp/0WMo0m0kngDsBnrXpms+N9M0jSTNYxPOxiLW7qF2yOEz83cdMV5HrfhePUf7Og0FfNBiy+wFvLwB9/0557da6Cfw7JY/Dq5E0cc8kMMgE0TktuJG0Y6Y4z34rOU48uvp+hrOinNN+RyTfEHxDd6k93qU0dzYSS+Y9nJGrRY9FBHGPWjx/caTres20+lWqWiyxIBHHHjcx5zx26e/WuUSCSd1WYpaxAbd8wKgep9T+AJr1zwRqOjW+kRS2dle3jWku1tQeKKFXIUMUGWyAAAcnnntmtGkmpLp2JTilytXvtc918Owi30SxhCrGyQp5iJwA2ORVHXHdtTgWPaPLXCKW4LtjIIPGMY/OvNtF+NWlpqk0FzYSQrLKEJVgVGON2c4H8q63U7n7ZqNzcrcRTWwVJIWVgQikc8gkHkVMrpqT0/r/gnHGk+ZjX8Qabp2pNaXc4huJoiyIqE4wSCB7f57VreHtYkutNt4dQtD8/MMi5IKdQSDypxng1jebHfqt5E6lwxDsRh48+mQMgH+dTTWuqNbgLM4VMSfu+svqSff0q4vmVpilFJabnD/ALSVoi+FLCcxDzEvxGso7o0bnH5iuJ+Aswi1TVw0oiVrdMt6YcfpXU/Hi+km8EWdtJt41FHOBjB8uQYxXNfs/AnVtaIYjFovA7/vBXRT+HU5JqzPa5mJhJMSsxZWCE4BX14zjr+tZkT3c0m7yzIUXgCXA3cjv35q7Pe20MMhESyXAwxRDwRRYalaC3+0XMqxc7TH1YE/w/8A16pOUdEr3KSTV2UGW5F2VaHZCBk4POc+35VckinnuUmmiha0VfkVMmQt3zngD3z+FWLy7gjgPksrSuMgkbgMe/H0rKGorKEjjky0f8LjAbse/wCtNzm/IpRTVzJ8Q2s/ifWEiMZS3tyOScHtnjt9a6NLY2v2a2tZkgtIF2lD95vxrltb8WXunXEaWKxTdA7Ebhj6jqR710ej6ouqabDdTZM8n3uMcduO1bVo1FCLeiXT/hzKNrtIr3iSaVPPfXEgnRnV1VnxtB4P+FYHiyG6vnW9spfMtrgY3Ku4jPTA9uf/AK1anizQ08SadHbi58t423BwuQT059agvdRTwZoWmWcFt9uTLRu7ZUde3vzW+Gk+aLhrN6NdLETWmuxp+Bba9soIzOjbGcsRuwQO3B+uetd0MEDbnmubt75pltpAJrcFQwiwABns2e/NdBGXEeZAA3Xg1wYiTlNyluyla2hIcf5NIW2A8f8A1qOo470EAmsUITcT6Uue/pRj1owc0wGMXVcjBHoRVC5t0m2vMuXGccVosCeOKinKoOcYHJ9qadtho5a21yZtaltBaYgBAWQ/xc0/xTHqD2Mi6OQt4zjB4BwPQ9u1XvOLykkYJ6HjH09a5/VU1K41aF7Kf93G+6X5/pjAzxXbBxc1JWjZeqIadrbmVr2n3txdWkcpha9dEEqlsgsByM8f5zVabTL7w/bLOjFpZThlhyAoHHArrLXQ/wDiZHUJJi7EZKk5ANbqwhkAZdwAyQf6Vo8ZyNJarr0/pD9mranKXccyaUlzBAXlZckseQaXQ7pry3V7iKWKWGTgAc89BjnrzXQas3kwhV4GemK5OM3IvlEblEG4k4z/AJFFNKpTey8wbdyDWvCrXurJeJdyQmEoHTGcfT/OBUV1cCPV7dbWNZ4pDhmcEAckHnFTar4xs7LXfsNzbzqUHlySxYKq2Mj5e/X+dPv7iFdWiMsMiM5CF07nNaxdVRSq6q2mxKcW/dO0tQottqfMo4FfP/7Qf/I6WeRj/iXp/wCjJK930/8Ad2xjAwg5Xk14P+0Bn/hMrPPX7An/AKMkryI/xDaRP+zkceObs4z/AMS+T/0ZHS/HXR49D8bW91YCOCG8gWdUgURiJwSp6epGc+9H7OJx47uv+wfJ/wCjI69h8d6ba3+u6N9uto5o/KmiXem4bjggNz0wGwexok7TZpRvexw/hPWnPgwzeJpfLWDCZjGXkUD5eh+915raRLG50y7FnbnTY3tEkElwEYyHeGzuXOBwAf1rQtE0iz/0O2USxtuGJPmUZGCMnjBArjfiDqECeGzp2nFFilxgpgL5YPAHOSOnT0rOSdNp7M9CCVb3VsMh8YW9lBdWsN2kkk7bUUyAjzCcZyOAuMcE13lj4aeN8ztBHqf2VySgAjYMuCe3IAx7gV4fpdnGdJNokKm8e4DrLKOCmBlB78da9j0rU/sdtaaK1qrAKpZo8gNjHI7H6ZHSlKopz53uVUozpxUY7E3gyx1m2jaPU1SSH5PLa2y3zDqeOxHrXN/EHx9daLftBpqhrsRhCHG5UIP3z7+3516rYyGG5VzKiQSLhDsJIbqC3+zycmvN/iR4JvNQ1ZL3R3tDeSxNHdQXTcN3DDjpjOD7DFaVKrm+Zrf5HLh+RStLY8/0Xxp40uNZs83Nxdi+mG1Ft428zkbto21Pp+uazZeO5jDHKdVnlMbq0Wzy+zADnOQPwP513vhLT9B8NRw3DvJL4pMIjYCMhVPTai4AHbnOT3rbttLgF9NfRMoluTvlIBJL4znOeoz7dKwqKKd0jqhVsmmtOl/6/wAx/iI6pL4bmvNPgD6h5Y2iYLnBzuOO/UmvOF8TzaKyW2vt5FzMoZoY4+GXoGcAdevvxXsFogiXdLEWjXGduG3HBwcZ4/KvJfFHgWTWtWvLzRgvntKXSMttDluXwWwBgnp71o2uTla+ZlQ+N6/5HWyJqfiPR7N9NnRir5dA3k7l4wR2yOeM1rX91LbQwQzSiWVUQSsGzuYL83PeuX8BaVrGg6t/xOjNGs2QIlGUwB7cduMV1t5pa31pceTcCK7XAQ4DKO53Dvxnp0q6k5ShGmrd/vM7QjVlLoULrUbi40+7TSW23TooUA4PBG4A+uCa3fDbXiaLE2pZF3GxUSkZcAnAB9TzWSmg3NvcxMUiba+7epDAFeQOcEdMHtS3cF5faRew2VwsT3KKi+ZnIIPJ45HGR+Jp053gqUrLXfr2IqwV+aBveQsMRnupTdELtDJlvck46Djv0qSyb7WxCL5aq+STgbsdOPr1rO8KaY2ieHTaSzGabeXdkUBSW42/N26elWBMZIpobOwkubpEKorDCA44zk8D1FFSyb5dTKOtuhxN/NGfFUttpKXDlTm6mR9se3JyrN93r06n+VS+JrK4/wCEfnt7Np5rtRi3VVxuYnnHqRn9O1aGh+F9SNq0bIQJJC87MwVN+7kqPUEY/DtWxrEX9lWtva212S20iUuobJzxgdBz/KuSpTjGC11PRjiH7Tlj0PnwfDfxZd4uGs1CtzvuLqNG/EM24fTFa2l+BPGq6fJZWtxbJZTPmSHzwAx6HnHT8cfWvTZ3MxcFnZP9o8/WpLKR7eVMFVTI5z0HrmrVaT0srCdG15KTuef6v8IdYjwLN7CNCvzyNM2wep+6az9Y1abwikWh+G5JZbi2GbyRm3RFjwQgPIB69q9tdJJxAbW4KKS5eMISSxA5BB478e1eB+M9Ml0Tx7fwag5+z3B8zegIBVuRnknIPBobvaL239SqL5pXk9dvT+mel+H9Zn1HRFuLYjeq+VcQnAZGBGc5716DHr2mxWUMk92kVu4CLv4+bofwH6V8+WGtmy8f+foyNdW95CgnijUsWJA3DGOoNehTizvvECabeKxgdBJD82w7+N0f4gdP9n3rWhFStz6J6+foZ4qnq+XoQ/tGSWx8FWscbRG4/tKNztYE7THLjIrzH4QakthrN6jnCzwbcgc5DA8V1Xxx0CLT9JW+hyBJdxJsJyVBjc9u3Fcr8HNOe/8AEVwyY2wwhmz6F1FddNQjbW6t+h5bu5HvkFlGw8+LOHjG1WGAARzkDuaqarp2nw22fJYzM+9WX5Tnqc+3FaX76CaGKONXhKks3dQAO315/OqcEgm8y4v5k2wP5QZV2qWHX8MnrWEV1W50c3fYy41DSw2t9eW8Ly4K2wbDMO3J55zVIabaQ6800t66hl4iOcAfgOBUmo6JpeoeILXWo7rhGU+SvO5lxt57dK5TVzNqetbkMgbcCQVKgEcDn0OBxXq4bDp395rTX17HNUqye1i/quhmLVJhNAz2koBDIxbnpjI6fzrooJm0TQ4Y1EcKMAgKjeXPpz36Va0mKewsliuSQUO1GAJIXHAPXPOevtS3zQTafc/bEEq7dzpENvI46Z4zWc63tZKMtV+Y1GyuZUM81+ZBbhoLiSMEYOAB1HPUe9dJ4OsFismF1PBPcbslVkEgX6Z71zugXi31vd2saJbxiMBTtxkemfStPwxpdza6kZHjWKMDHB+9/n1oqx5YShe3kJu7udZNb/6V5xXnjpn0x0q7EWZVBUj3NPBQsQGG49s805Rg46GvMbb3GQSTxxOEY8ntSrOjc8jHr3rL1LWNPjn8uK6jkukyDGhyxH9aDqWmi2adp1jbGQrkg/8A6619lLT3WTdb3NdZUYDninKynoQfpWHBrFk8Ss1xHtYDjd29aoTakLSKR42keIPyGXnnoOce3501Rle2zC99UdU+MfM20fWs68miQ7Xkyp6knrWVc3E93pfnW2Vl5GMZww/nXnWlXGtXHiBllNx8rAOMfJsJBIOev1roo4ZTTk5WsJt9Eek4i3sAeMjkc7R65rL0zQrbS9RuLv7Qz+Zztc/KB9a4vT/DN4vjDUdQ+2hraVSoiDZYZwQpHoOK0Nf1VZhPZWyyfZ42w0nAbHTpWqovm5KctHuPpdrU9It5BIoddpzypzkfhUE+opBII34Ld6zfDIEGkwxRuWGAQWGTmqt7a3lzeKVAKdeO30rmhTg5tN6IclI1Nbk8y2Rol3DPQdTXD6tLdWTo8SEPLyN3Jxnp+WTXdumyHaRuKr09TiuEs9ZOra6bCe0Qxjds4+ZWHf27/wCTXVhJNJtK6W5EkWbYpqGnSXsFvbPrYhIhaRQSSMgdeP8ACuT8J3XiFr27/t5Z/skK+ZvuogGDbgMKTjtn2rrl0iWC7LqG2E5XLnp2Ht2q94ptXk0d4YSG8w+WMnIzg/0qp1YQ92O0vwHGLbu9zmV8T3VheAxXUbwIQuyRuJF4Jwex/rXAfGrUbfVfEmn3do+6J7BMHuP3knB966zStLfR7L/ibSxLIRxGx4A56nsOa4X4owwxa3ZG3aJo5LNXBi+799xx+VTio09HBfPuCvfVnQfs5nHju5J/58JP/Q469V8Z61DH8QtI0besjzWshYHBETNkqeAcHCnt0NeTfs+TxW3jK+luHVIl02UszHAADxnOfwrotMm0YeJ9a1u81e3utUvZnW3hV8tFGcg5/wCA8Y7Ae9eXUaTbbOvDwk9UrkfjzVTp+mlYJEIcBFAUYBz/ABeuQM8/rXG6O02o/YNIkb7R8x8kjjA/uk45HJ+ldp4806O40iO3jvIBcyzK6xnIGAOFzj1J56c15jqFpPpOpJAbnNzHgnyiRtb0BPp61En7R3uenT/dQVl/Vz3TTtGggaGFEDGIA7ieQAeEPvxnr2q9ql1FY6laW/2cMTj94Tk/Nnv+HvzXmngbVdZl8T2FpDqDXCT7zKoy6Rrg5x6H+f416jcGKOSOXVng+1KRtkclQccgH0GQevtUQcU/fRFaMr2TuzzK9+K+vW2szPaQiGwV/LdHjDHAOD8w4B69K6q9+Is+oW8lza22nNBaOII42l2Syr2YdcA9vTnmuT+Jdq+i6jcaZpqRTrcDzWkjBJxJhyhHQkZ61xk2jXqRj7Cj3UvlCWRIULELj7wx1Axyexpvllbldio0kk5SV1a51PiL4m393fH+yoUhgVQT9ojBb1x1/DPU+3SvVPC+ptq+g2F3cRlnmgVz8uADj5iOOeQec184QWZe4gSfdEz8NleQM8dcV9F/DyFn0WOyhiacRMEiwcLtIyTk4HUn86tKEGrHNNTcW3sbM9zdOnkQSpCrAL8ylSckcA59zzmtDR9Elt2b7dJGW3CaFIIyEBJyQc5LHr6D2qLT7q2jkvUntpI5IZTExcHBbHUE9uo6dqZa3Mw+4Szl8q2OgzRzrW2xjyu1kYqPrt9rMkN7afYtLgdvMCqD54PKFT1yPUHFdJoltJHYW6XYd7kIQzJwduc4yO5qjPrEN1C8hhjmxJtOyUKFbuGyBjvRp+rT6k5a3sp9iIUlZ3QKoz1UcEjjp39qcqkZu6SQeznGNmN8Q6r/AGZoOoGx8q4uoleRYzLuLsO+Op4OeTn0rwO48b+LYL43bzzxH7xi8keV/wB84x3+teyMzPqV3bPpc8llnzFSNgxB9cDqD1xnHSuZv/Cl/fX+y6u57TRkIYRRRglkPGN3UEjg0qkYRnff1NqN3Brb0Os+H/iuHXfDR1WWDN28n2R7dWCqCFUl+nIPGB1HNXrfxi0d6kEEER3feYgrnnA29j6n6GsWGSz0t5NN0YWNtbA+X9kA3fNjlye546+mM1DBpcsd1DtltwYA7og4ZiwycDPUjP50QqQlzO2liZUGrc25119q95b2SRqEBK5yp6FuTkfUmsNrl7kB7okSKclmHb6f561A09wbWNVk2uAAwIzj2oh3AbXkNw/Qs3y/57Vz2vc6IxUBsm5FbBGGOemd3+cVLbrJdSxRQgtIzbVX69vaq1/Pb2FlJdXDeVDGuZG79OABXm0XxG1G11m3uzaGLTWcH5kOSueSD3pQTlKyV7GsrRhzN2PY/EGpWXhy6sbWT7RNPK2RJC+3ZgjnH8WSTgfWuP8AH+oR3fimXTwYleCLbPdeSXdmb7qAD0HJPXJ9sV3Cw6XcXtql9dC6vXUNArMEKAgHK9x09a5Px74NhuIptbsbmaC7iCwzLaHczjOAx9CAefaumVNVFCEVZ66976L/ACOOjUVOblNnk2n+addks7aQopmKxSL/AAyAdQRzjNenaX4dkuLW3ae6P9oorN56AvubsV59vz6U/wAE+C9K0/S7fVLiO4Ooi4KJHIxyV2/exjjk/pXYJOLfzLY27rLHHvV1IwiE/d/MmpnD2cuRbr+v6/zOiWJ9pG62PP8A43Xc8vgKzt71ka5jvozuiUhSvlycnPQ5J4/wrivgpe/Z9fvbZkDLdW4TJGcEOpH6iuu+NbS3PhRbiZjxeRIsYIIQbZOp754P41zvwCjhfxFqTTpuKWe5D/dPmLzXRR0i7nmVrc6sfQM5RLSSedmWNOWYDP0/WsaKwFxYPFsPls5c4bDcnOauz3kaWa+ZHv24YKvcg8HB/A1k6VdmVNsq4KOwbknIGcf0ojFxSkujBO6aM7T9Gt7DUmjXUIgjDCQEgsOB1/KqJ0e6i19ZwcqG/d7QVAGefrnGc1t3Gg2j34v5HKMeSoOADTPEcN3c6UZfDlxHLMDtfy3yy/UV6KrOUtHurNvYxskUdc1i7ivI7S2IZSAXLcFjnsfy7VPZaZcQzbjPFJExIK9cj0OOh5qHR/D98thcPqTxveyxsISTnYT0yfz/ADrM07TdZs4bqRopY1cCMK/Vju7D0A/nTUabXLTklbT18w13aKGuR3EGsQnSwiiN8bQORgZBx9T0rb8IJrM2sy/bHdbcLzkYGMdq1tB0uS3t0lvlAuXGAwT5u349K57xdrmpW2rGCydokTCZCgF8DOT7H3reE5V70oW23M5RUdXqyO+8UarBqzwBm+zBvlQgAAY+6TjIPbPr6V6TY3Umo6XH85jllhGGPVdy5BPvXM2NnZXOnpf31tGbp497tkjccdSB17V1Xh0Brea4XIVjxu5wAO9cWNqxlbljZoqnC2p5pbeEdTbWMz7YxE5bziAQenAP0qPxNIP7U8mOVR5fy7GkCHceOBgk5zW5eeNrdtRktI4nyhYH+AcHHvnv+VYF1oX9ta/HqthPCyeYHZnGGjI7Ed88gV2Q9ope0r6aaE3T0gWtNl0q71JrSO8Se/QcxKpVTgjIBzg+4rq2s47lmiZ3csy8HBACjAP1HTPcGuHj8K2+jeIpLqLU1Jcu0CFNu1m4BLZ7ZrsPCthdWb3NzfymXdzGc54PJz271liFG3PCXpf+kODa0ZtaTALWB05k3AlVc4JbsP0rNuL+T7Wv2WJXjLAZjBBI6HJPPXtVj/hI7MX8NsQfMkJCkHgH8aQoZJXaZUeYriTzEAOfXPfjoK5HGUHeot+5cbPY5a9k1yx8Q2dtpNlANMndGkaOIbecbyx7Y5q54g0O0jha+lguZlRgxSFhz279uaxb661eTV5YbfUPLC3PlC2bnKADJPfLEmu1jsG/s6a3upmk8wbfl4x9DXTKTp8srpem79fMXdC23k22nLdSjbboi7lU7yM4AGe+O59jWJYeLLdtRa25YvJsjYjAQngDt+mataxFY2Ogvp7zfZo5BtRgMkHsffvn6+1chc+D3gjtrtZ47uUbGDKuU2+vfn3pUKVFxcql9XoKUpN2XQ6261G8bU1jiVRBj19vzrSkitLZhOI40ndN3mFgpOewz3rlrWa6Se2FzkIQWeQH7uBwD71H4z0e58R29pFBciFI3JKNkbsgf+PD+tZyjFTjGTsu6NOVte6tTdsdR8/URAwbysHG48ZqloMWsXGrX76nGfswJSPcoyef4fbFX9PhEsasbYW0wBVQzBiO2QR1qhq+o3dt58tvlljf96uST0/hUdB2zSi1JuEUlf5ia5dSvrXhSz1TVfOvXuA/lqr26tsVtuQPm9Mdq8h+LkFvaeI7W0s41jgt7NI1VSTj5nPX8a9f0G4v72TddRuEZcLv5I9s15X8cEWPxZagABvsSbvc73/+tU1XOMvZzle33C6aI5/wHN5OvDMdxMjxMGhg3ZlAw207ecZUH8K1dSMMtyt7qEsKiHcY7ZwN8oJ4DFSOM8de1TfBLRYNb8cxQ3VxPBHDC8xEDFWkwQChYcgEMcmvddR+FXhrUriGSWK4jWIBQiy8Fc9On/1646lnLc7cPXjTg4tHjR8WQasFF5pL3kqcsqgAYxgZGc/r2qzd6P4Y13S4LjRU1G3vzO3nhsMkY29Aucnkcc9OvSvVL/4RaLcWMtvY3t3YSMwZZFVGC44wQACR+NeIeMvDeteBddQySmNAcwXlsjKkvfv39VzWap2+BnSsVGej1Oi8Om28Iai0EsMsmoXCBY5i20wk7WyB3GQQQeD+GaXxP4ke4v4ZdhaY/MqeSFVOT0+bJ6A+lc5L4wkv2gtrzzUQMA8mcnBGOR1wOT+JrWv7C4stGl1SVEnspE3JMzAlScAFc8nPSuaSlzLnR6NP2VnKD1MXxrrkV5c20todlwyBptpzh8AHB98dOwxR4E0i+1DxBbmB2j7M+/HBGNo+oyK5ppZLWdJZYlEgO4K6ggj3zX0B4M0HT5bDS7yD7XPc7Irn7LaqrLGzAMFJAyME9yPeuynTio26HnVcR7zfVdP1Oo1CXRbLQzBd6PHJEsOHLRA7COQDnk8jivIYvibOL8WmjwG2ViY0aQBjyeBjHHp617V/YeqapG0NxFFZQsDuaf52YEk4UDoffJqvp3w18O6XK94dOivNSbBMrglQf4iqZxnGaxUI398yddRVo731MrQBqc2gvd3ySyykhlRUwFJxtBJ5zn07mpNYjvxbyT3MElnaNICZZ5PKEYwMcscn8M10TR3EYSSW5jhsoOViBIz2AAz0ry34m6Xe6vrFtIusStGkZaSOQ744vmIyAPy70/ZyqNRpodOcW3KeiOn8Ca14SS/OmwzwXeoSM0kbMhTzMjIVVI+Ynn/69dNqmrW2TGi2d7NFkeQqKGBH8KnpntjPavEdC+Hl9cSJd2uo23mWsyySeUhEiEAMNpHHoM12XiW50/SbgvdspgUb/L4U45K8Aj5jkc9K1cIx0qysyHF1J3pq50UXiHUgD9taazeblLa3VQEJHcj7xGPx9KzbvStX1SUXFvqBmLoAplMsgIPXJ3j9BgVoafMNfsba/jSSSBlBQQsGXdjGcEbgwwecY444rTXzrWEoF8qJBtUY59+OvfvUSjGCTW41J3dlY4Wz8EX765e37XAjvGg8plZShDjGHVgcZ4H5mrXhe4vvJnt9SRk1O2YpIJW6OG656A8dK6eS/wBts6OG55y3fNWIzDaPqOr3MSpDPbKv7sEm4IPVu2cgDIxxRRk1K0V5FVpNxbmVJlSQh0THmjeIj8zA9wQORUP2RpG3tDMYgpMi5KAHuxJ6UvhvX7O+1KazKCGbb8oZw5yBuI9jjnPer+unbHcQmMvHcxkCNG2l1I5AP+NKtRdCVqmgqVb2itDVnmfxG8Pa34i+yzaIsd/YxRGNorWUFg3UsRxn/wCse1cXd2PjDX7Gy0ptMuJLe3PybYwACeOT0A46Zr2HTm0/QtLaIC7zMDv3YZ0JGNvy4HfGefWs7Ub9vC/h64vtLt7q8jmjHmSOpCxnPQ4zj68enHWmqlGnzKOtmrebZpy1qlk9Ll/TbbTbjxHaabNDILq1UxCTJ2xsgyARnJA9c1ralr9imk3SeG3j1C8iK4S3dWaIn7zlT1IPsccV4le+O/EGqpdi3W382ZPLMsCYlUEj5Q2SxGOOc1W8N6PpjATTXt6t6Yi5FsSrRn8OeO56c1p7Vtpy2SWl767v0REsM3e2rfXoe96cLq3W7k1a4P2Nynl/aHCBWP3snPHPauel8S/8VZJpMVvIrrbvGZFJcOcgg89ABnBrmIvFdtrPh1dL8SXqQ3sFwFi3OAZOoDydsnufb3rsvDOkRLbSMY7GTVUj8kSbizmIjBKt3ABxkYrKpKM5c34LbZJf8EqFJ0k1JHEfGN5ZPC7iaRyVu4dqtgjlGJ5/Kuc+B06wa7qjNGZSbIhUBxn94neu4+OcNtF4HjEEe1vtkZYk5J+Rup79f1rifgXZpf63rNtM5SN9NcFgcEfvI+a6aUoy1exwVU1I9ma6idEuIGTb/EAcKxPFV9Pkjt9RlhklAE6llYNjD98fXrUWleGk0vTZYYr5rqXzNxyACB2GPyrHFzHNqEkUmFcHEJHRh3HPQjpg1ry3clHZFRs15iadb68L7Um1ZpJLR3PlFmzuO7A2jqOCaueBNEvdP1Oe9ugUBiaJRkHf3HTjgDFa63EcdiYpy+dpUSBtrA9OKr6RY21nqsN0l7dZjUq0TEBWB6ZGe3611yrSnTl0v5dvyOfk5WklsWdRu7wz7rbcijptHQ9/pWrp/nyRoWYI2PmBrhfs8ulas0jateSxsQzLAduRnPzc49uM128UqXkHn2zZGcAH9P8A9VZ4qKjFKO3ewU9XrucZrGr3l14iaLzzFHHKY4dnG1lJGT69P1roxf6dcpaNqSWxuW+UGVCcMDg446ZrmhpgufFcty7SwB3JKIDsY565+vPFMXw9qF1rzzTS4tdysrBsZAPT2rplCk7XdrL+kJcy2O11PZFbXLwDzrrYTENpwD29q4zQvFF6l8BdP2JaIHO0Z6ED15rrdZu10m0zvZTnZuQjj3z+HA96padaQalaPLbBBM4AWTALH/PNctOfLBuUbp9S3FNq7IZ9JsXuLrUrGFZLl1B67gpbJPy9ia5/w5JNpQu59RgdLdpMFMFtxOcYHt611mmWFxp0U0plWWYnhz8uOmR9OKpa1OuoRi0SSNjw7bF29/164/WtqVRyTg9Y6akysn5lC/0KTVb2O6+077eQBvm+8ntz9MV1kBSOFYoCsjxjbnPAGOc+oOOg9K4iCbVEvo4omcqmFSAD5Sv9frXa+RHJZZCv54G1VRcEsP4t3c9uf61GJUrRjKWnQIvyIIfsEt6Q0cXnRDzFKNk7c46HkVqLPAX2naMnk9Rj+tc5a6HLbXK3TyOA/wAhI+YjPIGSOeRyBWlDHJGcMihwTxu5Irmq8t7RdzSKdtSSG4spZMRmAXwyWzgORn17/hViCIHfvOIzwM8n/P1rz260Oa38TTXaS74Q+6M5IKdM4Pf6dK7iWRbaIzyqEdyZHToADx+fJ/KnOMItKm73BqdryINb0yzv2330IMkA4Vx/D6+4zWfdaxb6ZHb28cEjFshI4iBx64PYe+KspfWt/hZXJCjBYjt657VHe6RY3kse/wCcr90q+M57e4NWpKDUK17ISi2rxLtq9pcWi3G0IpAYpJlWU98jt+tOBt5G+UAkDDMe+PT0rlbq+1ZNUbTbCxZUjOMkbjKPUseg4q9PbNaahG0OXiLAkCTgeoPPSrlhVu3vt/wSVUewuuXohuo4UZzyGIUEn659enTpTtcfzNJiklaIIDtd5MAhv4fcj1Heqni66fTJoXhS0ZGQZaTO9eOMEHHYVBFpa3fhkRyzzSl3aYSepbkgdhVxiowhN7XFq7pEMOrXGneGbptLa3lBuMARAfuVwecHOOxrxz4gX13qGrW0t+4klFsqhh3G5j/U163p2ywR7YRApPuTcRkbh79+/HWvJ/iNn+3o1MflhYAAMYyNzc0q7XvK3z6hyJK51H7Opx49mwM/6DJ+HzpX01CRycHI/SvmP9ndgnjyct0+wy9s/wASV9NRnC4wOea8yp8RSJ1PYE1T1nSbDXLA2OrQLPaEh9rj7rDow9DVzcGIAB4PftTl6ncTmoGnbU+avH3gaSz1m5jttPviFY+VLDHvSQlQQBjoBWv4t0HUIvh9pkLgPeWnko1pGGIZQOWbufrXrfjeD7Rpz5cwgAM0oGdgByTjuPUe9cL4aQzXZNu7/ZY4xCBLkMzs/PAJAwCGB6VbhzRUuzO+Fe+r0diXwz8GtJurWHUPE73N1eyYdoY28uNf9n1x+NekwqLS2jttNhS1to12rHEgAAA4BJodROY2YeYiptVe4x3/ABplsZXmEUMk6xoSSsqjgAevoeKTk3o9jkbcpOUtWy6tzsiEszCNP9tsDP41QfV5DbyzpsihUMVl4Ykg4AA/DOeeO1VNZ1GO4STS9y+Y7GKQ45X0289c9wa5G9u7PSIYJElkLucJvkAUnOMvuzycYwB+XWphF1JcsUWoJR5pGpr7LJFE8zGeaZvJjLkgDqTkjg/SsfWtNtrrTWu8SWRjUw3CKwdGOQRkkZA75Hp3rVS+jvrZ1eNN6MBIkmCgYY4P59RSsv8AaFhcwRRLLCWMcnlL5LKe23j2Byc12UpypJaWs9yJpS6nCX/ii38O6TJDBFNcyzMHdZpsiQsOGOMZGAMDpXFabpOp+MNaeOeSdof9ZIqIVReeAO3/AOo16fL4ettQilh84GSORcfMpcKBjHTA/D9K6Wyhi06ygS3jEXlKRhcc49fesq8UpuoddGslT9mlqVbLXdL8LyWGiO8h3qoHkjcqg/KMknPat25+z6gjQ29wDdIpBTGdxz6+vNYM19b3F3byS2cE8kZyjlOQe2Pap4tOjW7GpRblkUkFGA2r/h65qG6Uoa3TMXCopXK50y/uH2CF964Lg9UHvmta/tki00aeqm4UxfvWVsbWBB+U+x9Qe9c5rGp3l1bW0FnMZJJSyjyXBJPqSOmB/L8K0I5dSS5s7GVrfz3RTIzSfxcA49zg8fnWaXLCM4vd/kaS5pScZLZGVNpS+H9G1TXw32i6SNpI1k4AU9T7kg45+led6l4603Ubxbmc3Dyxzfuy7MDCgAHB5BBA+7x3wRXsWq3GkSWd3YXUkFzLEha6t4zghT1UN0zk49uteJap8M7q5gfUPDr+ba7iHgmYB4v+BdGHPXg+1aSVSs3UqPTYKdSNNWgtbnceDZoPHM9u0kkaafApSaAZWRpgflJIOQpXHT3HvXo2qeGIntJoVtIZIZVIkMefwypJBriPh34WbRvD/wBjuFDyzv5hlXs5wBjjpgCvQ9FvJYzFBcHk4Tkgjvg5wMZ/pXPOmtYrb+v69LFTqzupHyza6Pq9trlxZW2mu1yjHMbJxg5wAenbiuj8CW+r6V4tga4hEaSrLHLblQ3PltjKkYPIH86978U2sL3MFutsGknzlkxwo7nPXG7j0rx74gefBZC8sNRdnhuvKlWQYkQNxuBJ+6SMZ461NSSlHltrJW/Q66FVy9Fqefz+Fr2GzguJ40P2jBDZzyT0PvW5oviifwnanSntY3ljLufNbJjYkYClT0wc4PGRmiea5vtInsIPM+2wRi5Z2GSdpwVPHJOQQw9DmuLJuL2U3s8rSTFgCzHLMa01ndSen9W/UqSUWuWOv+W/z2LfiDxFqes2QTUL+aVfM3mEt8in1x0zXWfAIb/EmqxiQRu+nMEcjO1vMjwa53VvDzweGTqi2kyRl4/3sjbQQ24cKeeSO/8AWt34ETiDxRqDMpYfYHPB54kjPTv9K6YLlVorY8rFXdT3mepaRp2oabc3C3cjNPIuM9T/ALw/nV1NFSe5+1bg08h3gE8bh1I+vGa6JYorpBJIihB0IbGPrS/uLC5BaRVU4JUH+I5Gcc84zWtTEzqXl3MoqMdEcxqtu88cqxKfOibJB43YBGM+uDxn0rC8NXks981mVPloWwxbJQA8KSfy616Xd6d5uJLZwrldu0jhx/8Aq4rmbPTWt7m7VVbLbgyEFuvXkcZq6WIjGm4sco8zTRRurbR9XlitFu4XuGHySwnI56gHGCRjoa17TSpbFILe2uGW2jO53blnPT8qyb+Gz0KOykgia8likYQ7jtAPfj8as6Z4xlvbeZ/svl7Oc7COD356V0yjOUU6WsfO39f8EwvZ2luamqQhYZZYg/mBDIBnGT1Az2rBiu7pbtVGyWL5VwTtyT1C8cjnrmpE8W29zKqKXaVjgAjGSPep7nxBa6fukZIElVcs3l5Yf5zThTnT9xxu2TzKWtzU1W0s50WK5XllBIznHoKn0uOOGzSC3RI1xgYHT8a5PS9ZttS1E/aJpFn3cBx8rfQ9vWu2ECpbO0TRsFHJRufy7da5a8JQtTZpGSauVryCWe0eM4wx4x1rkPC3hu+svEU1x5gPO4lzxjnqPX6V0OlXk863QldUEY6gHj2H8vxrm4ob51v57O6Zt5Kg8gqd2D9CK6qUZQjKk5JJkXu7pHZaesct1LDBIJXU7S6DoPQfme9TTxpE/wC6Xc6cSODgDJ9Bwfw5rlNEtY7G2luSwRZXzk43vjvz6kVegklabbFLIqcDcW3dc/L74rlnStJtPQ0TvZM3YW82Oc718lBlZScYI6n6UO0QlUFVjO4cFuB6j3JouAywrFGgUHAKdOMcVRa3l2fKfvLyCc44rmTTeppbsUr2S0tppbq/kEMTMQm84Hr065rQkjhvdPEqt5yzAY8vngfX6jr61zmuaPc6nBD9mnhjnhm3ZkBxsPXaB1PT8quveGGRNOhilZcbcjj0Of0rpjTTScH736f15kyctn/X9ehLaaTDHM7sGWNCcxE5Y8Z5xxj2qPVrtrcK6JgKGAPQqPf8MVPrTSRaS7TT+RNKpjjIb7zDsDnrxXO+G7ORVIuZGdZSQomYZJyc8jjkcVagqsfazd7dCedxfKjdnQanpTiCIrPgbox1YcnjjkdO1ZenabqkQdmtGiRzlY8bAoGeTkDJ59O1VpmvrS52YVI4AE3Ennn5QPeqWr6VdXVwNWW9aPJ3fKTvUZ7c4xyOciuulDlXI5WT8rmcr3ulqdbqb6Qi2lnrEsD3r7dqMwBJ/rXMxa3cS64lkbZYdPJ2o46ggcfmKbqEGk+IZ9wnCasVVYmL5Ax2x3+v41bn0uHTUt7i4QT3qRjdsXJZumf/AK9OEKdNWne77/mvIV3J7/cakekwRYm2zTMPuxBvkTJHO3OM+9eK/Gh438VweUOFtFB46ne9euaJq11qV3dS3cBgs7dMjCnPHOPc9a8b+LWopqfiS3njiMa/ZEXBGCfmc5/WuCpTnGb5tbGnNdWNr9ng48ey/wDXlJ/6ElfTWABjPB4zXzL+zsT/AMJ/Jj/nyk/9CSvpuLGFyDurjqfENDlGD3IzUowDwcVC7uLlEH+r2MWGO+Rj+tTDnHOB0qARyfxUu5dP8E3t3byiOSLDLn+I5xt/HNeW/DXVrOVYXE4+1yhFEWw8bGPBA6k5HPHavSviraHWfD40SFkWS5YPI7NtCKoyOfUkCuT+Gllo+g3lrpy6lptxOrNNM6ShiWK4wD7YH+FONTkT1tc7YRvSV1fc9UkzEpjaJml4dmJAVM+nr9K57WtbIH2XTpGdyWRyp4J9/wDPSqfjzxLcwTW0OjWwvBNlHZWwF+pz/Oua1Pw9rmp2UFtE72l9vDHEeI8HP8XfGc0o3lrYVOmlrNnm+sfEbWLe6mh0zy7WBJCEcDLkA4yM9Kv23jZdXsIJ9WAfUYH2hY4ywuAV67R/F1J7fTNauveD/Ch1gWj6tPJdu2HijARA3fAwTgnpyK57WPCDaJ4j0d9KuC9sZFV2U8xtnJ69ciqpyi5J03r3OifNb3o6f12PQfC/i3StTtryyt7a6j1DBaTchG3k556gD1PPIrpbS2+y6fMljamY7MeZuGSp52sc9zx0rF8G+EIdM1K41WWUzXt18yJEVMexuMH2PH5VV8cXOp2un3E0dtMFRztWMlF2k/LnHUn8RWl5L7Vzn5YSlyxRteFkuI53muIpEiQ7n34AQYIYKOp5OMe1a1xZPdWcX2fIR+QO4B9c968o8M6d478TyoUintrEHJeZPKT8C3zHj0zXuFlpVwLZFuzskCqoRHyvAAPP60V5VKkrzSX9dSUoUfhlcwLaxe2gKug34K5zyPQ5rM8YNLbeGruKKRI5miLsSpYRr0zx35z+tdk/hm0kuFmPmEqeGZs8/Sq+p+B9J1aSGS+a8aSMY+SRQCCMHIwc8EisGuZWb/Mca8VLmPmhfHGoWaW409kRUVSIgmVBHOB3xzXquma6t5oYn177XFcTBJ2+zKpMaAEHO7GO54yfpmtWL4UWuja1Ld6Nbw3UMob5biXa8OR0XKkHnvkGuA+L1rr+jNavPbstsSVa4VfnOQOGYHaR3z69a2UaSXKle5o60qr5ua1j0TQtHs7PV/tNvG9w1yGx5mNoDctgHjkH371tFrjT2dbexSSAxgQGJ925TzgIP48Y+tfPFj43vLTVrGa28+S1h+SWOR8mZOMq3bjHGOlezDxTZSaZDc2l5CrtIBJbXbMm1SBwF7nj346VHLObSm/LUU1GN3E29TvfIFs2+SN5G27ACCOB2x1GR1p1rZEeXcO88YiJ5ZhufvyPzOfemXWmrezxeW0i28hV4wcbgcA9xnuPyq/aHEFwsiyPe7TEpcFuex3dh9KSXKvMzb0RneKNZ8vTJ4/tCQOULgL1Khgu1TjqSQOPWvLtHvbo+K4NM1G3dDe5V1YFlTI4B55AwBz064rt/iLZR3NtabJEje3miDF+h9Af+BbR/wDqrgdDlS9+JtikUXlWkfmgAtndtQnBA6fMB0rCEIuXN6/gv6/4B305ONOyPRNI8H6fY313cQJ5nnrt2u27YPQeg9q5uX4LC8vftWnamltFu3GFoicHOcDkYr0y0tEkJW3uWSTqwddyn1x3roLCzNoOXBbGDjoa0hePvNnHUrtaJnj/AMW9Dn0n4W363MyzYuoBGeSyrk8E+g7V5h8FGmXxdP5DFSbRwxHYbk/rivcf2g8f8KwvlCnieA5xx96vF/gRj/hKtQLMFA09yS2MY82LOa3pP3Wcs5ucuaR67qerTRaPcSWojkkjGCkgJXjGSfwo0u9TU4JJHicurDzGhJOGKj5k45Ht1FbAS2iVhtXYPmZfvbieCcVGl5ZW8hlWRAtucNGpGFOc844rZNqHKoheN73NPS5bq2BFy0rREgDdEcgYAz15PqKd4hhmk02a7sipeNN2OhGMnr2FeeeIJNUj1Ge5t728GZS0OxmKlP4QAOPaurS3ivLUy3VuguGXf5jjHzBRn8N2fw7UnRdNqTd7jvfXYydOu4PEcZtrxlt5FOUlRgwOeNpB4q+uk2GlWk9u7lmkXEkg4CA59fU1zk9vcJ4lFrYQyJBldrw5POBkn2z+gro9f01dRtnt45FjnYA7umW9D7cmutppxSlaL1t2M31OTsPClxLK1wuoWz6bnKSIxJUD27HFXhLoWuXVxZWd2v2xVIDMpAJGOnqP8a0NC0M6Lpd0mpzJ5cyHzIozkIgBHB7nHtXNeDbPRoPEcn2J5pJI8iFZVAOO+SO+DXW6jqKc7t8u1tjJRs0tCjJaSeGNWiNyI7gMPlCOzdsZJPfrXRX3iWXRbeykt7Yu1zH5haQkbRuwOB1z35rqJpEuU3TWsLgkhDInHHqe1PNtFeRobiG3mVR8sZjDBfQDPTpXNPFQnZ1I3tuaqnbQi0GdNS0j7WJGiNyuVWT+Bgex7jI/Kp1tcSFhCgfgHc20EZ747dD+FYN3JdLO8cKvCM/KqJgbR2GO3tXUaK88lqPtCgsRySO/b6/WuevBx9++4RdtDE17SpL94vK8oqqYKEcfXHWrdpCuj2KCVvnd/lCjvjt+VXdb1KPTbcyM4R2YKuFLGsy1vxqJgmtkKxpGWkM2cZyQP0BqXOcqST+EqKXMSR37zybGlWBwdwCYbcOOCe3Wud8ZXFxbWVsYvOkJ6/OVJI9R7E1oPpEk+rLceZtClTyOn09jWlrTWE0UiuqyBD/GmRnHJ9Rj+tdFGMKU4uPvdyJyck09DN0LXYl0ayeRv3hYqSG3fTnv36Vn+Kv7Qlu2mhneKMLvjCNtXtwT175x+VPtpobNo4/s++IEBmBDMmemV/hAH0NVPErXupatBBbho4EA2gdBkfePbjt6fhW8YqNbmSstdybc0bbl3+zrjV9G026/18kBlidWchS24YfnOeKpXWl3Om6asBhKoHycgFdu09Dk85/z0rqrH7Xa2SgHZ8mAAMjjH6/55q/Eyy+ZFJC+WPyhjx06nmuZYyUJcvS5bp6HKWNrqM8Vh5rBI41wXlPJGeD7nH41e1q6tNKs4llaNY8lcYyDk9OnIqfWfE2k2N3FbzTtHtzHujUkBuh5HQ81l+M9B/tjS4ZFmERjO5S3QqcZB9+Otar97OPtlyxZnflXuFK0urARHULO0hkVDxInZumD6Va0TVE124l+QKQWyynPPXPTjrU3hHR4NKtXWWUTPORuwnyKBnAwOp96t6tPZaDa/wCgwxC4cZ2t8qqD1Y1M3BydOF2+jLTatKRFJKLQfY3YbW5JA657V4h8WbOKy8Swi3yEktVkwe2Xcf0r12CWbU5Al3FB5q5KNDxj/ZIyea8v+NkLQ+J7FWBH+gIcHr/rJKwm3H3XuU7NXL37O4z49lGM5sZP/Qkr6cXAwDj8TzXzD+z2+zx3MQjSH7BMdijJblTgflX0vp93Bd2iTW0gaJuPdW7qR2YHgiuOp8QkTx7jNNuxwVA7cYz/ADLVI7qgy7BeepOKhmYRfvvMRQB8/mNgEc9+2Cf1ryr4peIb3U9CuF0OWCC3gO6S4E4bcvIIAA4PSs2m1oa0qftJWJPEniCDWdc1aw0jIM6fYEvwzALKV2lQOnXIz15OK8N8NadC+s2n26aNE84L5IJV2x26YAPTJPrXU/DrV9Niv9Ngnlfe7lCD0RieGHbnPU11nxL8CSXcEep6JbM99Ef3scLbg65JyvPVSenoe+KqF07Hc1BJI674fW8M0TR3KyPhwu2QEkZzjcfXGK9CMFrZwTfZlWOTyyoYDJAxxXnvwfTUpdKeTWGmZsZiEgweD+v/ANavQYjzwD2zkU5PWy0OSrfmab2PKvDXwzlg1WLVNSkNxMpL7MfKGOeffrXT6x4IjudM2WTNHMh3jc2S3r+ld0g3IMce+KjupBbwvL6Dp0ApKbi7oU686j1MTw5o8mlaHBBO8V1fRBmUZ4Uk52gn60mlW3n6rFdTvunhRpNp/hJO0fiMn864zx9reqQTwW2gIJrqQnDIdxU9sCug8F+GtZs7o6j4i1BZ7t0wIIs7UzgnPvx0HFLmnOTm9tf6SKdNU4avVnaAc8kknuTSsCce3Q04daafc80jmuNOQRjoeTinKckCk78dqVevNACnvu6e3JptxDFcwSQXMUc0Mg2yRuuVYehFPxkcijjGD0oBHB6h8KvDb2N1HpdsbKeQZQhyyBs5HBzgZ9MV5T8So5tD0640rWLPfO6KbadOVADfeY9iM446/pX0kpB4zWN4r8PWviPTvs1zFG8iZ8veCFIOAynHODgcjkEAjpQ5NvVnTRr8rtLY8n8AeOETQNOinspLmWGDy5pyo2hQSAfUnBGfzr0LVZbiJftVgkKXBRdqkkKcgjn07fTFc4ND0TQYLeOK0McW0Foi/ClWI5Y5J5X0HasT4geOZrSK3fR4cSs/zbhv2gHkfy9OKmtJJXje7f8AX6nTTp+0kkkX7+K21awuo7gmWWcgSpu3K5yemOSBkY47V5LFq02geJ7ya7KyXNluSPPO5nIHzepC5/GorLxvq9tcPNHBC8Kt+8RYyAF9D+vNP8VPZ6nq1vqpiwtyiO8P3V6Bd2R3GDn86zjGUWlJb/1+R2JaPke35f8AAZ7n8OPEtp4h07zo1VLuMATR5Pyn1HtXeR3kZQK5xk7emRmvnf4U201nr17NFJ5WnNGY0LKQWYHP16A/nXq0UMjySiOeVD98AD+L157VrNOOxwVacXJ9Cp+0Dz8L9Q6f66A8f74rwv4L3C2/ii63qzeZZtGCvbLpz+n61678YhOvwq1L7QxZzLDx6fvBzXj/AMGV/wCKx8wAlooGkGPUMtdWGXc4ai5XY9q8iQS7WO0EcljjjPQ4p8OgxusshZo7eZvnXqH9PpWzcRglAQzMoCu7cAZHAH+NYQa6l8akNbXT20cGPMLERKeOMEc5+vFdUasp3adrK4cqVlY2RbeYiwQxmOJMBi2eAD29eajurNiqgYVSQHyTj6gdM4/Kte3jb5mO0MTkYziufjtdSGrTzSFRajOM87s9gPx/SsKet3e1vxKd9CzpkdugwkweR3PzY9uBn6ioorqYao6mOIouB5hXax9ccciq13p0sN1DNZPzkb8qAD6HAGKL7XILO+WP7FLLKo3M27aFH4g5OMce9dEYczfLrdfcZydtynrZvTdsUyIiepGMdqrPpy6ZpM+p6Vbbr7p6quepCn/PNSeMQ0r2csJM1u8YYAdWOe/boRU/hSWciSR90EfVAAB5i/l17cV0uTjRjJdN138iFu0J4L1O9vdLvJ9XQxwR4wxAUEd/wrR0HU7a7mla2lV0RzkYzjBqbWYYb6ykiFxL5ZIy3m8ocgjKn+lVvDuk29vM0UM5kGDucuBk9QMduuR1+tcdSpCcZStZvp0RrGLXXQ25LyzBy4Y5+YYG7+nFSWkvmSBhkKMqR93H444/Oi7tJo0XZIF+bBbdz3/zmmWoKSKSNu3cAwGCD14HfPrXI7W0KRkeN5bW1tJbq8V5VtyGCR4JIJwOeneqPha5tr7SYLmCFxESySLIByfbHBA4/X0qvPqWoS67Np90YZLNywMYiwV54yc+vt+VdDEYEV/s2EiA5QcKMDnHbniumS5IqD1e+/QSbtco6hHdSWsy2bkzjGC3A2+g9cVjpZ3SWuybcxYk/P1AI6jpmrer3t0t3aW8Ttb+Y+Bk8dBj+db0kKPsF0+88AleOa6I1JU4R7PUyaTbuc9aaW6QgrFGiyN5jFQcsfxp+q30OlTW8kkiCSYkBJByzAHJH9eO1bWs3tvp9ikk0yKRyGzgAdvrXI3NkNUuUa7maQmKQqzg5TB9BjIIPUEH+VYxTnP2lTY257rlidPDOb5YLmFxHCQQwzjbjrz07iqN14ltYh5drdRzXAYBUbkDPGTj6YqGAWaaOdKlFzPEyBPNTAzx7msqx8MM17GYibj7O25STtboR8w/Hqc9KuNOm7ylpbYnW9kbAh0201JoUhWaR282QP8ANtb2PQDJ71l33iiJL1rWYBk3lSoI4A/rT9Z1i3j1SFIIJJrwkK7qPl38Dj3qC68PWkl4Lm9nMCEBnDEYLHpyenfitqSjF3rJ6oiWq916I6+yW3eCNQw8s8qgIyfeuXurpNS1gWyR72dzEWB3DIBwPoAK2LG2L6nHJFL+5VfkBHXitLw/4dtNLk86MF5RkKT2zjJ+vA5rDnhSvJ6toer6kmjaHaaRCVt4ljLcnaOM9TXhn7Qox40sv+wen/oySvojYEaRlJ+Y5I96+d/2hf8AkdLLt/xL0/8ARklcMZOU7yKk7ifs74/4WA2c/wDHnL+HK19Ba1r1rp19ZwyRtcXMisUCkfIBjOT29K+ZfhDdNaeLwybtz28iBVGS2ccV7tp9vHPi6jMciqASVHBGcn5h39qKkbyNKcE1dl3WvtetQMskkUCKwaOF1JQjn7x7n+XpXmN/ol1Y6PPaXiwrJcPltzFgT1AHtjHvnFb93Fqlnfy3EaXDKzEmTc2xxkjcGGfbC9PauG8cazeXNyFF8sLwwYmUYLSfNlRhT9Pcd+9d0r0afJFppjornnzPSxgp4b1NtctILHTZ4LgSLi4CsUQ5zuPXGO49q9x1PxNdWusRadE0Et2V8yc26nbFkfxE/dJ6496wvCes6s9laTQXUUektApK7lHz4w2Qeh3Zzz24roP7JnDyXmQ89yWkZwoTzFxg9OOnH0FcM6d1Hm/P+rHSppycvu0/q51nh+f7RbLG7HeuMt/hW3HgNsweB1PevPNP1X7HerCzv5nACbhj73p1z69uld5ZXLbMy5PHYZxUSSi7I55xluy/gRKzFjnFctr11dXEsdrbTAE8nA5/+tWld6gJFLorGMA+lN8L2ym1a+cBnuG3IveNBwB9TyfxqFaW4K9NczJ9F0uO0iWR1DXDAFmblifXNafXpzzzSjqOMD+VGQDnj/Pem3cxbb1YHAJFLkc4pgG4HjApxA78UyQ7+lLnnFA57H8ab83pSAf644NA/wA5oX8z3xTecgKeT2FMB2cdsUuSAcdaaw9skdqUDjv9KkZ5J8dNUPh1be7t4i4u0KMvYPk5b2JBrxbSm1fW9SgeR3aAyKvlHIDLnpx7V9C/GDTV1zRl0kKiSOolFzIRtiCnjI9yMe1c14Q0P7LcwXEk0VxIo/1UQK7MDAPOCRmphGNnKSv/AJeXY9WjVcYKzt/n5nnXh/4XeINQ1O8gvQmnwwMyPcyvwSD2A5b/AArpvE/gh7qbTdOh2OsEKQh2UqXwMFyf15rKu9Z1nULu71C11e5s47JnXdIRuZkP3iOgGWAx05I9jn+Ktf1e38X3TasJXWS33wxt93aygiRRxx1+n4VMpzmlok1r+H6/gdEIOEviunp/Xp3PT/BWhjS9Ia0u9kzRSNjenIU4wOfyzWvBPaRMZLJVjI+8v8Ljkce+a8h8J+N54r+K2cStBKoVoc5UDjBBzkEdfpn6V1134jW104yTvGZJUIidWBLoTnOBkcEda6Ytcl6hx1acnU9zUf8AGLV2l+Hl5bzeYJZJIlKFAu3Dg/0ry/4N3b2XiuaSOATg2rqy5OQCycj3ziut+Jd5d6h4HS5aMwQSlZR54xJKm8KGX2yPbjFYXwBt/tHjO6TcExYSHJ/30q6UlZtrqcleHJJLyPfICHiaTo2SB8xyABwPQ+tXreBIvmVuWwT0A/CsbWL620qBIlMSyNwHwCc9+O1ZuneJCt3Et5JgnhVZcbvTb/jWnsJyjzmXOr2R1V83kMXyACB35FYt7qKRXAVpGyEz5eep9fw5FPvrpJrNpGcIzAHb/ED9KwopfP8AJ+0tJJOvIAUcgnhc9jSpJX94vlbVzqYIpLmYAkIgy7uf41zwPpXP6toMF/qhuZJtyjP7sgDkgBucZ5FbfnE2jxwbUcjaVyWI4zjPTIz+NcXZWlxb6sjwN5SiQtMXPOD/AArjrn/a+tbYVNKU1KzsZzeux1MVqJFjhVYiiIR8y5AXIAx6dKx/ElxqltcaRa6dEDDLK0LyvyFJ6DgcdOorY+0l5CgLIwIwu4DPHt7jt7VJLMLRZXEczxjB2Lgkcc8nj0HrUU5tSvJX8vwLkk9CvdW12NIMcqQm4aQFiv3V/GpILRbYI8j75MBGwDguByfTHQc068L39rKLZjCxGYiPmKN3z6n6+lL4at9RSOeHVZkuQJAIpFUAsuAcnHTnIpSd4Xv8gV1saf2jy0KhCcDIweMdgO/TA4puszLY6ZcXbyDKqMFSflYmrd/OVVETeEUbeF6n6+lcB471SaaC0srMMC7mVmC5yV4A9Op/SlRpe0krkN9jY00T3C/vZA0cvzJKU25fdnGf5VLqUU6WMpVn8yM5wSSD2/T1rlbXUbvR/DcEdwX23EjKyIMKuO+BkjPbA7V0XhW/bU4jcSGYEZQrL345wfStvZOH71aq5Tlf3WYtnqdyuowfbsXtuzbPLkwzxuTwVcD2PB49x1robk3pvn2wGKBNpVy3MmeowOmP1rlPFPiZ9F8Sx2NvZQCYFSzeWCct0+lal3rt3cWhCkq7ZwdoIzjoK6JJ3jJKyZktb2HeItOh1C6juYmM10qYUFz8nAHA6DpV/RLImxRZwdyBlDtzt4w3HfPSuaht9p38mQhfmB+bePX0rq5tSi07To7i7ysZbyywxjJ//VU1YysoR1Ki+VanK3cl7ZXUpBQwJKIxEpGMFiMMeoJH165qzpuuLBdyy+U6yJmNox95fz69qvWDadrCz3rNmOJwGYuVyV6dD0+vrTbltMghWSLayR/Mzk5wB3J/A1u3GT9nKOpCel76GZ4e8qTUJLiezKzbmXc3TJP3lHoc1B42tZpmtXQgxRgggx7wXJ568cjGPoau2ms2stzGroYsfNxyCueCMc//AFzVHz7281xUfe1mWbG37uO2eOCKS5va3lpZFK3KranSeALGVdMjF05kbczZYc44GPTqCfxrsZMhflOMe1Z3h+IQWgQdMkgVok9ycV5VafPNsb00Ek5Q7T9K+df2hf8AkdLL/sHp/wCjJK+ieFjx2HSvnb9obnxpZf8AYPT/ANGS1nT+IbMP4RXtrY+NbaS8cxo8bxKwGcMwwM17d4j1jVNHksm0i3WVHkzNGibt2CAoI6gHn/GvAfh/YNqXii2t4i3mkFk2qDlhyPoPftX1F4W8PwaaEuLmb7VfhQpmfnYBztX0GTXReELTevkNXtYuWeixTWsf9qIJJGQfu9mFjHXbjv8AU5rO8Q/D7w7rhVprIwTbQDLbEISB2IwR+ldaCM8kH696UDMgAO3jqK541ZR2Y7szdC0Cw0LS47KwhxCpOWk+dnY92Peqerab9lja7tyWWIEtGB1XHOPyrYuJJY2iENs0wZwHYOqhBkc88n6Cri4fABHzYFS5tu7GpWPP7PTbPVd2rRkRAhljn6FxwQ3t/wDWq1a311bW0aqisADh3+UMBk5qt4VZrXwFaW7RILqCae0LHn5lc5P49fanwiaaEieNWRFLgLgE8dOv4fhSqJ3t0R1Qd9zJtZ5ofESwTTG5a4zPKgiYmFORkt0wD69c16P4fAGkw7TGVJPKHI61w194Uur+0tLgSiK8VcSsVLIy+jkenP8AP0rq/BwWDS5LQSLJLBIfMZTxljnI9v8ACt6ns/ZrlevY5puUm+xunPPHFAHXA9uKQHPHBozznPHWuczF4GMDP60iZOdwGPfkil6c9KYxDKcZ+lAD1Y4BZTye1OBBxTQflGaaVGVb+L60APz19qFYhfmCg98Gmr93Oc0meM5JPoBn9KAJB16f/WqvfXkVjbvNO+EX2z+QFSqGIGMgHpmvIPjJrOsSGbTdNhaOwgQtPfI/KELlhgdOCPzNZ1JNKy3OjD0vazs9hfiD4muomsjDChk1VXEEspHlJHGc/iT+HWsrwHrsD6s1jfLCskf3fsysFkU9j+I7evFeTTa3fRaZZ2099LPBB81qN3+pUk5A+uTx71698PfCk9rPLqF95ZluIkYJjsQf1z/KrhSmlJXsv6t+H6nfL2UYq+/6GVr3hlvEUk0Gg3DWvnSs80L/AOrkBYbnyehGBnHXj0rH8bXcV/rD2NzYXFo9khtxLjcTtBCkoQMA+meO3pXpNwLDw/do0csitkjbs3tt3cj6c8jrzWlqvhvRvEmoR6jqSTSM0Q5SYp5gH3GIAz09+lXVw8YqPL8Ouvn+vkRQxlpNz3PG08OT+Gr2C78SSrYWMiK0U1uvmmTcCVK47ccg8/SrR04ajpMpeSF7bcfKuYGO1BgnHTgnHIPIzXp3i/SrLXtHi0x3814NrwhGH7oL8oUnuME1H4N8D22hWU6GWfUEuVZbm3DbYzn+Lbnkjp7c0qcvilfTov66+uhU6ycU5bnk2p3kkvhHxHAXkubWK2s1iMrb/sz+au5FP58Cm/s/zLB42uWYgA2MgyTjHzpXb/EPQ4ND+GWuJZ2BtoZpojtfl1IlUBiSc8gcexrgPgWobxs+SOLSQ4xnPK1urctl/Wh51aXPO569NoVldSz4v2uU3bpP3gYxHnj2rmdPFvd65gtIw8z91vxzjp9B3xXQeHPCEeg69c3cV1NOsiMrRlBhckH5jnBI/Cl0/QreDU5ZLd3ZQ5fbkBFDevIz16V31a8bSXNfTToZ0YtWvZF3T7mz1KRktriFpIcCQptLKRnr3xxWB4nku4vMhsdwMcgwQO3XPNb1joGmaKk8unF3ndipYtzGvXaPQc96j1e9060nX7XbrJ5ShjKwHJx1/XuK5adSFOpzQ1Rs1KcbMfpEN1a6FLd32R+7L/NjA+nfOc1w1jHqGs6qlzEJ5IBJlpE5Unuc+uK6G98WQana3GniLZA8ZXDONxU5ywI4yOtGi6RFp+iXsel3MvnXA3CTIVgQOAAen19674VJ0oNzVpSfysc3KpPTZHSeRGrsWU8Lsy+Djpx+lN1CVTbRxR3LqU5EnB575/Q1hWV1cadYk6nO88rYZIWBeROOhxzn88Ctvw6ttqtv5tqBIDlSDxgjsRXGoezXNLVdzWTuy/bRpDallJd2YtjOBubk/h1ra0qPbpobku4yM8H0qJdNg3BsAkEMDt5HXOO3fvVuSdLe3ySAAOgrlk+Z6CbM27uHEMkcqrvXJAwSFx09K5XUbdnMEjNhUTG4DdjJ6/rXTC5tr+UorxswPAfjPSqO9ZzIkL5UKQYx2K9ce/NXFSiylKKKFtprXdw6Xscclkp+UleBg54989/1q9CbSxk22qHk8YUBQc5Iz1z9amN4Fk+zxxykKMK6gHr0OM5/HFZs6ROY3kX7gyRnliOPz4rRN25fwJbu7nIeLNOuX8RyXSxySXD4G4AfKO2c9MdBRpE0NhciG8llb5Cq5wyBiec46Z/pXQX2mXt6v2n51bduI6FhgY/CuZl0K5g1R3aKRfOBIAOQO/8AjXpU3GcOWbWxDuvhNR9Xgsbhhc2rEqcMY1BK46k57VJc6pb3jyJEkVxaSiMxwSZUh/b04yQec9KvTaFFckTS79zDBKEg9Bnn3x+lJa6RBbefEGdiYwMy/wALDlcDp1yfzrNVaWj6g4O++hm3960EKx2cEdvatzhVJy3fJPOc1s6Rpf2/wzqSyKyyzKyBtvPTAxUkdjAFBLrtjQkkjBPcn+tQf26lvHJ5Ep+U5SPd97jnP8/pUucprlprXuJpJas5TRNKvINa2NEWt0Y7lWIAuASA2cfTP/1q660tTHDKxh4aTcik4OPXP+elW/DmtSao8u5iHXqQOD/nFUNb8Qw6XepBMXVmBAX+Jsf3Rj3pYiVWpU5WtRxkkjd0K53TSxnK4IYZPTjkfmK3SARXCW2pE3UN1Ao8soAV28shGeT6g/yrt7aYTQo4OQy5rz6kbalSVhxPyHFfO37Q3PjSx6/8g9P/AEZJX0SThSCOa+df2hf+R0ss9f7PT/0ZJWdP4iWVPgMqt8QoMgEi3mIz2O2vpyEcZAA7GvmP4CDPxFt+SP8AR5un+73r6hXGF/X2pVfiKWxIinbx+dSHgDnjtzTVp4HOcdqm4IUZJ4yefypyqVwePTihcY561ma3qQs4HjhYfa2A2gjhQSBu/DNLfQpK7MHT7pJLnxXBFtH2bUy4b03DLDPbnNRRXpDzs7I8QGVySE3emcDI6dM+lQ6Js0i91WwuU4nmFwJ2feZScDJ9Vzn6e/WsP4x+IX8MeHo4bd4Df3L+Wo3BtqgElyBwOW49aUpwT5OvRHUoSvd7dzpYLuNoIbQq08ix4jV/us2M5+pP6VV8PX2o2eoTzXVrHFDJ/rUTIIxwOOfbvXivhL4gXum6np32oG4JxCZmlctsPHAzjOD6dhxXqcXiPGo7WkAhyFUkZ3AnBIPY5zXTRUpJxcf68iK0Yx2Z6ja3KXtss1syspGRkH9asdvwwK8u1fxLdaNaX+o2NuWWNDIVZgAdq5zj6YrifCnxu1U3kn9uW9rNA7Z+QMhRcHp19qwnGSei0IVJy0W59EdOAOnvTSoyCc8HOAa4PwP8T9G8VXctmqyWd7Hk7JOVdR/EG6fnXdRopPmxuSjf3W3K3uP/AK1QpdOpnKDjuPAAxn/GgKFIzkk+oqvqF7Bp9sZrtwidBgZJPoB61gzeNdIjICyMXY7VVvlLGk5pbscaU5/Cjp1OMAdKbI6KCZHVfcnFcL4o8cnS9NhnhtN7TyeXH84C5wScnvjHQV5Lqvi3W9XW3aGWbyku/nBP3gQPlH5n8qrlnL4UawoX+J2PafGXjK30PQ7m6tg07rG3lsBhQR796+VtT8Qapqep3NzcXU6yTMS6FzznsR0PHFfROteTqHhDybsFknjQQuekvQkHv1A5964TXvh1bXHmXy3Jtg+GcFPlGTztAHr0HpRCC5uaS3OmCUY8qdjmtF8KWmpaNb6lcamJJlVWFpFHk4UgEZPXCj0/OvTfBupXxnkjV5GhMeJFxlY8KSuDzjoAPxzWNo+inStKUJdxmzRTvLrsPB+8P09KgsviRp11eT2kEV1Cz/L5m/Ktj+I8Z4rulWhCDpRXM3+H4GEqcqkuduy/M9JvY7a4gF3qIWXZEGUkZ3njPy9x6564FTNEl9axAh1jcJGHX92Dx6D0zmuH0+GW3mWS71K6NmnyQxSJvYE4YgE9M4PHp3rtbHUrU2EaXAkmdwWCMMhhn9MVxPa0tfvNJQ5bOJzekeGLTR9VmlGo3l5d7CNs2SpUk5/D1rTh8RxG9WztoTI7puV+RtHrk/hnHpmsvxlr0elaG8iG0gd2Ii8xmJb8FHT3zXgUfinUV1g6g8zNITkqpIXHTAHp2ohJ1HpsvT9AmrK9Tqe7fG3WIJ/h9d26vGJZFiPlr7SIf6V5P8E7kWvi+WUvsxaPg+vzLxWHf38+r6ZdzEbUhKsw3ZxlgP5103wBtYbvx26XKhkWzkcA9MgrXQqfso+upxzacl2PcLd7i+YwRQj7OuMuwIznnBzx/j7Vn+KbyXTUWKOSJbVlO5mXBDZPHbgAfpXdhViiIijDAA4QcZ9q898Zxxain2eFiJowUx95h6//AK6ILnfvGkJq+iM6y1SaRfMYrcMSu/zW2IDyOmOfWr76RbX1t/pByZchGCnC5/r+Nc5f2o03SY5fKkkjGVfBPAxgfXnJqfT5bqz8L3k6GSFmiUBN+SSOGbPbJPYe9bUMJJpST62LrVlF2iXtE8N2+nTSzSBXCH92zjcpJGBwRz71Z0a38RPq9s08dhJZFiZHjCnjvjgHPTFReDWuZdDurqVSXbJjRz0H/wCsnHfiobPXLtDJHIq23X95jlj02jJ+tdzjUnzx0fTX9DjbWjaNPxjp63difJjKSIxDTIdrLweAQc9DWd4Ukl0Wzur1szscu+ck8Dtz14qs2vXT6gIJrh2uPMKMkZIQkdMg8cj+fWuhhjSQ7LYjay7duSAepz056YrGonSpqFTY0i+dspaV431LVLrZBYReQCdzDJKe2eh/A07V9VNx9qs3maOSYbI3aTYNxHY9Ryadqj2ui2yXF3LIluDjOQSfoACWqPUtNtNes4tSsZFwFLKyjAb2YHkHjFJxp8ymlaL2fmSrL3U9TM0K4mhlMaMZFdf3YZiZEcEKQTk575+ldHd3Z03ULe4xEMkgkKQZABzjJ9CfriqV9qll4fsY7u9UxsqJH+7Ub5WI6+3HvVbT9Tt9WtDfrL+5Mgi2zADa2Mjn+VNKVVe0a93b1/r+tRSai+VHTTtbrIiXNzDFlQVJHOzqOQeOMCq8uoWOobRbOxKthWyArH6/j3rhvE3hvUr6VWtpTIsQV3VTlumcAHgjNaWm6edHgMeqXUUc8zgszMSYwcY6DA47UfVqUYKald9g5p312OqtrgqwU7mkxxGhzk++egqC5/0h8xSbVXliOBitJ7V4LkkAsu1Rl+d6+3ryKoyKiQbTKcE4Abjnt9MnP4CuVTv7yNLdBzTi3t98nKLyMVk6lqf2iyE9ggkycMTyPbP4960EiN7ZNBKRnGM5zz0/pSaJY22miRTJvLYB449MfrW9J04R53qzOd27GJomqy3UskVwixoFBLY4ViPu+45/Srem6bZwyTqsnmicBQTz8oGMD8qq+I7BvPDZaJmOFVfTqTn1/wAKh8JWNy12SWkMUZI5OAeP8/jXRPllB1IO1+gRi46M6q0jt9NsykSlGZjkBSSOcAVzfiPw/baxdQzTSyRvEx27TgjOCe3SulntVmuE2zAshIYgklSTj8R7068SAPGqBlZFO0525A6jP+ehrhjVlGXNfUvQoLaQ26rAZBGw4ADdPQH9KVtbttIkSOaTbG4Bx/dz3+lY51dxqE6W0JlhC7l45Z+4xnIFZPimwtbqCKXUxKLpUBKRDgN6jP5VvCglJKq9GTKTktD1GC4jubYPGwYEcHOc18+ftCDb4zsh2/s9Mf8AfySu38F6pdQzvbiFvsvVOfXrgelcH8e5PM8XWLf9Q9Bz/wBdJKwq4d0KtmSndEPwFJHxEt8dTbzf+g19ORkBuQFz37nvXzB8CM/8LFtACATDMOf9w19PxblADMMnnArlq/EWtiyrHjmpR8qcBm9h1qJccc5NQ6hf2um2rXF7MsMQ/ib+QHesxpXLVxcR29u807BI0G4k9hXn41n+1L+eYlMg8xEfcXgDHGc4z+Nc34r17xFrmtxwac1uuhMwzGpG84P8Z6+/HH1xmti20wW901vGitu2yO0eWDY4+9+FbU4qN+da9Df2bSTTN7XdPTWLBDIqRxKuVabkpg9Txj868U1rSdI1tvLstRtDco6+fsKgE/d+QDAPTtmvZ9fhv9Q8HeJLKxWVZ/smbUuRkg8OvHcgHH1r5ZXTL25uo7SK0m89nCiPy2yCTjn0opQm5Xj0+f8AX+ZpGrGMGmereBvhvb2uoRatd30dzbRNvhVAVywP8Wa7NPCiC/lvI3t57XG4F5CwjJ7AdB+dJHpep6X4dtLTUEaW5iUEynjJXOCSTjAP51q6RKj6QJmljeRATMY2Gwt07dPSt7ztzJ+Rk3GLsthsqS26PHeaVHPAE2kIQwdCCCM9MdeteKa94EtLG9ZoL5/sztmOEgGQA9BwT29Aa9o0PVZ9RvryKeM/ZowcSY2bSDkKPUYyfqPeuO8V+A4bu4N3Ym1jUp8oZ9+Wzxk89vSsZQnSna/6/wDDG1KVOqveRx3h680Lw/4jhb7BPLNb/wCsUE7ixGCpDEgY7ng/TFereFvFmg+JddWx06bUtN1B1IVC4RJQBnGQSpbr1APHWvDJ9A1zTL1riWzaQOzEtERIDk5J4zXS+BtElm8dWl9cKIrRH8w7jz06gDnvUcrc7ylp8rfcbVIRdK8Y6o9f8a6Zrg8Pzp4XlaTVImLSI7oxaLnJTPIbpx0647V83WdtrKaszNa3Et0uS6Todx55znvX0F9vuhrEVwjCOJJTgK3J5wATjnvxnBrb8XSGRxMimdWTCtF84zjGAR+PFWqTg1oryOaNXWzbsjyv4dWerX1s1xdWznTHbY3nnagI6lF5ww9QAOvNT+LkstHvrLfdm2KMdkMj7yRgkn2LbuprutMvriLTlRI47dIgVEbqRhSQR/WvH/iFod3f6vPqt1PDaxTS+UhnO1SAP4MZyAAKyrL3+VaI66MpSTmld9jvYo7zXrK2utNEgsoolEW/aNuTliwwMkjHI/TFadgP7QW4gmjkVOjZbPT1/LOazPCF9Z6b4YjtLW8imxEFeRW3LnHH8j+dXfBUV5DeXt5IyPbKpPHcHtXTSnD2UrP4djlrRmqiutzmfFtqbLSpLGORwpBRApyHB9cdQO1cl4b8JKt0lxfzMkanop25/GvWJba3uWSKN13K5Z1POFPOBXIfEDfHbmKyGBjAxWEJS1a3Z0yUJJJ9C6k9jO7eU+ShCJADuB6c81s28IuTHaB3B2YBViDkHPWvOPBlpqFtdJNNGXXOAMete1adaxLGkpAUkZODit1Tsv3juYVKiWsFY828Q+HWuLmWJpiCseAjEk4//XXPWHgaJ0je6MjHdghTivUvE8Ecl6Jojk4wadZWBitWm25zzj3ralFQhzswqVud8pgeKvBOm6F8LtdurOLEzRxMzMck/vU/LrXC/ArULbTPGk1zeSbIlspR0JJOVwABySfSuv8AiP4qkPhLUtLcHM6IvA44dT/SvO/hXdW1l4sS5u4/MWKF2Uf7WOP61leVVu+tzGSUbXPf9Q8RaheLFHYwXNvZld007BfMx0wvXjpnPNRRafAXjadQFJyCuRuByee5Ofel0+7S/V3gaVTOT5qyIBknuuOlUNDvnF3IspVYQu9F54wfWh0pWfkaRlFL3TeexDcykCPBBULnOOnWuF8S6rrdprElvYDyrVW2IDEMuff2PrXWXXiC0js5JoptkcThQ7HcWJ6gAZyetc5pl2dUvpVtXL3a/MEkOxsA9g2MgexruwacU5Tjou5hValZXOj0m5lltoluICHCgyJ91cntz1PtWBZXurya26T2sQtGb5twGwKPbpWnrM1/E8UMG1GYfMu8ZOe4yc1zt/rbW5aKRN08eFw3yL1+7nuT+Va0oOSbik7/AIEu3XoTS+G7rUvGH9o2c8K6arr8hBGxRgEbOmTjr7100yHTPKMUUz7WLKxbcTnqAR0HJFQ6bdkaRDNaRupkx8hGec4wPrzzUdjqtwtyfOjlWQ8nCHgZ6H/61YTdWro9o6WNFaOy3K/ijQF8T6bA0UiQXMJIUSAhcEfQ+gPSr/hLTf7A0FbO5u4n8xm37m2qSeMLnHpnPqa2HdZY2aXcmwAkjGNx559Rziuc1zRH1u9sX+1bYoGxIo6upwcD0Pbk1EajnH2U3aKBrqty/rWiQ6nZPa3w/wBHZxKjQn5ww4BB6cZNZ8nhizsdDl0uFX8mVlYu0g80kdx0Aq94xS6vNDWDTiglWVJAAwUnGR37dap38WqtpcSfuzcAAbhyBn1x3GDRS5lFLntd/cDk272MTTVuPDbyPLqTXKSjYsQUtuAPUkngisbXxqOu3wlsXX5+FDEjc3v29eelb91oN7PYbTMgl4AbbwfUYPUciur0fQ1t9LWUL9yMDaBk7uOQPpW1TERou8XeRUYKWstEY0Gp3en6PZW14zTSKMFxnnBAH+eKm1C9u5LWOS3l8vzPlywAKjHft9KVIZZWYBH2k5ZVUqVz2YdauWDRT2ctvLbgQq+F3oFBY+ncmuJVk5XcdTR0oxW5yXhi/nh1VrTUrh3LuVUMSdrjk/8AAfc1v+Hb66muViu4ocz7m3wfcDKenPbpV1NPhtpJJfLjRgQCwyx44PP48d6mttK+xpK8LwpETvclsnIHQcdPXvW1WvCV2o7mSp2tqWNsMpUTx5H3sY5BHbHpzVy5iVRth/dQf3QQD07n6+lPtYoI4A+NokTDlnzkHk9KoXxh3oEAIQYB6Hjt9OTXJFtlO17D4FErYMoIiOAxfoPbP60y/le0G9Y2lUHJEa7nPIA+vU/hVGzlUSlWO6Llg+4DaeMg57dMVYsSMym4DSFGbAxu4yAcVTjZ6i9CpFbQw3fmRQPtdTv2qOOeD+OK5tJYNZlkV43iETYCdCSP58c1s6pY6tJrcM1s6JbFRvCnHb0HrzWjJbW8aN5KBZCuSd2eSMn6ZxXQ6kaaUm7t/h6kpSbIdCltY1RAh6E7iO5P5gV4z8cQ48WWnm/fNkhPv+8kr0XS7a9i1OeWY7oV4QA98jr6cZrzf41SJJ4nsvLcOq2KLkf78n51nVgozuncV9NRPgaxX4hWxA3EQTYGcc7DX0408UKbpZI41Hd2wB+NfI/w/vL6y8UWz6UCbt1eNcAZGVIyM8fn+tewabaTaprDLrMkk0yLsQSM0ignIyWPv2AArnnTcne+n9dDWEU1dnol3rcFtPJBYA3dw+Xdg/7qI4HBPbp90fpmsHULOS/3SSyebduRifGduOiheijv6/WsTwPcX8OizRayPJMdwViEke0MvHTAwRnNVrQT6FJq5nnSea6uDMixkkouSeT+mK2jQdKTSfvL8f8Agf0wUk1toy9BY/ZrpI1uFuZy3ReQpPYnrXWRWUVrEkfzsc/M4JUsR9O3pXD6R/rkazZ7eKffJIzjAXP8WeO/fjiu00mxubeNnlv1uYWGUCLwvTkHuazm5NuU3qaztFKMdi7qV5FpOl3Uce5xuUImclmByR9MVxWreK9SLXZiWytl8ve8sg3NIF5wOOoxjNTP4iU68bVrVUt2YovUsCOpz64yDVrUfD+nT2N2dPh+0kHcA+cbgeNuOD3/AFyOaieGldKWl/672+8ujVpxWquUrbWtX1nwpfTaqykBVkicRhTwwyMA4IPbmpPB4cadLIwVVmbLb+FAx3z256Z7VqWyywaPYwFoZY5EZPMZwVGBlgccAD09qWxe11PSX0211G1mdRz9nX/aBxjjv/PrXQqqjGVGKtG/TYwcdpsW1g0qfTri1e4il3j955R2Meckg9xx19KqeIUj/s2L+z4ykaKysIxkhSByM55+UVah8O2enWqtCm6ZSFZ15x198D8K5nV4dUh121ktrkGykXZLHt5U8/Nj8Ac1XOou8JXW+olHm3WvkQS3RiSP7QFSBBmEKBuwAQeB69ahl8Mrq9xp12j2kitzBIGfZnHRsDJOOvIOeK4GbxLcWnim7uYd86OGhAYjO3PbggdPyr1eyjc6VZWUCi3hKh/K6kkgMSc8/eNcTm5yVR6N/d/n/XQ9JxdJezWqOo8M6bbwuHk5uYciIgYVUIwAo7EDg5q/rGpxadbTNIIjFEAxVcEheh/rXPxSSWqhlZpE4y3Qip4L1HURTB5gZA0qyEt5qd1NTJvZnNy3fMc1qV7cXgS6t5JpLe4BVEGM7T2x25FYfjzR72x0fw9ewwyT3CXEnmRbcnaVH8sH86zPGGpz6NqbWmizFbSLlFOMjPOPp/hWt4d8W/23aNb3Uuy8RcZyOT61oqvPBRSVv0NHT9lPnTZzul2Ui38Ftptu6m6ceeDkjGP0rb8d6vceGLCGwsiRKy/Mx5rovD1l5GtoxlCs38PWqXxa8ONcypeL82BgjFOcIuyXzD2zlKzVjm/h9rM948z3nzuT96vQf7Li1AguFPSuR8GabBaaf8wAYnJrudLnjjwMgc5reMYx+ExrTdyUaZbWcGVXgVzOseIGtpTGhAUcV1OtSs1tmM/lXntzp0l9dleuTzmso81Sdhx5eW7Jb3WXa33ryxGaveHPEbm3kXUDsgCnkVctPC8LwqMd+nPP41s2fhyGFPLe3R4z1BGa9Bqn7NxucblaaZwHj6whu/CF/f2ux4VwwIJJHzqP61598NrP7d4nSHzPLJhkIbbnnFe6/ErRLK2+HOtNaxLblIQxVR8p+de1eCeAL2Sw8SRTRfe8t16Z4IrlpcznaD16FVGpWZ794bs3sbOVHkEz7y4UcEHFYs6NbwTmYKHbCKc4CjnJP5f/AK63fD9yl5aRSMAH+6CRy2B1qbU9K8z5SjOkhzgHHPtXRCq1UftdyXa3unna6aNVlS3ineLcQ6SKmYyRyAD1rrfBvg7ULS6geSSPyIpGlyQzMWYY4zwM11/h/wANWenIjupeYdNzcL/TPaug+6v3vl6AelGIzByThT2JULavc4Wx+HQGvtquo6rPdSby6xlcAegJzz+AFdRL4b0meTfcWUUsnA3OgyRzjn8TWoDkg5z9aAPUnn0GK5J4mrUlzSlr935BFKKtHQgGnWwCqEYBeFGelRvpNuSpTKlTnhquAtt759DSg4bJB/Cs1NrqO5zXiDSZzbhrONGdAzAAck9q4DR5datdVAeG4Xc3zeYOAefYY/OvZCxJOfwqGaJJc7guTxnHNdNPF8kHCUb3E1dps4nSHzdu1xcgvIRhipUDHOM4we/epb/UYYJLqRIndY0+VM4zzyfxIzWjdaK6y7g+5TxtAwPx9+lF9bW8RBEaCUjapLAAnGDnPYf0pSlTvzblK55/fa815dfZMA+edhRDkZ7V6jocKQ6VFjf+9UMQ3bjj6VwEumWNvey3IhwUYbivIAI6jPuTXf2N3HdWy+WxAAHy56DH+NRiJRk04KyKa5VYslUldwXLMeCw6n2z/hXN+MJ2s4FlgQLHGeQvAwB6e1a0k8kNwUjjPlpjJPf6Vzniidru9s4ULKjjzG2nHBONp/Xms6XxXsEb31Zy1h4muLjUms1YyA5wSNoXOOM+taGs6xqlhdR28bFIYiCF6+Yp689+ay9V0ptRki/seaFGjkPmNG+QenNb+tSFYLGK7tGuPL28qOVJGCQR6969JxhzJJXvuuxL20LX2mYWRuxIpQqvBAU5JA5PSsS4+2X904IEUa/Kf3uCDx7fX8q6d4h/Y05WIPuUYjI4HX8Dyv8AKsfTLfMMpESxuQSQ455Pr9eawhKMIuS6OxfxOzIFZfD0ImuGLseDhAc568fl+Vbuj6rDe25NlKV2cKABgceua5/U7lJbtLG7jLxg7VboSCMcGtrRdNttOgEUEe1Bkc9TRVacbz+J/cSvLY2o3Qx+YgB3DO5+c/8A1q429vdbTxS8BQy6W67g4jwF+Xk7h3B7Vt3Ewj3bcKo9DwBUNzNMjRmJB5P/AC0LMFUDvWFOyvdJ3XUppmV/aTPIbe4AaI/w4yMkjtXkfxasxZeJoUV94e2Vh7Dc4x+le0PZ28TlsIW4I2/zxXjvxjOfFFvjp9kXH/fb1pKpFu1NWRDi92cho+oSaXqUF7DHFJJCdyrKCVzjvgg/rXXW3xN1eAuy2WmM7nJZ4nJH0+fiiis7XFzNaCXPxN1ycKHhsOOp8kkkenLH9KrT/ELV57cwvFZhC5f5UYHnqPvdKKKFFJproVzy2uOvfiJq95piWU8NkyKysH2Nu+XoPvYI/Cr+kfFjXtL06OzhttNkjjJIaSNy3Jz2cCiiqbbjyPYi+tyvP8TNXnuBPJZ6YZAwYnynO7GeDl+lXLr4veIriwms2h05YpUMZKxuGUEYODv+v50UUrbeQ+ZmDpnjXU9Psrm1hS3eK4Dbt4YkblKnGGHY/oKk0DxzqWiXwurO3smlAwBIrkY+gYUUVo6s3e733Jstjo1+NPiJFwtnpI5znypOf/IlVJvizrUz7nsNJOQQR5UmDnr/AB0UVlyotSaOW/4SGUakt7HZWUcincFUPtz9C1dDD8T9aicsttp5JGOY36f990UUcqLlWqS0bJW+K+uMpBtdMwf+mT//ABdQj4na2Af3Fhnjny3/APiqKKXJF9CVUktmczqut3Op3z3VykQkYg4XcAPzNLpuuT6dcie3gt/MHOWDH+tFFUtNgdST6nQw/EnV4b0XSW1h5o9UfH/odaOofF/Xr+38mey0nbjGRFJn/wBDooqeVA6knq2YB8baqJAyC3QDPyqpwf1q1H8RNZjA2x2efXY3/wAVRRVJcuwpTlLdl3/hauu+XsNvpxGMcxv/APF1Sh+ImrxTGRILHcevyP8A/FUUUbC5nsalt8XtetyClppZx6xSf/F1dHxw8Rj/AJcNG/78y/8Axyiihq+4ih4k+LeveINEudLu7TS4re4TYzQxOGAyDwS5Hb0rjNA1ebRNSS9tooJZFVl2TpuUgjHIyKKKSSWw7nWRfFPXYpNyQafgfdUxMQv0+arlt8YvEMDFhaaW57b4pDtHoPn6UUU2k9xFn/hd/iXIP2PSOP8ApjJ/8cpw+OHiUf8ALnpH/fqT/wCOUUVPJHsFw/4Xj4l/589I/wC/Mn/xyj/hePib/nz0j/v1J/8AHKKKOVAB+OPiUj/jy0f/AL8yf/HKP+F4+JcY+x6R/wB+pf8A45RRRyoBG+OHiVgf9D0gZ7iKT/45Qfjh4l5/0PSB9IZP/jlFFHKuwDW+NviR+GstIPf/AFUn/wAcqvL8YtflK77HSSFO4AxSHB/77ooo5UCM65+JmtXMjvNBp53HIAiYBenAw3I475qS0+KWu2piMUFgGi+6dj59/wCPnNFFX05egGk/xq8SM+Ta6Vt/u+S+P/Q6o3fxW1u5uFnez0xXCFPkicAg+vz/AOc0UVKilsO7Rn6R8QNU0lZxa21j+++8XRz+XzVpL8WdeGP9F0046Zjf/wCLooqpNzlzS3FcWf4ueIJYGiWDTogRgGOJ8r9MuRVOx+Jeu2sLRutpcktuDzozMvsCGHFFFJaKwdbkc/xF1ea5SdrexDIcqAj4H/j1Xn+LGvsm0wafjAH+rft/wKiim3ffoFys3xO11w29LJsnPMR4Hpw1EvxN158fLZqAQcCNvy+9RRStYLsi/wCFja2GyFswMYx5R/xrn/EGtXevXqXV95fmrGIxsXaMAk/1NFFFguz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunoperoxidase stain of a bone marrow biopsy from a patient with primary (AL) amyloidosis. Evidence for a monoclonal plasma cell disease is provided by the intense staining for lambda light chains (left panel) with almost no staining for kappa light chains (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16998=[""].join("\n");
var outline_f16_38_16998=null;
var title_f16_38_16999="Toxoplasmosis in immunocompetent hosts";
var content_f16_38_16999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxoplasmosis in immunocompetent hosts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Howard M Heller, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/16999/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/38/16999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis, an infection with a worldwide distribution, is caused by the intracellular protozoan parasite, Toxoplasma gondii. Immunocompetent persons with primary infection are usually asymptomatic, but latent infection can persist for the life of the host. However, there is a risk of reactivating infection at a later time should the individual become immunocompromised, even if infection was asymptomatic or only mildly symptomatic initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxoplasmosis in immunocompetent persons will be reviewed here. Toxoplasmosis in HIV-infected and pregnant patients and congenital and ocular toxoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link\">",
"     \"Overview of TORCH infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felines are the only animals in which T. gondii can complete its reproductive cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/1\">",
"     1",
"    </a>",
"    ]. Following feline ingestion of any of the forms of T. gondii, the parasite infects the gut epithelial cells and reproduces. The feline then excretes infectious oocysts in feces.",
"   </p>",
"   <p>",
"    When non-felines, including humans, ingest T. gondii oocysts, the organisms invade intestinal epithelium and disseminate throughout the body. They then encyst in any type of nucleated cell and can lie dormant within tissues for the life of the host.",
"   </p>",
"   <p>",
"    There are four means of acquiring toxoplasmosis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ingestion of infectious oocysts from the environment (usually from soil contaminated with feline feces)",
"     </li>",
"     <li>",
"      Ingestion of tissue cysts in meat from an infected animal",
"     </li>",
"     <li>",
"      Through vertical transmission from an infected mother to her fetus",
"     </li>",
"     <li>",
"      Via blood transfusion or organ transplantation from an infected donor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ingestion of undercooked meats is responsible for the majority of toxoplasmosis cases in some parts of the world including Europe, Nepal, and in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A case-control study of adults recently infected with T. gondii was conducted from 2002 through 2007 within the United States to identify risk factors for acquisition of toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/5\">",
"     5",
"    </a>",
"    ]. In a multivariate analysis, an elevated risk of recent T. gondii infection was associated with eating raw or undercooked foods (ground beef and lamb) and drinking unpasteurized goat's milk. In addition, working with meat or ownership of three or more kittens was also associated with an elevated risk of infection. In contrast, in most resource-limited settings, infection is more likely due to environmental exposure since meats are usually not eaten undercooked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In seroepidemiologic surveys in the United States, 11 percent of persons aged 6 to 49 are seropositive for T. gondii [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence is higher in non-Hispanic blacks compared with non-Hispanic whites and in persons born outside the United States. For persons aged 12 to 49 born in the United States, the seroprevalence declined from 14 to 9 percent between 1999 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/6\">",
"     6",
"    </a>",
"    ]. Seroprevalence is as high as 77.5 percent in some areas of Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty to 90 percent of acute T. gondii infections in immunocompetent hosts are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/8\">",
"     8",
"    </a>",
"    ]. When symptomatic infection does occur, the most common manifestation is bilateral, symmetrical, non-tender cervical adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/9\">",
"     9",
"    </a>",
"    ]. The lymph nodes are usually smaller than 3 cm in size and are non-fluctuant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Twenty to 30 percent of symptomatic patients will have generalized lymphadenopathy. Constitutional symptoms, such as fever, chills, and sweats, may be present, but are mild. Headaches, myalgias, pharyngitis, diffuse non-pruritic maculopapular rash, or hepatosplenomegaly may also occur.",
"   </p>",
"   <p>",
"    Most immunocompetent patients have a benign, self-limited course lasting from weeks to months, rarely longer than a year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/10\">",
"     10",
"    </a>",
"    ]. Lymphadenopathy usually resolves, but in rare cases may persist chronically [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/11\">",
"     11",
"    </a>",
"    ]. Extremely rare cases of severe disease with pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/12\">",
"     12",
"    </a>",
"    ], acute respiratory distress syndrome, myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/16\">",
"     16",
"    </a>",
"    ], polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], hepatitis, or encephalitis have been reported.",
"   </p>",
"   <p>",
"    T. gondii is one of the most common pathogens to cause chorioretinitis (a posterior uveitis) in immunocompetent hosts. This infection typically occurs congenitally or postnatally. Adults with acquired disease in infancy or childhood can present with bilateral eye involvement, scarring, and frequent recurrences secondary to reactivation disease. Patients more than 40 years of age are at higher risk of recurrence than younger patients; clusters of episodes can occur after prolonged disease-free intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/19\">",
"     19",
"    </a>",
"    ]. Adults with acute infection usually present with unilateral ocular disease in the absence of prior scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have a slight lymphocytosis or atypical lymphocytosis, usually less than 10 percent of the total leukocyte count. Hepatic transaminases may be slightly elevated. Otherwise, laboratory findings are non-specific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On histopathologic examination, lymph nodes typically have follicular hyperplasia, focal distension of sinuses with monocytoid cells, and irregular clusters of tissue macrophages with eosinophilic cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/21\">",
"     21",
"    </a>",
"    ]. Granulomata and abscesses are not seen.",
"   </p>",
"   <p>",
"    Parasites are rarely visible with standard stains, but may be observed with immunoperoxidase or fluorescent antibody stains. Parasites may also be detectable with DNA amplification by polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/22\">",
"     22",
"    </a>",
"    ]. Although tachyzoites are difficult to demonstrate pathologically, they can sometimes be identified on fine needle aspiration specimens from patients with toxoplasmic lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxoplasmosis may be mistaken for acute Epstein-Barr virus or cytomegalovirus infection, especially since mild atypical lymphocytosis can be seen with toxoplasmosis. Approximately 1 percent of acute EBV-seronegative mononucleosis syndromes are due to toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/24\">",
"     24",
"    </a>",
"    ]. Also, since many of the symptoms of acute toxoplasmosis overlap with the symptoms of HIV infection (eg, fever and generalized lymphadenopathy), testing for primary HIV should be included as part of the initial evaluation. Diagnostic testing for acute HIV infection is discussed elsewhere.",
"   </p>",
"   <p>",
"    Other considerations in the differential diagnosis include: syphilis, sarcoidosis, Hodgkin's disease, and lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of methods for diagnosing toxoplasmosis; however, serologic tests are the usual means for establishing the diagnosis, although there are inherent problems with these diagnostic assays, which are discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/25\">",
"     25",
"    </a>",
"    ]. ELISA is most commonly employed due to overall performance and cost.",
"   </p>",
"   <p>",
"    Since the clinical presentation in immunocompetent hosts resembles many other infections, and even malignancy, a high index of suspicion needs to be maintained in order to consider toxoplasmosis. Emphasis should not be placed on prior exposure to cats, since patients can acquire toxoplasma without direct contact with felines. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The discussion below addresses all of the diagnostic tests available (eg, serology, histology, polymerase chain reaction, culture) and the situations where they may be considered in the immunocompetent host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, serologic testing is the most common diagnostic test used for toxoplasmosis. In acute infection, IgM antibodies appear within the first week of infection. The diagnosis of toxoplasmosis can be made with greater confidence when the initial serologic testing demonstrates a positive IgM antibody and a negative IgG result with both tests becoming positive two weeks later. This pairing of results is consistent with acute infection occurring about two weeks before the first positive IgM and eliminates the possibility of a \"non-specific\" IgM response. If follow-up IgG remains negative two to four weeks later, but IgM is still positive, then it is likely a false positive result.",
"   </p>",
"   <p>",
"    However, paired serologies showing this type of response are uncommon. Serologic assays often demonstrate the presence of both IgM and IgG antibodies, since IgM antibodies appear as early as two weeks after infection and IgG antibodies can persist for months to years after infection. IgG antibodies peak in six to eight weeks and then decline over the next two years. The usefulness of a rising IgG titer has never been adequately evaluated and is subject to error because of lack of reproducibility in many laboratories.",
"   </p>",
"   <p>",
"    On the other hand, a negative IgG antibody essentially rules out prior or recent infection in an immunocompetent host since IgG antibodies remain detectable for life.",
"   </p>",
"   <p>",
"    There is also considerable variation in the sensitivities and specificities of the various commercially available serologic assays described below, so the diagnosis of acute infection generally should not rely on any single test. A study comparing six commercially available IgM ELISA test kits found the sensitivity ranged from 93 percent to 100 percent, and the specificity ranged from 77.5 percent to 99.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/26\">",
"     26",
"    </a>",
"    ]. Another problematic aspect of serologic testing is that the various assays differ in the interpretation of the titers of the IgM and IgG fractions that are formed.",
"   </p>",
"   <p>",
"    Thus, to establish whether positive",
"    <span class=\"nowrap\">",
"     IgM/IgG",
"    </span>",
"    antibody testing reflects recent or chronic infection or a false positive result, confirmatory testing must be obtained with additional testing, (eg, IgG avidity assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/27\">",
"     27",
"    </a>",
"    ]. The extent to which diagnostic testing will be pursued often depends on the clinical scenario. For example, in a pregnant woman or the immunosuppressed host, a full panel of diagnostic testing will be desired; in the immunocompetent host with receding asymptomatic cervical lymphadenopathy, the need for absolute certainty is less compelling. However, the clinician needs to be aware of these diagnostic uncertainties and consult a reference laboratory when necessary (eg, the Palo Alto Medical Foundation Toxoplasma Serology Laboratory, which is the reference laboratory of the Centers for Disease Control and Prevention, at",
"    <a class=\"external\" href=\"file://www.pamf.org/serology\">",
"     file://www.pamf.org/serology",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sabin-Feldman dye test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sabin-Feldman dye test is the gold standard against which all other serologic assays are compared [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/28\">",
"     28",
"    </a>",
"    ]. It is a neutralization assay in which live organisms are lysed in the presence of complement and IgG antibody. Only a few reference laboratories in the United States offer this test (eg, Palo Alto Medical Foundation, Palo Alto CA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Enzyme-linked immunosorbent assay (ELISA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IgG-ELISA is the standard test used by most laboratories to detect IgG antibodies to T. gondii [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/29\">",
"     29",
"    </a>",
"    ]. No single level of IgG antibody can be used to determine the duration of the infection.",
"   </p>",
"   <p>",
"    IgM antibodies can be detected using the \"capture\" or \"double-sandwich\" ELISA and it is the most-widely used assay for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Indirect fluorescent antibody (IFA) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IFA measures the same IgG antibodies as the Sabin-Feldman dye test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/30\">",
"     30",
"    </a>",
"    ], but is more readily available in commercial laboratories since it does not use live organisms. False positive results may occur in patients with antinuclear antibodies (ANA) and false negative tests can occur with low titer IgG antibodies.",
"   </p>",
"   <p>",
"    The test is also available for detecting IgM antibodies, but false positive results can occur due to ANA or rheumatoid factor (RF).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Immunosorbent agglutination assay (ISAGA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ISAGA measures IgG or IgM antibody by causing agglutination of acetone or formalin-preserved whole organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/31\">",
"     31",
"    </a>",
"    ]. The \"differential\" agglutination test is helpful in distinguishing acute from chronic infection. Antibodies produced at distinct times during infection will react differently depending upon which preservative is used to treat the organisms.",
"   </p>",
"   <p>",
"    This test is widely available commercially and is more sensitive and specific than IFA for detecting IgM antibodies. False positive results due to ANA and RF do not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     IgG avidity test",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG antibodies made early in toxoplasma infection bind to antigen less avidly than antibodies made later, which bind with high avidity. Although the change of avidity from low to high varies from individual to individual, the presence of high avidity indicates that the infection occurred at least 3 to 5 months earlier.",
"   </p>",
"   <p>",
"    Avidity testing is only a confirmatory test and needs to be accessed from a reference laboratory. This test is most helpful in evaluating toxoplasmosis during pregnancy since further evaluation and treatment critically depends upon the timing of the infection relative to the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute infection the organism can be isolated from blood either by cell culture or by mouse inoculation. The former is less expensive, easier, more readily available, and yields results within three to six days. Mouse inoculation is more sensitive (73 versus 53 percent for tissue culture of amniotic fluid specimens), but may take three to six weeks to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/35\">",
"     35",
"    </a>",
"    ]. Culture of the organism is rarely performed in immunocompetent hosts, but may be considered in neonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     DNA amplification by polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. gondii DNA can be detected by polymerase chain reaction (PCR) in blood during acute infection in immunocompetent patients. However, the sensitivity varies, and this test is rarely necessary for confirmation of the diagnosis. Sensitivity may be as low as 53 percent in patients with acute toxoplasmic lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Aqueous humor analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, which included 137 immunocompetent patients with posterior uveitis with a suspected infectious etiology, aqueous humor analysis was evaluated as a method for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/37\">",
"     37",
"    </a>",
"    ]. Intraocular antibody production and PCR analysis were evaluated for investigating a variety of pathogens including toxoplasma, herpes simplex, varicella zoster, and cytomegalovirus. Of 37 patients with diagnostic positive results, three-fourths had evidence of toxoplasma infection. Most of these patients were diagnosed using measurements of intraocular antibody production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HIV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of either acute or chronic toxoplasmosis does not, by itself, necessitate testing for concurrent HIV infection. However, if the presentation of the toxoplasmosis manifests in a syndrome typical for",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    (eg, multiple central nervous system abscesses), then HIV testing is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the immunocompetent host with acute onset of lymphadenopathy, diagnostic testing should include serology. In the patient with IgM antibodies alone with subsequent seroconversion, a diagnosis of toxoplasmic lymphadenitis can be made; in the patient without any evidence of either IgM or IgG antibodies, the diagnosis is eliminated.",
"   </p>",
"   <p>",
"    However, serologic testing often demonstrates the presence of IgM and IgG antibodies in varying titers, which may represent recent or chronic infection or simply a false positive test. Additional testing must be pursued at a reference laboratory for confirmation of equivocal assay results (eg, Sabin-Feldman dye test). DNA amplification of toxoplasma antigens from blood can also confirm acute infection, but this test may not be readily available, is expensive, and has variable sensitivity. Whether confirmatory testing is pursued will often depend on the clinical scenario.",
"   </p>",
"   <p>",
"    In the immunocompetent host with suspected ocular disease, intraocular sampling may be considered for supportive evidence of antibody production against toxoplasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompetent, nonpregnant patients generally do not require treatment unless symptoms are severe or prolonged beyond a few weeks. The medications used for treatment in these circumstances are the same as those administered for toxoplasmosis in immunosuppressed patients, but lower doses generally suffice. Treatment is usually given for two to four weeks. Treatment of pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     First line regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of two regimens is typically prescribed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (100 mg loading dose PO followed by 25 to 50 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      PO in 4 divided doses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (100 mg loading dose PO followed by 25 to 50 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (300 mg PO four times daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    calcium (folinic acid, 10 to 25 mg orally daily) should be given to all patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon activity in immunosuppressed patients, the following alternatives could be considered in immunocompetent, nonpregnant patients who are intolerant to the standard treatments. However, there are no supportive clinical data in immunocompetent hosts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (100 mg loading dose PO followed by 25 to 50 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (500 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      (100 mg loading dose PO followed by 25 to 50 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      (750 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     Trimethoprim",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg/daily)",
"    </span>",
"    plus sulfamethoxazole (50",
"    <span class=\"nowrap\">",
"     mg/kg/daily)",
"    </span>",
"    has been shown to be an effective regimen in the treatment of CNS toxoplasmosis in patients with AIDS, so may be considered as a non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    alternative for patients unable to tolerate this medication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/16999/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocompetent persons with primary infection with toxoplasma are usually asymptomatic, but latent infection can persist for the life of the host. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans can acquire toxoplasma infection via ingestion of contaminated meat, through vertical transmission, or via blood transfusion or organ transplantation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seroprevalence rates vary greatly depending on geographic location, from approximately 9 percent in the United States to 78 percent in areas of Brazil. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eighty to 90 percent of acute T. gondii infections in immunocompetent hosts are asymptomatic. When symptomatic infection does occur, the most common manifestation is bilateral, symmetrical, non-tender cervical adenopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of toxoplasmosis includes primary HIV infection, infectious mononucleosis, lymphoma, and other diagnostic considerations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic testing for acute toxoplasmic lymphadenopathy in an immunocompetent host is usually accomplished through serologic testing. IgM antibodies can be detected using the \"capture\" or \"double-sandwich\" ELISA, which is the most-widely used assay for this purpose. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      However, serologic testing is often equivocal and demonstrates varying titers of both IgM and IgG antibody fractions. Due to limitations in sensitivity and specificity, confirmatory testing is recommended in a reference laboratory, particularly if treatment is being considered. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is rarely necessary since most clinical illness resolves spontaneously. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/1\">",
"      Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/2\">",
"      Baril L, Ancelle T, Goulet V, et al. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand J Infect Dis 1999; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/3\">",
"      Rai SK, Matsumura T, Ono K, et al. High Toxoplasma seroprevalence associated with meat eating habits of locals in Nepal. Asia Pac J Public Health 1999; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/4\">",
"      Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000; 321:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/5\">",
"      Jones JL, Dargelas V, Roberts J, et al. Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis 2009; 49:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/6\">",
"      Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg 2007; 77:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/7\">",
"      Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009; 39:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/8\">",
"      Remington JS. Toxoplasmosis in the adult. Bull N Y Acad Med 1974; 50:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/9\">",
"      McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987; 9:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/10\">",
"      O'Connell S, Guy EC, Dawson SJ, et al. Chronic active toxoplasmosis in an immunocompetent patient. J Infect 1993; 27:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/11\">",
"      Sheagren JN, Lunde MN, Simon HB. Chronic lymphadenopathic toxoplasmosis. A case with marked hyperglobulinemia and impaired delayed hypersensitivity responses during active infection. Am J Med 1976; 60:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/12\">",
"      Leal FE, Cavazzana CL, de Andrade HF Jr, et al. Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review. Clin Infect Dis 2007; 44:e62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/13\">",
"      Montoya JG, Jordan R, Lingamneni S, et al. Toxoplasmic myocarditis and polymyositis in patients with acute acquired toxoplasmosis diagnosed during life. Clin Infect Dis 1997; 24:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/14\">",
"      Chandenier J, Jarry G, Nassif D, et al. Congestive heart failure and myocarditis after seroconversion for toxoplasmosis in two immunocompetent patients. Eur J Clin Microbiol Infect Dis 2000; 19:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/15\">",
"      Franco-Paredes C, Rouphael N, M&eacute;ndez J, et al. Cardiac manifestations of parasitic infections. Part 2: Parasitic myocardial disease. Clin Cardiol 2007; 30:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/16\">",
"      Cunningham T. Pancarditis in acute toxoplasmosis. Am J Clin Pathol 1982; 78:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/17\">",
"      Behan WM, Behan PO, Draper IT, Williams H. Does Toxoplasma cause polymyositis? Report of a case of polymyositis associated with toxoplasmosis and a critical review of the literature. Acta Neuropathol 1983; 61:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/18\">",
"      Calore EE, Minkovski R, Khoury Z, et al. Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii. J Rheumatol 2000; 27:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/19\">",
"      Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 2008; 145:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/20\">",
"      Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis 1996; 23:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/21\">",
"      Dorfman RF, Remington JS. Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med 1973; 289:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/22\">",
"      Weiss LM, Chen YY, Berry GJ, et al. Infrequent detection of Toxoplasma gondii genome in toxoplasmic lymphadenitis: a polymerase chain reaction study. Hum Pathol 1992; 23:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/23\">",
"      Zaharopoulos P. Demonstration of parasites in toxoplasma lymphadenitis by fine-needle aspiration cytology: report of two cases. Diagn Cytopathol 2000; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/24\">",
"      REMINGTON JS, BARNETT CG, MEIKEL M, LUNDE MN. Toxoplasmosis and infectious mononucleosis. Arch Intern Med 1962; 110:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/25\">",
"      Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol 2004; 42:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/26\">",
"      Wilson M, Remington JS, Clavet C, et al. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997; 35:3112.",
"     </a>",
"    </li>",
"    <li>",
"     Montoya J, Kovacs J, Remington J. Toxoplasma gondii. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Sixth Ed, 2005. Vol 2, p.3170.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/28\">",
"      Reiter-Owona I, Petersen E, Joynson D, et al. The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis. Bull World Health Organ 1999; 77:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/29\">",
"      Balsari A, Poli G, Molina V, et al. ELISA for toxoplasma antibody detection: a comparison with other serodiagnostic tests. J Clin Pathol 1980; 33:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/30\">",
"      Walton BC, Benchoff BM, Brooks WH. Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii. Am J Trop Med Hyg 1966; 15:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/31\">",
"      Thulliez P, Remington JS, Santoro F, et al. [A new agglutination reaction for the diagnosis of the developmental stage of acquired toxoplasmosis]. Pathol Biol (Paris) 1986; 34:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/32\">",
"      Liesenfeld O, Montoya JG, Kinney S, et al. Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis 2001; 183:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/33\">",
"      Zotti C, Charrier L, Giacomuzzi M, et al. Use of IgG Avidity test in case definitions of toxoplasmosis in pregnancy. New Microbiol 2004; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/34\">",
"      Candolfi E, Pastor R, Huber R, et al. IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. Diagn Microbiol Infect Dis 2007; 58:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/35\">",
"      Derouin F, Thulliez P, Candolfi E, et al. Early prenatal diagnosis of congenital toxoplasmosis using amniotic fluid samples and tissue culture. Eur J Clin Microbiol Infect Dis 1988; 7:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/36\">",
"      Angel SO, Matrajt M, Margarit J, et al. Screening for active toxoplasmosis in patients by DNA hybridization with the ABGTg7 probe in blood samples. J Clin Microbiol 1997; 35:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/37\">",
"      Rothova A, de Boer JH, Ten Dam-van Loon NH, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology 2008; 115:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/16999/abstract/38\">",
"      Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006; :CD005420.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5699 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_16999=[""].join("\n");
var outline_f16_38_16999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sabin-Feldman dye test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Enzyme-linked immunosorbent assay (ELISA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Indirect fluorescent antibody (IFA) test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Immunosorbent agglutination assay (ISAGA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - IgG avidity test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DNA amplification by polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Aqueous humor analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      First line regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=related_link\">",
"      Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_17000="Diagnosis and treatment of oropharyngeal dysphagia";
var content_f16_38_17000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of oropharyngeal dysphagia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Anthony J Lembo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17000/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/38/17000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia can be classified as either oropharyngeal or esophageal. Initial evaluation of oropharyngeal and esophageal dysphagia differs, making their distinction important. In most cases a comprehensive examination and a careful history are sufficient to guide appropriate evaluation.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of oropharyngeal dysphagia will be reviewed here, while esophageal dysphagia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .) A guideline issued by the American Gastroenterological Association (AGA) on this topic is also available (",
"    <a class=\"graphic graphic_algorithm graphicRef54485 \" href=\"UTD.htm?22/24/22912\">",
"     algorithm 1",
"    </a>",
"    ). The AGA guideline for oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . The physiology of normal swallowing, and the pathogenesis and clinical manifestations of oropharyngeal dysphagia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination can usually distinguish between an esophageal and oropharyngeal cause of dysphagia (",
"    <a class=\"graphic graphic_algorithm graphicRef70866 \" href=\"UTD.htm?31/33/32287\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, they can often predict the cause of oropharyngeal dysphagia, which should be confirmed by specific testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, specific clues in the history can help establish the cause of the dysphagia (",
"    <a class=\"graphic graphic_table graphicRef52707 \" href=\"UTD.htm?16/45/17117\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with any cause of oropharyngeal dysphagia complain of symptoms immediately upon swallowing; in contrast, the onset of symptoms after swallowing is delayed in patients with esophageal dysphagia. Patients with oropharyngeal dysphagia point toward the cervical region when asked to identify the site of their symptoms; however, because the interpretation of visceral innervation is imprecise, dysphagia related to distal esophageal disease, such as a peptic stricture, may sometimes be felt in the suprasternal notch.",
"     </li>",
"     <li>",
"      Older patients presenting with oropharyngeal dysphagia, particularly those with a history of alcohol abuse, smoking, or weight loss, should raise concern about a malignant cause. Referred pain, such as otalgia (ear pain), may indicate a hypopharyngeal lesion [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/4\">",
"       4",
"      </a>",
"      ]. Referred otalgia is not just a symptom of hypopharyngeal cancer but can also occur at other sites such as the larynx, pharynx, and base of the tongue.",
"     </li>",
"     <li>",
"      Patients who have difficulty transferring food from the mouth to the pharynx will often reposition their body to optimize alignment of the bolus for presentation to the pharynx. Such patients may report extending their arms and neck during swallowing, and will often use their finger to move food into proper position. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\", section on 'Physiology of swallowing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of dry mouth or eyes may indicate inadequate salivary production. In such cases it is particularly important to obtain a detailed review of medications. Anticholinergics, antihistamines, and certain antihypertensive agents can reduce salivary flow. Sj&ouml;gren's syndrome is also a consideration. A history of radiation therapy to the head and neck should also be noted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changes in speech may provide important clues, and often implicate neuromuscular dysfunction. Hoarseness or a weak cough may represent vocal cord paralysis. Slurred speech may indicate weakness or incoordination of muscles involved in articulation and swallowing. Dysarthria (abnormal articulation), and nasal speech or regurgitation of food into the nose may represent weakness of the soft palate or pharyngeal constrictors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/5\">",
"       5",
"      </a>",
"      ]. The combination of hoarseness, dysphonia (difficulty or pain in speaking), and nasal speech accompanying dysphagia is associated with the muscular dystrophies.",
"     </li>",
"     <li>",
"      Food regurgitation, halitosis, a sensation of fullness in the neck, or a history of pneumonia accompanying dysphagia may be the result of a Zenker's diverticulum, which may be associated with a noncompliant or a hypertensive upper esophageal sphincter (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52971 \" href=\"UTD.htm?20/38/21102\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, patients with a Zenker's diverticulum sometimes report coughing several minutes to hours after ingestion of a meal, which occurs during emptying of the diverticulum. Patients with intrinsic dysfunction of the upper esophageal sphincter (UES) may also present with frequent food impaction or aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=see_link\">",
"       \"Zenker's diverticulum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain upon swallowing (odynophagia) can result from inflammation, infection, malignancy, or neoplasia.",
"     </li>",
"     <li>",
"      Dysphagia developing late in a meal may suggest myasthenia gravis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharyngeal dysphagia is common after intubation, especially in patients with a history of prolonged intubation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive examination should be part of the initial evaluation of all patients with oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the oral cavity, head and neck, and supraclavicular region may reveal lymphadenopathy, a mass, facial muscle weakness, poor dentition, or other abnormalities associated with dysphagia.",
"     </li>",
"     <li>",
"      Neurologic examination should include testing of all cranial nerves, especially those involved in swallowing (sensory components of cranial nerves V, IX, and X, and motor components of cranial nerves V, VII, X, XI, and XII). The neurologic examination also may detect disorders with more subtle physical findings. As an example, decreased proximal strength may indicate dermatomyositis or polymyositis. Bilateral ptosis, muscle weakness, or repetitive efforts at swallowing are other signs suggestive of muscle disease. The presence of cogwheeling, rigidity, or a shuffling gait may indicate Parkinson disease. Motor and sensory abnormalities should raise the suspicion for multiple sclerosis, which is frequently associated with oropharyngeal dysphagia, but usually in the setting of longer disease duration and significant motor disability [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five major tests that can be used for the evaluation of oropharyngeal dysphagia:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography, videofluoroscopy, upper endoscopy, fiberoptic nasopharyngeal laryngoscopy, esophageal manometry. The choice of specific testing depends upon the clinical presentation and available expertise. Patients with acute neurologic injury, for example, may benefit most from videofluoroscopy, which may identify whether aspiration is present and also assist in planning the best options for rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many patients, testing begins with videofluoroscopy, in which swallowing is videotaped during fluoroscopy, permitting detailed analysis of swallowing mechanics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Videofluoroscopy'",
"    </a>",
"    below.) Standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    testing involves ingestion of a thick barium solution while obtaining a sequence of x-rays. Lesions in the oropharynx can be seen with more detail via nasopharyngeal laryngoscopy.",
"   </p>",
"   <p>",
"    The finding of a mass or other mucosal lesions (such as an esophageal web) on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies usually requires confirmation or treatment during upper endoscopy. However, it is usually",
"    <strong>",
"     inadvisable",
"    </strong>",
"    to proceed directly to endoscopy without prior barium studies. Intubation of the upper esophagus is the least well visualized part of upper endoscopy. As a result, pathology in the upper esophagus or pharynx (such as a stricture, malignancy or diverticulum), may be associated with perforation during intubation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70946 graphicRef51936 \" href=\"UTD.htm?38/16/39169\">",
"     image 2A-B",
"    </a>",
"    ). Information provided by contrast radiography can help avert such a catastrophe. In addition, upper endoscopy is not a sensitive means of detecting abnormal swallowing function.",
"   </p>",
"   <p>",
"    Patients who have oropharyngeal dysphagia despite an unrevealing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    study or endoscopy may benefit from esophageal manometry. However, the value of esophageal manometry for oropharyngeal dysphagia is less certain than for esophageal dysphagia. Manometry rarely leads to alteration in management in patients with oropharyngeal dysphagia but may be useful in cases in which surgical myotomy is being considered. The AGA technical review for the clinical use of esophageal manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/12\">",
"     12",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Videofluoroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies is videofluoroscopy, which permits accurate visualization and analysis of the rapid sequence of events which make up a swallow. It is ideal for viewing the elevation of the hyoid and larynx, the relaxation of the upper esophageal sphincter (UES), and contraction of the pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The video, taken from both anteroposterior and lateral directions, can be replayed at much slower speeds or even frame-by-frame to facilitate accurate analysis. This helps identify abnormal movement of a bolus, such as aspiration, pooling in pharyngeal recesses, movement of anatomic structures, muscle activities throughout the area, and exact oral and pharyngeal transit times. The effects of different",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    consistencies and positions should be tested. Thick or solid boluses should be used for patients who primarily complain of solid food dysphagia.",
"   </p>",
"   <p>",
"    Examination during standard videofluoroscopy is limited to the cervical esophagus. Thus, it does not exclude lesions in the distal esophagus, which may sometimes give rise to symptoms referable to the cervical region. A study of 51 consecutive dysphagic patients referred for videofluoroscopy found the reliability of the test to be acceptable only for penetration or aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/15\">",
"     15",
"    </a>",
"    ]. This study suggests the need for better definitions of the parameters assessed by videofluoroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fiberoptic endoscopic evaluation of swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiberoptic endoscopic evaluation of swallowing (FEES) involves passing a flexible fiberoptic endoscope transnasally to visualize the laryngeal and pharyngeal structures. Food and liquid boluses are then given to the patient so that the structure and functioning of the pharyngeal phase of swallowing can be evaluated. Sensory testing can also be performed by administering pulses of air at sequentially increased pressures to elicit the laryngeal adductor reflex.",
"   </p>",
"   <p>",
"    Several studies have shown good correlation between FEES and videofluoroscopy, although interobserver reliability of results has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Barium swallow",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow may identify anatomic abnormalities associated with dysphagia and document the presence of aspiration. The indications for the test should be carefully communicated to the radiologist since modification of the technique may help identify specific causes of dysphagia. Specifically requesting ingestion of a solid bolus, typically bread, or a barium tablet, is important. Subtle abnormalities, such as a small ring or diverticulum, may be missed by a standard examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65175 \" href=\"UTD.htm?43/7/44158\">",
"     image 3",
"    </a>",
"    ). In addition, reproduction of symptoms while demonstrating slow passage or obstruction of the solid bolus establishes the location giving rise to symptoms. This is particularly useful if more than one abnormality is observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nasopharyngeal laryngoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More detailed examination of the oropharynx, hypopharynx, larynx, and proximal esophagus is often required, and can be accomplished with a nasopharyngolaryngoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/4\">",
"     4",
"    </a>",
"    ]. This procedure is usually performed at the bedside by an otolaryngologist, and is associated with minimal discomfort to the patient. A clear view of the oropharynx, larynx, and vocal cords can be obtained. The vallecula, piriform sinuses, and perilaryngeal regions can be inspected for pooled secretions or food material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard manometric study of the UES provides quantitative evaluation of the pressures and relative timing involved in the pharyngeal contraction and deglutitive UES relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A high resolution manometry system allows for more accurate analysis of the deglutitive UES relaxation (",
"    <a class=\"graphic graphic_figure graphicRef57536 \" href=\"UTD.htm?7/6/7273\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manometry can also be used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography to establish a more complete understanding of both the movement and pressures involved in a particular patient's condition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/6,19,21\">",
"     6,19,21",
"    </a>",
"    ]. Combined manometry and multichannel intraluminal impedance can also be used to predict ineffective pharyngeal swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/22\">",
"     22",
"    </a>",
"    ]. The AGA technical review for oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/23\">",
"     23",
"    </a>",
"    ] and the AGA guideline for esophageal manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/24\">",
"     24",
"    </a>",
"    ] can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    An abnormality of the UES should be suspected if the pharyngeal wave does not occur within the period of UES relaxation. UES dysfunction can be broadly divided into alterations in its resting tone or relaxation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormally high resting pressure of the UES (cricopharyngeal hypertension) may cause functional obstruction leading to dysphagia. Elevated resting pressures may occur as a primary disorder or, more commonly, may be associated with underlying gastroesophageal reflux. Reflux into the esophagus may result in reflexive UES contraction which is primarily due to esophageal distension, although acid may also play a role [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormally low resting pressures of the UES (cricopharyngeal hypotonia) have been described in a variety of neuromuscular disorders (such as myasthenia gravis, motor neuron disease [amyotrophic lateral sclerosis], and myotonic dystrophy). Dysphagia in such patients usually results from concomitant weakness of the pharyngeal musculature [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities in UES relaxation may also lead to oropharyngeal dysphagia. Delayed UES relaxation is observed in patients with Riley-Day syndrome or familial dysautonomia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete failure of UES relaxation (cricopharyngeal achalasia) is unusual. It has been described in association with oculopharyngeal muscular dystrophy and following neck surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. More often, the diagnosis is used to describe functional obstruction of the UES seen by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies. In such cases, poor opening of the UES is due to pharyngeal muscle weakness, poor elevation of the hyoid or decreased elasticity of the UES, rather than failure of its relaxation.",
"   </p>",
"   <p>",
"    Similarly, patients with a cricopharyngeal bar seen on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies (a defect in the upper esophagus at the level of the cricopharyngeus muscle), usually have reduced muscle compliance of the cricopharyngeus rather than hypertension or failure of relaxation of the UES [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of oropharyngeal dysphagia are to improve food transfer and to prevent aspiration. The approach chosen depends in part upon the cause of the dysphagia (",
"    <a class=\"graphic graphic_algorithm graphicRef54485 \" href=\"UTD.htm?22/24/22912\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neoplasms usually call for resection, chemotherapy or radiation therapy. Efforts should be coordinated with an otolaryngologist and oncologist.",
"     </li>",
"     <li>",
"      Following stroke, head or neck trauma, surgery, or in degenerative neurologic diseases, rehabilitation can be achieved through techniques that facilitate oral intake.",
"     </li>",
"     <li>",
"      Patients with esophageal webs or strictures usually benefit from therapeutic endoscopy.",
"     </li>",
"     <li>",
"      Surgical myotomy may benefit selected patients (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Swallowing rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a full evaluation, appropriate postural, nutritional, and behavioral modifications can be suggested. Successful rehabilitation depends largely on the cause of oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Simple remedies should not be overlooked. As an example, partially dentulous elderly patients who have difficulty masticating may benefit from prosthetic teeth. When specific swallowing training is required, referral to a specialist in swallowing disorders is helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The AGA technical review for oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/23\">",
"     23",
"    </a>",
"    ] can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Several maneuvers during swallowing may reduce oropharyngeal dysphagia, and their use should be based upon the specific defect leading to dysphagia (",
"    <a class=\"graphic graphic_table graphicRef81927 \" href=\"UTD.htm?16/4/16461\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tilting the head back and placing the bolus posteriorly on the stronger side of the mouth can counterbalance reduced oral mobility.",
"     </li>",
"     <li>",
"      Bending the neck forward can offset delayed pharyngeal contraction by assisting laryngeal elevation and closure.",
"     </li>",
"     <li>",
"      Turning the head to the weaker side while tilting it to the stronger side can facilitate directing and propelling of the bolus, and can help compensate for unilateral pharyngeal dysfunction.",
"     </li>",
"     <li>",
"      Oral motor exercises can strengthen the lip and tongue and control drooling while assisting bolus formation and propulsion.",
"     </li>",
"     <li>",
"      Use of the effortful swallow (modified Valsalva maneuver) can offset impaired tongue base retraction and decreased pharyngeal control.",
"     </li>",
"     <li>",
"      The supraglottic swallow improves laryngeal closure and airway protection.",
"     </li>",
"     <li>",
"      Use of Mendelsohn's maneuver (purposeful prolongation of anterosuperior laryngeal traction at mid-swallow) can assist laryngeal elevation, closure of the larynx, and opening of the upper esophageal sphincter (UES).",
"     </li>",
"     <li>",
"      Deliberate multiple swallows help clear pooling in the pharynx [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dietary modifications may also improve swallowing and help avoid aspiration. Some patients are more tolerant of solid, soft, or liquid consistencies. For patients with intolerance to liquids, for example, commercially available food additives that thicken liquids may be helpful since increasing bolus viscosity can improve swallowing function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/39\">",
"     39",
"    </a>",
"    ]. Other patients benefit from a reduction in the volume of their mouthfuls, or an alternation of solid and liquid boluses, which can facilitate transfer. In some cases, feeding with a particular implement, such as a cup, straw, or spoon, may improve swallowing.",
"   </p>",
"   <p>",
"    Assistance provided by a caretaker during meals can also be helpful. For patients whose dysphagia is related to neurologic dysfunction, administering meals during times of maximal attentiveness may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neuromuscular electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular electrical stimulation involves direct stimulation of muscles to recruit motor units and increase muscle strength. It has been applied to patients with oropharyngeal dysphagia in an attempt to improve swallowing function.",
"   </p>",
"   <p>",
"    Only a few studies have been published. A meta-analysis of seven studies found a small but significant improvement in swallowing overall but the results differed among the individual reports [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/40\">",
"     40",
"    </a>",
"    ]. Further studies are needed to clarify the role of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients found to have an esophageal web or a benign stricture usually benefit from endoscopy with dilation. Endoscopic therapy in such patients may be curative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=see_link\">",
"     \"Esophageal webs and rings\"",
"    </a>",
"    .) The rare patient with UES dysfunction due to failed or partial sphincter relaxation, a lack of pharyngoesophageal coordination, or a reduction in muscular compliance (referred to as primary cricopharyngeal dysfunction) may benefit from balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cricopharyngeal myotomy may be considered for patients who have inadequate pharyngeal contraction, lack coordination between the pharynx and the UES, or have inadequate UES",
"    <span class=\"nowrap\">",
"     relaxation/reduced",
"    </span>",
"    muscular compliance. Myotomy decreases or removes obstruction due to the relative high-pressure zone caused by the UES. Surgery for Zenker's diverticulum may also involve cricopharyngeal myotomy in conjunction with diverticulum suspension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=see_link\">",
"     \"Zenker's diverticulum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of the literature regarding outcomes of cricopharyngeal myotomy suggested that success was associated with appropriate patient selection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/43\">",
"     43",
"    </a>",
"    ]. Successful outcomes were associated with the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intact voluntary initiation of swallowing",
"     </li>",
"     <li>",
"      Adequate propulsive force generated by the tongue and pharyngeal constrictors",
"     </li>",
"     <li>",
"      Videofluorographic demonstration of obstruction to bolus flow at the level of the cricopharyngeus muscle",
"     </li>",
"     <li>",
"      Manometric evidence of relatively elevated UES pressure in comparison to the pharynx",
"     </li>",
"     <li>",
"      A relatively good neurologic prognosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the presence of dysarthria predicts a poor response to myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cricopharyngeal myotomy is not without its risks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In one series of 23 patients who underwent cricopharyngeal myotomy for a variety of conditions, 22 percent had complications (two with self-limiting pharyngeal leaks, and three with aspiration pneumonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/45\">",
"     45",
"    </a>",
"    ]. In another series of 40 patients, complications included a retropharyngeal hematoma in one patient and intraoperative death in another [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/44\">",
"     44",
"    </a>",
"    ]. A more recent series examined 253 patients who underwent cricopharyngeal myotomy by a single surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/47\">",
"     47",
"    </a>",
"    ]. Complications occurred in 40 patients (16 percent). The complications included wound or retropharyngeal infection, aspiration pneumonia, retropharyngeal hematoma, and fistula formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Botulinum toxin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin is a potent inhibitor of the release of acetylcholine from nerve endings and has been used successfully for decades to treat certain spastic disorders of skeletal muscle, such as blepharospasm and torticollis, and more recently achalasia. Limited experience suggests that botulinum toxin therapy may also have a role as an alternative to cricopharyngeal myotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series, injection of botulinum toxin into the cricopharyngeus muscle (performed under general anesthesia with electromyographic guidance) was associated with complete or marked relief of dysphagia in five of seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/49\">",
"     49",
"    </a>",
"    ]. Repeat injections may be required, which is similar to the use of botulinum toxin for the treatment of achalasia. Clinical experience with this approach has suggested safety concerns related to the potential for disrupting swallowing function. Thus, this approach is probably best reserved for centers that have considerable experience with it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another series, 21 patients with oropharyngeal dysphagia (eight with central nervous system abnormalities, five with peripheral nerve disease, and eight with idiopathic) underwent injection with 5 to 10 units of Botox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17000/abstract/50\">",
"     50",
"    </a>",
"    ]. Nine of the 21 patients had improvement in symptoms; however, one patient died due to a massive aspiration seven days after Botox injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=see_link\">",
"       \"Patient information: Dysphagia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysphagia can be classified as either oropharyngeal or esophageal. Initial evaluation of oropharyngeal and esophageal dysphagia differs, making their distinction important. In most cases a comprehensive examination and a careful history are sufficient to guide appropriate evaluation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination can usually distinguish between an esophageal and oropharyngeal cause of dysphagia (",
"      <a class=\"graphic graphic_algorithm graphicRef70866 \" href=\"UTD.htm?31/33/32287\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are five major tests that can be used for the evaluation of oropharyngeal dysphagia:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      radiography, videofluoroscopy, upper endoscopy, fiberoptic nasopharyngeal laryngoscopy, esophageal manometry. The choice of specific testing depends upon the clinical presentation and available expertise. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment of oropharyngeal dysphagia are to improve food transfer and to prevent aspiration. The approach chosen depends in part upon the cause of the dysphagia (",
"      <a class=\"graphic graphic_algorithm graphicRef54485 \" href=\"UTD.htm?22/24/22912\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/1\">",
"      American Gastroenterological Association medical position statement on management of oropharyngeal dysphagia. Gastroenterology 1999; 116:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/2\">",
"      Rothstein RD. A systematic approach to the patient with dysphagia. Hosp Pract (Minneap) 1997; 32:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/3\">",
"      Barloon TJ, Bergus GR, Lu CC. Diagnostic imaging in the evaluation of dysphagia. Am Fam Physician 1996; 53:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/4\">",
"      Shapiro J. Oropharyngeal dysphagia: pathophysiology, clinical assessment and management. Rev Gastroenterol Mex 1994; 59:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/5\">",
"      Duranceau A. Oropharyngeal dysphagia and disorders of the upper esopharyngeal sphincter. Ann Chir Gynaecol 1995; 84:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/6\">",
"      Cook IJ, Gabb M, Panagopoulos V, et al. Pharyngeal (Zenker's) diverticulum is a disorder of upper esophageal sphincter opening. Gastroenterology 1992; 103:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/7\">",
"      Skoretz SA, Flowers HL, Martino R. The incidence of dysphagia following endotracheal intubation: a systematic review. Chest 2010; 137:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/8\">",
"      Hendrix TR. Art and science of history taking in the patient with difficulty swallowing. Dysphagia 1993; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/9\">",
"      Kahrilas PJ. Current investigation of swallowing disorders. Baillieres Clin Gastroenterol 1994; 8:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/10\">",
"      Poorjavad M, Derakhshandeh F, Etemadifar M, et al. Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 2010; 16:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/11\">",
"      Koch WM. Swallowing disorders. Diagnosis and therapy. Med Clin North Am 1993; 77:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/12\">",
"      Pandolfino JE, Kahrilas PJ, American Gastroenterological Association. AGA technical review on the clinical use of esophageal manometry. Gastroenterology 2005; 128:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/13\">",
"      Rubesin SE. Oral and pharyngeal dysphagia. Gastroenterol Clin North Am 1995; 24:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/14\">",
"      Dodds WJ, Stewart ET, Logemann JA. Physiology and radiology of the normal oral and pharyngeal phases of swallowing. AJR Am J Roentgenol 1990; 154:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/15\">",
"      Stoeckli SJ, Huisman TA, Seifert B, Martin-Harris BJ. Interrater reliability of videofluoroscopic swallow evaluation. Dysphagia 2003; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/16\">",
"      Kelly AM, Drinnan MJ, Leslie P. Assessing penetration and aspiration: how do videofluoroscopy and fiberoptic endoscopic evaluation of swallowing compare? Laryngoscope 2007; 117:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/17\">",
"      Kelly AM, Leslie P, Beale T, et al. Fibreoptic endoscopic evaluation of swallowing and videofluoroscopy: does examination type influence perception of pharyngeal residue severity? Clin Otolaryngol 2006; 31:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/18\">",
"      Castell JA, Castell DO. Upper esophageal sphincter and pharyngeal function and oropharyngeal (transfer) dysphagia. Gastroenterol Clin North Am 1996; 25:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/19\">",
"      Castell JA, Dalton CB, Castell DO. Pharyngeal and upper esophageal sphincter manometry in humans. Am J Physiol 1990; 258:G173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/20\">",
"      Ghosh SK, Pandolfino JE, Zhang Q, et al. Deglutitive upper esophageal sphincter relaxation: a study of 75 volunteer subjects using solid-state high-resolution manometry. Am J Physiol Gastrointest Liver Physiol 2006; 291:G525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/21\">",
"      Olsson R, Castell JA, Castell DO, Ekberg O. Solid-state computerized manometry improves diagnostic yield in pharyngeal dysphagia: simultaneous videoradiography and manometry in dysphagia patients with normal barium swallows. Abdom Imaging 1995; 20:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/22\">",
"      Omari TI, Dejaeger E, Van Beckevoort D, et al. A novel method for the nonradiological assessment of ineffective swallowing. Am J Gastroenterol 2011; 106:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/23\">",
"      Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/24\">",
"      Pandolfino JE, Kahrilas PJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: Clinical use of esophageal manometry. Gastroenterology 2005; 128:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/25\">",
"      Gerhardt DC, Shuck TJ, Bordeaux RA, Winship DH. Human upper esophageal sphincter. Response to volume, osmotic, and acid stimuli. Gastroenterology 1978; 75:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/26\">",
"      Thompson DG, Andreollo NA, McIntyre AS, Earlam RJ. Studies of the oesophageal clearance responses to intraluminal acid. Gut 1988; 29:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/27\">",
"      Kilman WJ, Goyal RK. Disorders of pharyngeal and upper esophageal sphincter motor function. Arch Intern Med 1976; 136:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/28\">",
"      Margulies SI, Brunt PW, Donner MW, Silbiger ML. Familial dysautonomia. A cineradiographic study of the swallowing mechanism. Radiology 1968; 90:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/29\">",
"      RILEY CM. Familial dysautonomia. Adv Pediatr 1957; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/30\">",
"      Bender MD. Esophageal manometry in oculopharyngeal dystrophy. Am J Gastroenterol 1976; 65:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/31\">",
"      Bonanno PC. Swallowing dysfunction after tracheostomy. Ann Surg 1971; 174:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/32\">",
"      Duranceau A, Jamieson G, Hurwitz AL, et al. Alteration in esophageal motility after laryngectomy. Am J Surg 1976; 131:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/33\">",
"      Dantas RO, Cook IJ, Dodds WJ, et al. Biomechanics of cricopharyngeal bars. Gastroenterology 1990; 99:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/34\">",
"      Miller RM, Langmore SE. Treatment efficacy for adults with oropharyngeal dysphagia. Arch Phys Med Rehabil 1994; 75:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/35\">",
"      Langmore SE. Efficacy of behavioral treatment for oropharyngeal dysphagia. Dysphagia 1995; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/36\">",
"      Rosenvinge SK, Starke ID. Improving care for patients with dysphagia. Age Ageing 2005; 34:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/37\">",
"      Smith Hammond CA, Goldstein LB. Cough and aspiration of food and liquids due to oral-pharyngeal dysphagia: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:154S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/38\">",
"      Bates B, Choi JY, Duncan PW, et al. Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: executive summary. Stroke 2005; 36:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/39\">",
"      Clav&eacute; P, de Kraa M, Arreola V, et al. The effect of bolus viscosity on swallowing function in neurogenic dysphagia. Aliment Pharmacol Ther 2006; 24:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/40\">",
"      Carnaby-Mann GD, Crary MA. Examining the evidence on neuromuscular electrical stimulation for swallowing: a meta-analysis. Arch Otolaryngol Head Neck Surg 2007; 133:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/41\">",
"      Solt J, Bajor J, Moizs M, et al. Primary cricopharyngeal dysfunction: treatment with balloon catheter dilatation. Gastrointest Endosc 2001; 54:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/42\">",
"      Ali GN, Wallace KL, Laundl TM, et al. Predictors of outcome following cricopharyngeal disruption for pharyngeal dysphagia. Dysphagia 1997; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/43\">",
"      Buchholz DW. Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Dysphagia 1995; 10:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/44\">",
"      Poirier NC, Bonavina L, Taillefer R, et al. Cricopharyngeal myotomy for neurogenic oropharyngeal dysphagia. J Thorac Cardiovasc Surg 1997; 113:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/45\">",
"      Campbell BH, Tuominen TC, Toohill RJ. The risk and complications of aspiration following cricopharyngeal myotomy. Am J Med 1997; 103:61S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/46\">",
"      Ca&ntilde;ete-G&oacute;mez J, Ram&iacute;rez-Plaza CP, L&oacute;pez Rueda B, et al. [Diverticulectomy and cricopharyngeal myotomy for the treatment of Zenker's diverticulum. a presentation of 33 cases]. Cir Esp 2012; 90:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/47\">",
"      Brigand C, Ferraro P, Martin J, Duranceau A. Risk factors in patients undergoing cricopharyngeal myotomy. Br J Surg 2007; 94:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/48\">",
"      Blitzer A, Brin MF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg 1997; 116:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/49\">",
"      Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 1994; 103:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17000/abstract/50\">",
"      Zaninotto G, Marchese Ragona R, Briani C, et al. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. J Gastrointest Surg 2004; 8:997.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2237 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17000=[""].join("\n");
var outline_f16_38_17000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Videofluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fiberoptic endoscopic evaluation of swallowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nasopharyngeal laryngoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Swallowing rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neuromuscular electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Botulinum toxin injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2237|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/24/22912\" title=\"algorithm 1\">",
"      Eval Rx oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/33/32287\" title=\"algorithm 2\">",
"      Diagnosis of dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2237|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/38/21102\" title=\"diagnostic image 1\">",
"      Zenkers diverticulum UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/27/2495\" title=\"diagnostic image 2A\">",
"      Pharyngocele AP Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/37/5727\" title=\"diagnostic image 2B\">",
"      Pharyngocele lateral Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/7/44158\" title=\"diagnostic image 3\">",
"      Killian Jamieson diverticulum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2237|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/6/7273\" title=\"figure 1\">",
"      Deglutitive UES relaxation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/45/17117\" title=\"table 1\">",
"      Causes oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/4/16461\" title=\"table 2\">",
"      Swallowing therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=related_link\">",
"      Zenker's diverticulum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_17001="Pathophysiology, etiology, and differential diagnosis of vertigo";
var content_f16_38_17001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, etiology, and differential diagnosis of vertigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Joseph M Furman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/38/17001/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/38/17001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is a symptom of illusory movement. Almost everyone has experienced vertigo as the transient spinning dizziness immediately after turning around rapidly several times. Vertigo can also be a sense of swaying or tilting. Some perceive self-motion whereas others perceive motion of the environment. Vertigo is a symptom, not a diagnosis. It arises because of asymmetry in the vestibular system due to damage to or dysfunction of the labyrinth, vestibular nerve, or central vestibular structures in the brainstem.",
"   </p>",
"   <p>",
"    Vertigo is only one type of dizziness. Other disorders that present with dizziness include presyncopal faintness, disequilibrium, and nonspecific or ill-defined light-headedness. The initial approach to the patient who complains of dizziness is to localize the cause of the symptom into one of these broad categories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology, etiology, and differential diagnosis of vertigo will be reviewed here. The clinical approach, diagnosis, and treatment of vertigo are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=see_link\">",
"     \"Treatment of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The end organs of the vestibular system, the semicircular canals and the otolith organs, sense angular and linear motion, respectively. As a result, a patient's description of a spinning sensation is likely to indicate an abnormality of the semicircular canals or the central nervous system structures that process signals from the semicircular canals. Similarly, an illusory sensation of floating or tilting may indicate an otolith system disorder.",
"   </p>",
"   <p>",
"    Important to the pathogenesis of vertigo is the fact that there is a vestibular labyrinth on each side of the body. The central nervous system receives signals from both the right and left labyrinths and compares these signals with one another. When the head is still, tonic discharges in both vestibular afferents are exactly balanced. During motion, the right and left labyrinths are alternately excited and inhibited, leading to a left-right difference in eighth nerve activity, which is recognized as motion. The spurious left-right differences that result from an acute unilateral peripheral vestibular disorder are also interpreted by the central nervous system as motion or vertigo.",
"   </p>",
"   <p>",
"    The central nervous system, at the brainstem level, processes visual motion in a manner similar to that of self-motion. This normal, physiologic aspect of the vestibular system underlies the experience of self-motion when viewing large-screen movies. This ambiguity between motion of self and motion of surround relates directly to the lack of uniformity in patients' complaints of vertigo as either self-motion or motion of the surroundings.",
"   </p>",
"   <p>",
"    Information from the vestibular labyrinth is relayed via the vestibular portion of cranial nerve VIII to the brainstem vestibular nuclei and from there to the cerebellum, ocular motor nuclei, and spinal cord; there are also less well-defined cerebral projections. Vestibuloocular connections are responsible for coordinated eye movements during head motion, while vestibulospinal pathways help maintain upright posture. Cerebellar connections help modulate these activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of nystagmus\", section on 'Basic clinical vestibular physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF VERTIGO",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is customary to organize causes of vertigo into peripheral and central disorders (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"UTD.htm?24/29/25051\">",
"     table 1",
"    </a>",
"    ). These have distinctive clinical features, but with some overlap. Peripheral causes of vertigo generally comprise 80 percent of cases; of these, benign paroxysmal positional vertigo, vestibular neuritis, and Meniere disease are the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of the more common disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"UTD.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERIPHERAL ETIOLOGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Benign paroxysmal positional vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal positional vertigo (BPPV) is probably the most commonly recognized cause of vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/2\">",
"     2",
"    </a>",
"    ]. It is most commonly attributed to calcium debris within the",
"    <strong>",
"     posterior",
"    </strong>",
"    semicircular canal, known as canalithiasis.",
"   </p>",
"   <p>",
"    Classically, patients describe a brief spinning sensation brought on when turning in bed or tilting the head backward to look up. The dizziness is quite brief, usually seconds, rarely minutes. It may be severe enough to halt activity for this duration. Patients may experience nausea but rarely vomit. Ear pain, hearing loss, and tinnitus are absent.",
"   </p>",
"   <p>",
"    The diagnosis of BPPV is generally made by its historical description. The Dix-Hallpike maneuver can provide further evidence of its presence, but is positive in only 50 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the patient with vertigo\", section on 'Dix-Hallpike maneuver'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of BPPV is one of repeated, brief vertiginous episodes that are predictably provoked and continue for weeks or months. Episodes may recur. BPPV is generally attributed to otolithic debris within a semicircular canal and can be treated by canalith repositioning maneuvers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link\">",
"     \"Benign paroxysmal positional vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, patients presenting with positional vertigo have central nervous system abnormalities with a less favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Usually, the symptoms are somewhat more prolonged. Patients with atypical positional vertigo or nystagmus who do not respond to treatment should undergo magnetic resonance imaging (MRI) of the brain to rule out a posterior fossa abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link\">",
"     \"Benign paroxysmal positional vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vestibular neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neuritis, also known as vestibular neuronitis and labyrinthitis, is believed to be a viral or postviral inflammatory disorder, affecting the vestibular portion of the eighth cranial nerve.",
"   </p>",
"   <p>",
"    Vestibular neuritis is characterized by the rapid onset of severe, persistent vertigo, nausea, vomiting, and gait instability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/6\">",
"     6",
"    </a>",
"    ]. Physical examination findings are consistent with an acute peripheral vestibular imbalance: spontaneous vestibular nystagmus, a positive head thrust test (",
"    <a class=\"graphic graphic_figure graphicRef52022 \" href=\"UTD.htm?17/19/17715\">",
"     figure 1",
"    </a>",
"    ), and gait instability without a loss of the ability to ambulate. In pure vestibular neuritis, auditory function is preserved; when this syndrome is combined with unilateral hearing loss, it is called labyrinthitis.",
"   </p>",
"   <p>",
"    A diagnosis of vestibular neuritis is largely based on clinical information. There are no specific diagnostic tests. However, the clinical features of cerebellar hemorrhage or infarction may be similar to vestibular neuritis, and brain imaging is therefore often required to rule this out [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with vestibular neuritis generally suffer from severe vestibular symptoms for one to two days, followed by a gradual diminution of symptoms and a return of equilibrium. Recovery may be hastened with corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link\">",
"     \"Vestibular neuritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Herpes zoster oticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often called the Ramsay Hunt syndrome, this syndrome is believed to represent activation of latent herpes zoster infection of the geniculate ganglion.",
"   </p>",
"   <p>",
"    In addition to acute vertigo",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hearing loss, ipsilateral facial paralysis, ear pain, and vesicles in the auditory canal and auricle are typical features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Ramsay Hunt syndrome (Herpes zoster oticus)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy with corticosteroids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    should be considered, although these modalities are not of proven value [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment of herpes zoster infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meniere disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniere disease is a peripheral vestibular disorder attributed to excess endolymphatic fluid pressure, which causes episodic inner ear dysfunction. Issues related to Meniere disease are discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link\">",
"     \"Meniere disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients present with spontaneous episodic vertigo lasting for minutes to hours, usually associated with unilateral tinnitus, hearing loss, and ear fullness. The vertigo associated with Meniere disease is often severe and associated with nausea and vomiting and disabling imbalance. The disequilibrium may last for several days. Horizontal-torsional nystagmus is typically seen on examination during an attack.",
"   </p>",
"   <p>",
"    The diagnosis of Meniere disease is suggested by the history. A low frequency sensorineural hearing loss on audiometry and a unilateral reduced vestibular response on electronystagmography help confirm the diagnosis.",
"   </p>",
"   <p>",
"    Exacerbations of Meniere disease may last for months or years during which time episodes can occur as frequently as every few days. The condition can go into remission spontaneously or with treatment, and it can recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Labyrinthine concussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labyrinthine concussion refers to traumatic peripheral vestibular injury following direct concussive head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This may also occur with abrupt changes of head motion not necessarily associated with impact. A more severe, direct injury to cochlear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vestibular structures usually occurs in the setting of transverse fractures of the temporal bone. Hemotympanum and sensorineural hearing loss often accompany vertigo in this setting.",
"   </p>",
"   <p>",
"    In both of these injuries, symptoms of vertigo, nausea and vomiting, and imbalance are maximal at onset and improve over days to months, depending on the severity of the injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H20#H20\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Post-traumatic vertigo'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequelae of labyrinthine concussion may include BPPV and, occasionally, post-traumatic endolymphatic hydrops (Meniere disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These sequelae may be delayed for weeks to months after the head injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Perilymphatic fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an infrequent complication of head injury, barotrauma, or heavy lifting in which a fistula develops at the otic capsule, permitting a transfer of pressure changes to the macular and cupular receptors. This explains the clinical syndrome of episodic vertigo",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hearing loss provoked by sneezing, lifting, straining, coughing, and loud sounds. The latter, so-called Tullio phenomenon, occurs because sound-induced pressure waves are abnormally distributed through the inner ear.",
"   </p>",
"   <p>",
"    The diagnosis is difficult as clinical tests are insensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/14\">",
"     14",
"    </a>",
"    ]. Computed tomography (CT) scanning may show fluid in the region of the round window recess [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment with bed rest, head elevation, and avoidance of straining is the first step; failure to resolve after several weeks of conservative therapy is an indication to consider a surgical patch [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Recurrences occur in 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Semicircular canal dehiscence syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In semicircular canal dehiscence syndrome, the bone overlying the superior aspect of the superior semicircular canal becomes thin or even absent, thereby allowing pressure to be transmitted to the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/18\">",
"     18",
"    </a>",
"    ]. Vertigo is provoked by coughing, sneezing, and Valsalva maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Patients may experience nausea and instability during brief episodes of vertigo.",
"   </p>",
"   <p>",
"    Loud sound may also induce vertigo in this condition (Tullio phenomenon), as sound-induced pressure waves are abnormally distributed through the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ]. This phenomenon can be tested through a click-evoked vestibuloocular reflex, which is typically high magnitude and low threshold in patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ]. Cochlear hypersensitivity is another diagnostic indicator for this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Some patients also have hearing loss, with air-bone gaps on audiometry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/28\">",
"     28",
"    </a>",
"    ]. One case report noted torsional pendular nystagmus that was synchronous with the palpated pulse, and suppressed by Valsalva maneuver or lying supine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is a rare syndrome. A 2005 review revealed less than 100 reported cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the condition may be underdiagnosed. The diagnosis can be established with an MRI or high resolution CT of the temporal bone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/30\">",
"     30",
"    </a>",
"    ]. Some patients benefit by surgical repair of their anatomical deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cogan's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cogan's syndrome is an autoimmune condition that can cause interstitial keratitis and vestibuloauditory dysfunction.",
"   </p>",
"   <p>",
"    Patients have Meniere-like attacks consisting of vertigo, ataxia, nausea, vomiting, tinnitus, and hearing loss. Vestibular dysfunction may also cause oscillopsia, which is the perception of objects jiggling back and forth after abruptly turning the head to one side or the other. Caloric testing often reveals absent vestibular function.",
"   </p>",
"   <p>",
"    Systemic steroids and other immunosuppressants may be required. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/42/12968?source=see_link\">",
"     \"Cogan&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrent vestibulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vestibulopathy is a descriptive diagnosis used for patients who experience spontaneous episodes of vertigo unassociated with otologic complaints (ie, no hearing loss, tinnitus, or ear fullness, and unassociated with migrainous phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/31\">",
"     31",
"    </a>",
"    ]. Symptoms often include nausea, vomiting, and disequilibrium. Vertigo may occur infrequently, for example, every one to two years. Once vertigo is resolved, patients return to normal without sequelae.",
"   </p>",
"   <p>",
"    The pathophysiology of recurrent vestibulopathy is uncertain. The condition is thought to represent a vestibular disorder of uncertain localization. Some cases appear to cluster in families [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/32\">",
"     32",
"    </a>",
"    ]. This disorder may overlap with migrainous vertigo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Vestibular schwannoma (acoustic neuroma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the tumor grows slowly, the subtle imbalances in vestibular input are compensated for by the central nervous system, and patients often do not experience significant vertigo. Imbalance or a vague feeling of swaying or tilting may be the only manifestations of vestibular injury. Unilateral hearing loss or tinnitus is more likely to bring the patient to medical attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Aminoglycoside toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several aminoglycoside agents, notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , are selectively vestibulotoxic, causing peripheral vestibular damage without affecting hearing, presumably by damaging the hair cells of the inner ear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because both vestibular end organs are equally affected, there is no",
"    <span class=\"nowrap\">",
"     right/left",
"    </span>",
"    imbalance of vestibular input to the central nervous system, and, therefore, the patient does not experience vertigo. Patients may experience oscillopsia (to-and-fro illusion of environmental motion) with head movement, indicating a deficient vestibuloocular reflex. Bilateral vestibular loss is associated with abnormal head thrust testing (",
"    <a class=\"graphic graphic_figure graphicRef52022 \" href=\"UTD.htm?17/19/17715\">",
"     figure 1",
"    </a>",
"    ) in both horizontal directions, as well as reduced visual acuity during head shaking, and can be documented with both caloric and rotational testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/35\">",
"     35",
"    </a>",
"    ]. Severe bilateral vestibular loss leads to chronic disequilibrium and oscillopsia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media may be associated with vestibular symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/37\">",
"     37",
"    </a>",
"    ]. Nonspecific dizziness is more common than vertigo; however, a serous or suppurative labyrinthitis may complicate otitis media, producing frank vertigo. Patients with acute bacterial labyrinthitis are quite ill with fever, hearing loss, and nausea and vomiting in addition to vertigo. Hospitalization and intravenous antibiotics are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H104578870#H104578870\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Balance and motor problems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If tragal stimulation provokes dizziness in a patient with otitis, a CT scan of the temporal bone should be done to rule out a fistula of the bony labyrinth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CENTRAL ETIOLOGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Migrainous vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is increasingly recognized as a cause of recurrent vertigo. However, the mechanism whereby migraine causes vertigo is not understood, and the diagnosis remains somewhat controversial.",
"   </p>",
"   <p>",
"    Migrainous vertigo may have both central and peripheral vestibular manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/39\">",
"     39",
"    </a>",
"    ]. The severity of vertigo is variable. Its duration is also highly variable, with some patients complaining of fleeting, seconds-long symptoms, as is characteristic of benign paroxysmal positional vertigo (BPPV). Episodes lasting for several minutes to a few hours are more typical [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diagnosis of migrainous vertigo relies on historical information, in which at least some attacks of vertigo are associated with migraine headache or other migrainous phenomenon (visual aura, photophobia, or phonophobia) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/41\">",
"     41",
"    </a>",
"    ]. Episodes of migraine-related dizziness generally occur spontaneously but, similar to migraine headache, can be triggered by certain foods, certain sensory stimuli, and certain situations.",
"   </p>",
"   <p>",
"    A condition called benign recurrent vertigo of childhood is considered a childhood manifestation of migraine-related dizziness or vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/42\">",
"     42",
"    </a>",
"    ]. Many of these children go on to develop more typical migraine headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link\">",
"     \"Migrainous vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Brainstem ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolic, atherosclerotic occlusions of the vertebrobasilar arterial system will produce brainstem ischemia. While vertigo may dominate the clinical presentation, it is rarely the sole manifestation of brainstem ischemia. Nonetheless, a cerebrovascular origin of symptoms should be excluded in patients who present with vertigo if they have vascular risk factors, because of the relatively high risk of recurrent stroke, which may be mitigated by appropriate interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While infarction produces sustained symptoms that improve over several days and weeks, transient ischemic attacks (TIA) involving the brainstem more usually last several minutes, perhaps hours. It is debated whether vertigo without brainstem symptoms can occur with vertebrobasilar ischemia; however, it seems reasonable to consider the diagnosis in older patients or those with vascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/44\">",
"     44",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) with diffusion-weighted imaging may be helpful, but its sensitivity is less than 50 percent; magnetic resonance angiography (MRA) may demonstrate arterial occlusive disease in the posterior circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3627222\">",
"    <span class=\"h4\">",
"     Rotational vertebral artery syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rotational vertebral artery syndrome (also called rotational vertebrobasilar insufficiency or bow hunter syndrome) refers to a rare but well documented phenomenon of symptomatic vertebral artery compression by bony elements of the spine (usually at CI-C2) that occurs with physiologic head rotation. Most patients with this condition report vertigo or nonspecific dizziness with head turning. The diagnosis is made by vascular imaging that includes the neutral as well as the symptomatic position [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. Degenerative bone disease as well as congenital foraminal narrowing can be causative; disease or hypoplasia of the noninvolved vertebral artery is usually described.",
"   </p>",
"   <p>",
"    Surgical decompression may be successful when conservative approaches (eg, avoiding movements that precipitate symptoms) fail [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Noninvasive interventions, such as traction and enhanced external counterpulsation (EECP) are under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Wallenberg's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wallenberg's syndrome, or lateral medullary infarction, is associated with the acute onset of vertigo and disequilibrium. The blood supply to the lateral medulla is the posterior inferior cerebellar artery. Most patients with Wallenberg's syndrome have an occlusion of the ipsilateral vertebral artery that gives rise to the posterior inferior cerebellar artery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link&amp;anchor=H8#H8\">",
"     \"Posterior circulation cerebrovascular syndromes\", section on 'Lateral medullary infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While vertigo often dominates the clinical presentation, examination usually uncovers other neurologic deficits: abnormal eye movements, an ipsilateral Horner's syndrome, ipsilateral limb ataxia, and a dissociated sensory loss (loss of pain and temperature sensation on the ipsilateral face and contralateral trunk). Hoarseness and dysphagia are often present.",
"   </p>",
"   <p>",
"    Wallenberg's syndrome usually occurs as a result of atherosclerotic or lipohyalinotic arterial occlusion, but it is also a common presentation for traumatic vertebral artery dissection. A history of neck injury or neck pain suggests the latter. The diagnosis of medullary infarction is established definitively with MRI. MRA of the head and neck should be performed as well to rule out arterial dissection. Patients usually recover their equilibrium after several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other stroke syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labyrinthine infarction may occur with occlusion of the internal auditory artery, a branch of the anterior inferior cerebellar artery (AICA). This is really a peripheral lesion of the vestibular system and is characterized by abrupt vertigo, hearing loss, and sometimes tinnitus.",
"     </li>",
"     <li>",
"      A more proximal occlusion of the AICA will also involve the lateral pons and cerebellar peduncle, causing gait and limb ataxia and facial paralysis in addition to vertigo and hearing loss.",
"     </li>",
"     <li>",
"      More restrictive brainstem infarctions have been described that affect isolated vestibular structures. Thus, their clinical manifestations are very similar to vestibular neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cerebellar infarction and hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cerebellar hemorrhage or infarction may produce sudden, intense vertigo accompanied by nausea and vomiting. This syndrome may be clinically indistinguishable from vestibular neuritis at presentation. Limb ataxia is helpful in suggesting cerebellar involvement but is often absent if the lesion is more medially or inferiorly placed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cerebellar lesions, the patient falls toward the side of the lesion, and nystagmus is more pronounced to the side of the lesion, while in labyrinthine disease or vestibular neuritis, the direction of falls (toward the lesion) and nystagmus (away from the lesion) are opposite. In general, gait is more impaired with acute cerebellar lesions than in vestibular neuritis. However, these caveats are often of limited value in clinical assessment, because it is often difficult to persuade patients with acute, severe vertigo to attempt to walk.",
"   </p>",
"   <p>",
"    Cerebellar infarction and hemorrhage typically occur in older patients (&gt;60 years) and in those who have risk factors, particularly hypertension and diabetes.",
"   </p>",
"   <p>",
"    Neuroimaging may be required to exclude these disorders in patients presenting with acute sustained vertigo, in particular if the patient is older",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has other vascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/8,54\">",
"     8,54",
"    </a>",
"    ]. A computed tomography (CT) scan can exclude cerebellar hemorrhage and should be done urgently if MRI is not immediately available, as patients can deteriorate abruptly. A brain MRI is more sensitive for cerebellar infarction, especially in the acute setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chiari malformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Chiari I malformation is a congenital anomaly in which the cerebellar tonsils extend below the foramen magnum. This is usually asymptomatic but may be associated with a constellation of neurologic deficits (headache or neck pain, weakness with long tract signs, dysphagia, and other lower cranial nerve impairments) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Vertigo and gait imbalance are common complaints in symptomatic individuals and may represent cerebellar or brainstem pathology",
"   </p>",
"   <p>",
"    When present, vertigo is often positionally induced, particularly by neck extension, perhaps manifesting pressure on brainstem and cerebellar structures or their blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/55\">",
"     55",
"    </a>",
"    ]. Vertiginous symptoms are generally mild and often resolve when the patient alters his or her head position. Downbeating nystagmus is often associated with this syndrome, but other patterns of central nystagmus may be seen as well. The diagnosis is confirmed with sagittal MRI.",
"   </p>",
"   <p>",
"    Surgical decompression may be required to relieve symptoms and is usually successful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo has been estimated to occur in 20 percent of multiple sclerosis (MS) patients, most commonly with plaques near the vestibular nuclei and in the root entry zone of cranial nerve VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/55,59\">",
"     55,59",
"    </a>",
"    ]. A syndrome similar to vestibular neuritis may occur, with acute sustained vertigo with peripheral characteristics. It may be associated with symptoms reflecting dysfunction of adjacent cranial nerves such as hyper- or hypoacusis, facial numbness, and diplopia.",
"   </p>",
"   <p>",
"    Vertigo can also occur with plaques within the brachium conjunctivum and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/60\">",
"     60",
"    </a>",
"    ]. This localization is more commonly associated with acute, sustained vertigo that has more central characteristics, as in cerebellar infarction.",
"   </p>",
"   <p>",
"    The diagnosis is usually evident in patients with an established history of multiple sclerosis (MS). When vertigo is the presenting symptom, the diagnosis requires a high degree of suspicion; suggestive features include a history of prior neurologic symptoms and abnormal findings on neurologic examination (eg, afferent pupillary defect, long tract signs). Demyelination should not be assumed to be the cause of vertigo in a patient with MS. One series noted that among 25 patients with MS complaining of vertigo, BPPV, not MS, was the underlying cause in more than half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms related to an MS flare last days to weeks. A short course of corticosteroids may shorten disabling attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Episodic ataxia type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodic ataxia type 2 (EA-2) is an autosomal dominant condition caused by mutations in a brain-specific",
"    <span class=\"nowrap\">",
"     P/Q",
"    </span>",
"    type calcium channel gene on chromosome 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/62\">",
"     62",
"    </a>",
"    ]. Attacks of severe vertigo, nausea, and vomiting, and ataxia begin in childhood or early adult life. These can last a few hours or a few days. Gaze-evoked, rebound, or downbeat nystagmus may be evident not only during but also between attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The attacks respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    in a dose of 250 to 750",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the hereditary ataxias\", section on 'Episodic ataxias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8272202\">",
"    <span class=\"h2\">",
"     Disembarkment (mal de debarquement) syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perception of self-motion and imbalance is described by some individuals following exposure to passive motion. Water travel is the most usual trigger, but others (air or land travel, flight simulators, water beds) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Persons with this syndrome do not in general describe rotational vertigo but rather disequilibrium and a sense of swaying or rocking, or walking on uneven ground. There is often a latency of several minutes to an hour or two between return to solid ground and symptom onset. Patients are not nauseous and physical examination is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/66\">",
"     66",
"    </a>",
"    ]. Short durations, usually several minutes or a few hours, of these symptoms are common in sea travelers, but even a day or two of symptoms may be considered normal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncommonly, cases of persistent and disabling symptoms lasting for weeks and years are reported in individuals ages 15 to 77 years and demonstrate a female preponderance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65,66,69\">",
"     65,66,69",
"    </a>",
"    ]. A history of motion sickness or seasickness during the initial exposure or otherwise is present in some patients, but not clearly the majority. Interestingly, re-exposure to passive motion, whether the initial trigger or an alternative (eg, riding in a car) is typically associated with temporary mitigation of symptoms during the exposure, but exacerbation afterward. Motion sickness is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=see_link\">",
"     \"Motion sickness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to imbalance and a sense of motion, patients describe difficulty tolerating complex visual stimuli (eg, video games); they also report disabling cognitive difficulties and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Many patients develop depression and anxiety. These are believed to be a reaction to symptoms, not a cause. However, psychiatric comorbidity may contribute to symptom refractoriness if not addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatment options are limited. The longer symptoms persist, the less likely they are to remit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients who recover from an episode may be susceptible to recurrences of increasing duration. Benzodiazepines can provide limited symptomatic relief;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    0.25 to 0.5 mg twice daily is most often used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65,69\">",
"     65,69",
"    </a>",
"    ]. Higher doses are not likely to be more effective. Physical therapy and vestibular rehabilitation have not been reported to be helpful.",
"   </p>",
"   <p>",
"    The pathogenesis of disembarkment syndrome is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/67\">",
"     67",
"    </a>",
"    ]. Vestibular tests are normal or nonspecifically abnormal, as are structural and functional neuroimaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Some patients demonstrate postural instability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/38/17001/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is a symptom of illusory movement. Vertigo is a symptom, not a diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertigo arises because of asymmetry in the vestibular system due to damage to or dysfunction of the labyrinth, vestibular nerve, or central vestibular structures in the brainstem. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vertigo is only one type of dizziness. Other disorders that present with dizziness include presyncopal faintness, disequilibrium, and nonspecific or ill-defined light-headedness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"       \"Approach to the patient with dizziness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is customary to organize causes of vertigo into peripheral and central disorders (",
"      <a class=\"graphic graphic_table graphicRef66539 \" href=\"UTD.htm?24/29/25051\">",
"       table 1",
"      </a>",
"      ). These have distinctive clinical features, but with some overlap. Peripheral causes of vertigo generally comprise 80 percent of cases; of these, benign paroxysmal positional vertigo, vestibular neuritis, and Meniere disease are the most common. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Peripheral etiologies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Central etiologies'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The clinical features of the more common disorders are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef81596 \" href=\"UTD.htm?9/14/9453\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Peripheral etiologies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Central etiologies'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/1\">",
"      Kroenke K, Hoffman RM, Einstadter D. How common are various causes of dizziness? A critical review. South Med J 2000; 93:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/2\">",
"      Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med 1999; 341:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/3\">",
"      Froehling DA, Silverstein MD, Mohr DN, et al. Benign positional vertigo: incidence and prognosis in a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 1991; 66:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/4\">",
"      Watson P, Barber HO, Deck J, Terbrugge K. Positional vertigo and nystagmus of central origin. Can J Neurol Sci 1981; 8:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/5\">",
"      Dunniway HM, Welling DB. Intracranial tumors mimicking benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 1998; 118:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/6\">",
"      Baloh RW. Clinical practice. Vestibular neuritis. N Engl J Med 2003; 348:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/7\">",
"      Hotson JR, Baloh RW. Acute vestibular syndrome. N Engl J Med 1998; 339:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/8\">",
"      Norrving B, Magnusson M, Holt&aring;s S. Isolated acute vertigo in the elderly; vestibular or vascular disease? Acta Neurol Scand 1995; 91:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/9\">",
"      Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/10\">",
"      Friedman JM. Post-traumatic vertigo. Med Health R I 2004; 87:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/11\">",
"      Hoffer ME, Gottshall KR, Moore R, et al. Characterizing and treating dizziness after mild head trauma. Otol Neurotol 2004; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/12\">",
"      Gordon CR, Levite R, Joffe V, Gadoth N. Is posttraumatic benign paroxysmal positional vertigo different from the idiopathic form? Arch Neurol 2004; 61:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/13\">",
"      Ernst A, Basta D, Seidl RO, et al. Management of posttraumatic vertigo. Otolaryngol Head Neck Surg 2005; 132:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/14\">",
"      Seltzer S, McCabe BF. Perilymph fistula: the Iowa experience. Laryngoscope 1986; 96:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/15\">",
"      Casselman JW. Diagnostic imaging in clinical neuro-otology. Curr Opin Neurol 2002; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/16\">",
"      Kozuka M, Nakashima T, Fukuta S, Yanagita N. Inner ear disorders due to pressure change. Clin Otolaryngol Allied Sci 1997; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/17\">",
"      Maitland CG. Perilymphatic fistula. Curr Neurol Neurosci Rep 2001; 1:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/18\">",
"      Baloh RW. Superior semicircular canal dehiscence syndrome: Leaks and squeaks can make you dizzy. Neurology 2004; 62:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/19\">",
"      Minor LB. Superior canal dehiscence syndrome. Am J Otol 2000; 21:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/20\">",
"      Minor LB, Cremer PD, Carey JP, et al. Symptoms and signs in superior canal dehiscence syndrome. Ann N Y Acad Sci 2001; 942:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/21\">",
"      Welgampola MS, Myrie OA, Minor LB, Carey JP. Vestibular-evoked myogenic potential thresholds normalize on plugging superior canal dehiscence. Neurology 2008; 70:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/22\">",
"      Watson SR, Halmagyi GM, Colebatch JG. Vestibular hypersensitivity to sound (Tullio phenomenon): structural and functional assessment. Neurology 2000; 54:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/23\">",
"      Hirvonen TP, Carey JP, Liang CJ, Minor LB. Superior canal dehiscence: mechanisms of pressure sensitivity in a chinchilla model. Arch Otolaryngol Head Neck Surg 2001; 127:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/24\">",
"      Aw ST, Todd MJ, Aw GE, et al. Click-evoked vestibulo-ocular reflex: stimulus-response properties in superior canal dehiscence. Neurology 2006; 66:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/25\">",
"      Rosengren SM, Aw ST, Halmagyi GM, et al. Ocular vestibular evoked myogenic potentials in superior canal dehiscence. J Neurol Neurosurg Psychiatry 2008; 79:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/26\">",
"      Minor LB, Carey JP, Cremer PD, et al. Dehiscence of bone overlying the superior canal as a cause of apparent conductive hearing loss. Otol Neurotol 2003; 24:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/27\">",
"      Halmagyi GM, Aw ST, McGarvie LA, et al. Superior semicircular canal dehiscence simulating otosclerosis. J Laryngol Otol 2003; 117:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/28\">",
"      Lempert T, von Brevern M. Episodic vertigo. Curr Opin Neurol 2005; 18:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/29\">",
"      Hain TC, Cherchi M. Pulse-synchronous torsional pendular nystagmus in unilateral superior canal dehiscence. Neurology 2008; 70:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/30\">",
"      Belden CJ, Weg N, Minor LB, Zinreich SJ. CT evaluation of bone dehiscence of the superior semicircular canal as a cause of sound- and/or pressure-induced vertigo. Radiology 2003; 226:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/31\">",
"      Rutka JA, Barber HO. Recurrent vestibulopathy: third review. J Otolaryngol 1986; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/32\">",
"      Oh AK, Lee H, Jen JC, et al. Familial benign recurrent vertigo. Am J Med Genet 2001; 100:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/33\">",
"      WERSALL J, HAWKINS JE Jr. The vestibular sensory epithelia in the cat labyrinth and their reactions in chronic streptomycin intoxication. Acta Otolaryngol 1962; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/34\">",
"      Minor LB. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998; 279:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/35\">",
"      Weber KP, Aw ST, Todd MJ, et al. Horizontal head impulse test detects gentamicin vestibulotoxicity. Neurology 2009; 72:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/36\">",
"      Zingler VC, Weintz E, Jahn K, et al. Follow-up of vestibular function in bilateral vestibulopathy. J Neurol Neurosurg Psychiatry 2008; 79:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/37\">",
"      Meyerhoff WL, Kim CS, Paparella MM. Pathology of chronic otitis media. Ann Otol Rhinol Laryngol 1978; 87:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/38\">",
"      Minor LB. Labyrinthine fistulae: pathobiology and management. Curr Opin Otolaryngol Head Neck Surg 2003; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/39\">",
"      von Brevern M, Zeise D, Neuhauser H, et al. Acute migrainous vertigo: clinical and oculographic findings. Brain 2005; 128:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/40\">",
"      Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol 2003; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/41\">",
"      Neuhauser H, Leopold M, von Brevern M, et al. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 2001; 56:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/42\">",
"      Abu-Arafeh I, Russell G. Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia 1995; 15:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/43\">",
"      Lee CC, Su YC, Ho HC, et al. Risk of stroke in patients hospitalized for isolated vertigo: a four-year follow-up study. Stroke 2011; 42:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/44\">",
"      Baloh RW. Vertebrobasilar insufficiency and stroke. Otolaryngol Head Neck Surg 1995; 112:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/45\">",
"      Ho CY, Douglas-Akinwande AC, Rankin JL. Multichannel computed tomography angiography and its role in the evaluation of rotational vertebrobasilar insufficiency. J Comput Assist Tomogr 2008; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/46\">",
"      Dabus G, Gerstle RJ, Parsons M, et al. Rotational vertebrobasilar insufficiency due to dynamic compression of the dominant vertebral artery by the thyroid cartilage and occlusion of the contralateral vertebral artery at C1-2 level. J Neuroimaging 2008; 18:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/47\">",
"      Bulsara KR, Velez DA, Villavicencio A. Rotational vertebral artery insufficiency resulting from cervical spondylosis: case report and review of the literature. Surg Neurol 2006; 65:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/48\">",
"      Miele VJ, France JC, Rosen CL. Subaxial positional vertebral artery occlusion corrected by decompression and fusion. Spine (Phila Pa 1976) 2008; 33:E366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/49\">",
"      Petridis AK, Barth H, Buhl R, Mehdorn HM. Vertebral artery decompression in a patient with rotational occlusion. Acta Neurochir (Wien) 2008; 150:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/50\">",
"      D'Angelo VA, Galarza M, Catapano D, et al. Lateral ventricle tumors: surgical strategies according to tumor origin and development--a series of 72 cases. Neurosurgery 2005; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/51\">",
"      FISHER CM, KARNES WE, KUBIK CS. Lateral medullary infarction-the pattern of vascular occlusion. J Neuropathol Exp Neurol 1961; 20:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/52\">",
"      Kim JS. Vertigo and gait ataxia without usual signs of lateral medullary infarction: a clinical variant related to rostral-dorsolateral lesions. Cerebrovasc Dis 2000; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/53\">",
"      Kim HA, Lee H. Isolated vestibular nucleus infarction mimicking acute peripheral vestibulopathy. Stroke 2010; 41:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/54\">",
"      Schwartz NE, Venkat C, Albers GW. Transient isolated vertigo secondary to an acute stroke of the cerebellar nodulus. Arch Neurol 2007; 64:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/55\">",
"      Solomon D. Distinguishing and treating causes of central vertigo. Otolaryngol Clin North Am 2000; 33:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/56\">",
"      Fern&aacute;ndez AA, Guerrero AI, Mart&iacute;nez MI, et al. Malformations of the craniocervical junction (Chiari type I and syringomyelia: classification, diagnosis and treatment). BMC Musculoskelet Disord 2009; 10 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/57\">",
"      Klekamp J, Batzdorf U, Samii M, Bothe HW. The surgical treatment of Chiari I malformation. Acta Neurochir (Wien) 1996; 138:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/58\">",
"      Dones J, De Jes&uacute;s O, Colen CB, et al. Clinical outcomes in patients with Chiari I malformation: a review of 27 cases. Surg Neurol 2003; 60:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/59\">",
"      Frohman EM, Kramer PD, Dewey RB, et al. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 2003; 9:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/60\">",
"      Anagnostou E, Mandellos D, Limbitaki G, et al. Positional nystagmus and vertigo due to a solitary brachium conjunctivum plaque. J Neurol Neurosurg Psychiatry 2006; 77:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/61\">",
"      Frohman EM, Zhang H, Dewey RB, et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 2000; 55:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/62\">",
"      Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/63\">",
"      Vighetto A, Froment JC, Trillet M, Aimard G. Magnetic resonance imaging in familial paroxysmal ataxia. Arch Neurol 1988; 45:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/64\">",
"      Baloh RW, Yue Q, Furman JM, Nelson SF. Familial episodic ataxia: clinical heterogeneity in four families linked to chromosome 19p. Ann Neurol 1997; 41:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/65\">",
"      Cha YH. Mal de debarquement. Semin Neurol 2009; 29:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/66\">",
"      Cha YH, Brodsky J, Ishiyama G, et al. Clinical features and associated syndromes of mal de debarquement. J Neurol 2008; 255:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/67\">",
"      DeFlorio PT, Silbergleit R. Mal de debarquement presenting in the Emergency Department. J Emerg Med 2006; 31:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/68\">",
"      Gordon CR, Spitzer O, Doweck I, et al. Clinical features of mal de debarquement: adaptation and habituation to sea conditions. J Vestib Res 1995; 5:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/69\">",
"      Hain TC, Hanna PA, Rheinberger MA. Mal de debarquement. Arch Otolaryngol Head Neck Surg 1999; 125:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/38/17001/abstract/70\">",
"      Nachum Z, Shupak A, Letichevsky V, et al. Mal de debarquement and posture: reduced reliance on vestibular and visual cues. Laryngoscope 2004; 114:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5101 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17001=[""].join("\n");
var outline_f16_38_17001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF VERTIGO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERIPHERAL ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Herpes zoster oticus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Labyrinthine concussion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Perilymphatic fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Semicircular canal dehiscence syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cogan's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrent vestibulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Aminoglycoside toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Otitis media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CENTRAL ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Brainstem ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3627222\">",
"      Rotational vertebral artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Wallenberg's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other stroke syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cerebellar infarction and hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chiari malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Episodic ataxia type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8272202\">",
"      Disembarkment (mal de debarquement) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5101|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/19/17715\" title=\"figure 1\">",
"      Head thrust test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/29/25051\" title=\"table 1\">",
"      Causes of vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/14/9453\" title=\"table 2\">",
"      Causes vertigo Clin Features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/42/12968?source=related_link\">",
"      Cogan&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=related_link\">",
"      Motion sickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_17002="Voriconazole: Drug information";
var content_f16_38_17002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Voriconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/39/33397?source=see_link\">",
"    see \"Voriconazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"    see \"Voriconazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      VFEND&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VFEND&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral;",
"     </li>",
"     <li>",
"      Antifungal Agent, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aspergillosis, invasive, including disseminated and extrapulmonary infection:",
"     </b>",
"     Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression (Walsh, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Initial: Loading dose: 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     IDSA recommendations (Walsh, 2008): May consider oral therapy in place of I.V. with dosing of 4 mg/kg (rounded up to convenient tablet dosage form) every 12 hours; however, I.V. administration is preferred in serious infections since comparative efficacy with the oral formulation has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Scedosporiosis, fusariosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Initial: Loading dose: 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Candidemia and other deep tissue",
"     </b>",
"     <b>",
"      <i>",
"       Candida",
"      </i>",
"     </b>",
"     <b>",
"      infections:",
"     </b>",
"     Treatment should continue for a minimum of 14 days following resolution of symptoms or following last positive culture, whichever is longer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Initial: Loading dose 6 mg/kg every 12 hours for 2 doses; followed by maintenance dose of 3-4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s recommendations: Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     IDSA recommendations (Pappas, 2009): Initial: Loading dose: 400 mg every 12 hours for 2 doses; followed by 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endophthalmitis, fungal (unlabeled use; Pappas, 2009):",
"     </b>",
"     I.V.: 6 mg/kg every 12 hours for 2 doses, then 3-4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal candidiasis:",
"     </b>",
"     Oral: Treatment should continue for a minimum of 14 days, and for at least 7 days following resolution of symptoms:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Meningitis (secondary to contaminated [eg,",
"     </b>",
"     <b>",
"      <i>",
"       Exserohilum rostratum",
"      </i>",
"     </b>",
"     <b>",
"      ] steroid products) (unlabeled use) (CDC [parameningeal], 2012; Kauffman, 2012): Note:",
"     </b>",
"     Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Therapy duration is &ge;3 months; trough serum concentrations must be maintained between 2-5 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 6 mg/kg every 12 hours. If patient does not improve or has severe disease, consider adding amphotericin B (liposomal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral (only in mild disease in adherent patients whose trough concentrations/response to therapy can be closely monitored): 6 mg/kg every 12 hours (CDC [parameningeal], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteoarticular infection involving the spine, discitis, epidural abscess or vertebral osteomyelitis (secondary to contaminated [eg,",
"     </b>",
"     <b>",
"      <i>",
"       Exserohilum rostratum",
"      </i>",
"     </b>",
"     <b>",
"      ] steroid products) (unlabeled use) (CDC [osteoarticular], 2012; Kauffmann, 2012):",
"     </b>",
"     I.V.: 6 mg/kg every 12 hours for &ge;3 months.",
"     <b>",
"      Note:",
"     </b>",
"     Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Trough serum concentrations must be maintained between 2-5 mcg/mL. If patient has severe disease, consider adding amphotericin B (liposomal). Patients may be switched to oral therapy if condition has improved or stabilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Osteoarticular infection not involving the spine (secondary to contaminated [eg,",
"     </b>",
"     <b>",
"      <i>",
"       Exserohilum rostratum",
"      </i>",
"     </b>",
"     <b>",
"      ] steroid products) (unlabeled use) (CDC [osteoarticular], 2012; Kauffman, 2012):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Therapy duration is &ge;3 months. Trough serum concentrations must be maintained between 2-5 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. If patient has severe disease, consider adding amphotericin B (liposomal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral (only in mild disease in adherent patients whose trough concentrations/response to therapy can be closely monitored):  6 mg/kg every 12 hours  for 2 doses, then 4 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients unable to tolerate treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Dose may be reduced to 3-4 mg/kg every 12 hours, depending upon condition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Dose may be reduced in 50 mg decrements to a minimum dosage of 200 mg every 12 hours in patients weighing &ge;40 kg (100 mg every 12 hours in patients &lt;40 kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant CYP450 enzyme inducers or substrates:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efavirenz: Oral: Increase maintenance dose of voriconazole to 400 mg every 12 hours and reduce efavirenz dose to 300 mg once daily; upon discontinuation of voriconazole, return to the initial dose of efavirenz",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Increase voriconazole maintenance dosage to 5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Increase voriconazole dose to 400 mg every 12 hours in patients &ge;40 kg (200 mg every 12 hours in patients &lt;40 kg)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"      see \"Voriconazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Aspergillosis, invasive including disseminated and extrapulmonary infection in HIV-exposed/-positive patients: (unlabeled; CDC, 2009):",
"     </b>",
"     Children &gt;2 to &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Loading dose: 8 mg/kg/dose (maximum: 400 mg/dose) every 12 hours for 2 doses on day 1, followed by maintenance dose of 7 mg/kg/dose (maximum: 200 mg/dose) every 12 hours for &ge;12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Loading dose: 6-8 mg/kg/dose (maximum: 400 mg/dose) every 12 hours for 2 doses on day 1, followed by maintenance dose of 7 mg/kg/dose (maximum: 200 mg/dose) every 12 hours for &ge;12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F234789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute, accumulation of the intravenous vehicle (cyclodextrin) occurs. After initial I.V. loading dose, oral voriconazole should be administered to these patients, unless an assessment of the benefit:risk to the patient justifies the use of I.V. voriconazole. Monitor serum creatinine and change to oral voriconazole therapy when possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. dosing",
"     <b>",
"      NOT",
"     </b>",
"     recommended since cyclodextrin vehicle is cleared at half the rate of voriconazole and may accumulate.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic dysfunction (Child-Pugh class A or B): Following standard loading dose, reduce maintenance dosage by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Should only be used if benefit outweighs risk; monitor closely for toxicity",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 200 mg [contains cyclodextrin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 40 mg/mL (70 mL) [contains sodium benzoate, sucrose; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VFEND&reg;: 50 mg, 200 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer 1 hour before or 1 hour after a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 1-2 hours (rate not to exceed 3 mg/kg/hour). Do not infuse concomitantly into same line or cannula with other drug infusions, including TPN.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     WLR, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 20 mEq,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     WNS. Per manufacturer: Do not infuse",
"     <b>",
"      concomitantly",
"     </b>",
"     into same line or cannula with other drug infusions, including TPN or blood products. May be infused simultaneously with TPN through a separate I.V. line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, caspofungin, doripenem, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Tigecycline.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of invasive aspergillosis; treatment of esophageal candidiasis; treatment of candidemia (in non-neutropenic patients); treatment of disseminated",
"     <i>",
"      Candida",
"     </i>",
"     infections of the skin and viscera;  treatment of serious fungal infections caused by",
"     <i>",
"      Scedosporium apiospermum",
"     </i>",
"     and",
"     <i>",
"      Fusarium",
"     </i>",
"     spp (including",
"     <i>",
"      Fusarium solani",
"     </i>",
"     ) in patients intolerant of, or refractory to, other therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6156604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fungal infection prophylaxis in intermediate or high risk neutropenic cancer patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), neutropenic allogeneic hematopoietic stem cell recipients, and patients with significant graft-versus-host disease; empiric antifungal therapy (second-line) for persistent neutropenic fever; empiric treatment of fungal meningitis or osteoarticular infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14694838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voriconazole may be confused with fluconazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hallucinations (4% to 12%; auditory and/or visual and likely serum concentration-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual changes (dose related; photophobia, color changes, increased or decreased visual acuity, or blurred vision occur in ~21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (1% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (&le;6%), chills (&le;4%), headache (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 5%), vomiting (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (4% to 5%), AST increased (2% to 4%), ALT increased (2% to 3%), cholestatic jaundice (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Photophobia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Acute tubular necrosis, adrenal cortical insufficiency, allergic reaction, alopecia, anaphylactoid reaction, ataxia, atrial arrhythmia, atrial fibrillation, AV block, bigeminy, bone marrow depression, bone necrosis, bradycardia, brain edema, bundle branch block, cardiac arrest, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, chest pain, CHF, cholecystitis, cholelithiasis, chromatopsia, color blindness, coma, cyanosis, delirium, dementia, depersonalization, depression, diabetes insipidus, diarrhea, DIC, discoid lupus erythematosus, duodenal ulcer perforation, DVT, dyspnea, edema, encephalopathy, endocarditis, erythema multiforme, exfoliative dermatitis, extrapyramidal symptoms, fixed drug eruption, gastrointestinal hemorrhage, glucose tolerance decreased, Guillain-Barr&eacute; syndrome, hepatic failure, hepatitis, hydronephrosis, hypercholesterolemia, hypoxia, intestinal perforation, intracranial hypertension, lung edema, lymphadenopathy, lymphangitis, melanoma, MI, multiorgan failure, myasthenia, myopathy, nephritis, nephrosis, neuropathy, night blindness, nodal arrhythmia, oculogyric crisis, optic atrophy, optic neuritis, orthostatic hypotension, osteomalacia, osteoporosis, palpitation, pancreatitis, papilledema, paresthesia, peripheral edema, peritonitis, petechia, photosensitivity, pleural effusion, pseudomembraneous colitis, pseudoporphyria, psychosis, pulmonary embolus, purpura, QT interval prolongation, renal failure (acute), respiratory distress syndrome, retinal hemorrhage, seizure, sepsis, spleen enlarged, squamous cell carcinoma, Stevens-Johnson syndrome, suicidal ideation, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombophlebitis, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, uremia, urinary retention, uveitis, vasodilation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to voriconazole or any component of the formulation (cross-reaction with other azole antifungal agents may occur but has not been established, use caution); coadministration of CYP3A4 substrates which may lead to QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (cisapride, pimozide, or quinidine); coadministration with barbiturates (long acting), carbamazepine, efavirenz (with standard [eg, not adjusted] voriconazole and efavirenz doses), ergot derivatives, rifampin, rifabutin, ritonavir (&ge;800 mg/day), sirolimus, St John&rsquo;s wort",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias/QT prolongation: QT interval prolongation has been associated with voriconazole use; rare cases of arrhythmia (including torsade de pointes), cardiac arrest, and sudden death have been reported, usually in seriously ill patients with comorbidities and/or risk factors (eg, prior cardiotoxic chemotherapy, cardiomyopathy, electrolyte imbalance, or concomitant QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs). Use with caution in these patient populations; correct electrolyte abnormalities (eg, hypokalemia, hypomagnesemia, hypocalcemia) prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Rare cases of malignancy (melanoma, squamous cell carcinoma) have been reported in patients (mostly immunocompromised) with prior onset of severe photosensitivity reactions and exposure to long-term voriconazole therapy. Other serious exfoliative cutaneous reactions, including Stevens-Johnson syndrome, have also been reported. Patients should avoid strong, direct exposure to sunlight; may cause photosensitivity, especially with long-term use. Discontinue use in patients who develop an exfoliative cutaneous reaction or a skin lesion consistent with squamous cell carcinoma or melanoma. Periodic total body skin examinations should be performed, particularly with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: Visual and/or auditory hallucinations have been observed. Possibly dependent on serum concentrations and may be more common with the I.V. formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Visual changes, including blurred vision, changes in visual acuity, color perception, and photophobia, are commonly associated with treatment; postmarketing cases of optic neuritis and papilledema (lasting &gt;1 month) have also been reported. Patients should be warned to avoid tasks which depend on vision, including operating machinery or driving. Changes are reversible on discontinuation following brief exposure/treatment regimens (&le;28 days); reversibility following long-term administration has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Serious (and rarely fatal) hepatic toxicity (eg, hepatitis, cholestasis, fulminant failure) has been observed with azole therapy. Use with caution in patients with pre-existing hepatic impairment; monitor liver function closely and dosage adjustment or discontinuation may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Monitor pancreatic function in patients (children and adults) at risk for acute pancreatitis (eg, recent chemotherapy or hematopoietic stem cell transplantation). There have been postmarketing reports of pancreatitis in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid the use of I.V. voriconazole in patients with renal impairment. See &ldquo;Dosage forms specific issues: Injectable&rdquo; below. Acute renal failure has been observed in severely ill patients; use with caution in patients receiving concomitant nephrotoxic medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use caution in patients taking strong cytochrome P450 inducers, CYP2C9 inhibitors, and major 3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injectable: Avoid/limit use of intravenous formulation in patients with renal impairment; intravenous formulation contains excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in renal insufficiency. Anaphylactoid-type infusion-related reactions may occur with intravenous dosing. Consider discontinuation of infusion if reaction is severe. Do not infuse concomitantly with blood products or short-term concentrated electrolyte solutions, even if the two infusions are running in separate intravenous lines (or cannulas).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Tablets contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sucrose: Suspension contains sucrose; use caution with fructose intolerance, sucrase-isomaltase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Voriconazole may enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astemizole: Voriconazole may increase the serum concentration of Astemizole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir. Management: Voriconazole should not be used in a patient who is being treated with ritonavir-boosted atazanavir unless the benefits of the combination outweigh the potential risks.  Extra monitoring for both loss of effectivness and toxicity is warranted.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Voriconazole may increase the serum concentration of AtorvaSTATin.  Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Voriconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Voriconazole.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Methohexital; PENTobarbital; Secobarbital; Thiopental.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Cobicistat. Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Voriconazole may decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Voriconazole may increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): Voriconazole may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Topical): Voriconazole may increase the serum concentration of Diclofenac (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Voriconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Voriconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Voriconazole may increase the serum concentration of Elvitegravir.  Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Voriconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Voriconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Voriconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Voriconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Voriconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen: Voriconazole may increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meloxicam: Voriconazole may increase the serum concentration of Meloxicam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Voriconazole may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with voriconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Voriconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Voriconazole may increase the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OxyCODONE: Voriconazole may increase the serum concentration of OxyCODONE.  Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): Voriconazole may increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole.  Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Delavirdine; Etravirine; Rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Voriconazole may increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Voriconazole. Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Voriconazole may increase the serum concentration of Sildenafil.  Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Voriconazole may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Voriconazole may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Voriconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Voriconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Voriconazole. Telaprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and voriconazole should be avoided due to the uncertain impact on drug concentrations and effects unless the benefit/risk ratio justifies its use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Voriconazole may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Voriconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as voriconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: Voriconazole may enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Voriconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease voriconazole absorption. Grapefruit juice may decrease voriconazole levels. Management: Oral voriconazole should be taken 1 hour before or 1 hour after a meal. Avoid grapefruit juice. Maintain adequate hydration unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease voriconazole levels. Management: Concurrent use of St John's wort with voriconazole is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Voriconazole can cause fetal harm when administered to a pregnant woman. Voriconazole was teratogenic and embryotoxic in animal studies, and lowered plasma estradiol in animal models. Women of childbearing potential should use effective contraception during treatment. Should be used in pregnant woman only if benefit to mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F234766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk has not been investigated; avoid breast-feeding until additional data are available.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F234767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Should be taken 1 hour before or 1 hour after a meal. Voriconazole tablets contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Suspension contains sucrose; use caution with fructose intolerance, sucrose-isomaltase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Vfend IV Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $162.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Voriconazole Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $152.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Vfend Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (75 mL): $1076.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vfend Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $470.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $1881.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Voriconazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $351.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $1407.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic function at initiation and during course of treatment; renal function; serum electrolytes (particularly calcium, magnesium and potassium) prior to therapy initiation; visual function (visual acuity, visual field and color perception) if treatment course continues &gt;28 days; in meningitis or osteoarticular infections trough serum concentrations must be maintained between 2-5 mcg/mL; monitor trough serum concentrations on day 5 of therapy and weekly thereafter for 4-6 weeks or when dosing adjustments are made; for other infections, may consider obtaining voriconazole trough level in patients failing therapy or exhibiting signs of toxicity; pancreatic function (in patients at risk for acute pancreatitis); total body skin examination yearly (more frequently if lesions noted)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      VFEND (AR, AT, AU, BE, BG, BR, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, ZA);",
"     </li>",
"     <li>",
"      Vorcum (VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with fungal cytochrome P450 activity (selectively inhibits 14-alpha-lanosterol demethylation), decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting fungal cell membrane formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed after oral administration; administration of crushed tablets is considered bioequivalent to whole tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 58%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2C19 (major pathway) and CYP2C9 and CYP3A4 (less significant); saturable (may demonstrate nonlinearity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Variable, dose-dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 1-2 hours; 0.5 hours (crushed tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites; &lt;2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Breit SM, Hariprasad SM, Mieler WF, et al, &ldquo;Management of Endogenous Fungal Endophthalmitis With Voriconazole and Caspofungin,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2005, 139(1):135-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/15652837/pubmed\" id=\"15652837\" target=\"_blank\">",
"        15652837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Interim Treatment Guidance for Central Nervous System (CNS) and Parameningeal Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012.  Available at",
"      <a href=\"file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html\" target=\"_blank\">",
"       file://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Interim Treatment Guidance for Osteoarticular Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012. Available at",
"      <a href=\"file://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html\" target=\"_blank\">",
"       file://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowen EW, Nguyen JC, Miller DD, et al, &ldquo;Chronic Phototoxicity and Aggressive Squamous Cell Carcinoma of the Skin in Children and Adults During Treatment With Voriconazole,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2010, 62(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/19896749/pubmed\" id=\"19896749\" target=\"_blank\">",
"        19896749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dodds-Ashley ES, Zaas AK, Fang AF, et al, &ldquo;Comparative Pharmacokinetics of Voriconazole Administered Orally as Either Crushed or Whole Tablets,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2007, 51(3):877-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/17145785/pubmed\" id=\"17145785\" target=\"_blank\">",
"        17145785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand ML, Kim IK, D&rsquo;Amico DJ, et al, &ldquo;Successful Treatment of Fusarium Endophthalmitis with Voriconazole and Aspergillus Endophthalmitis With Voriconazole Plus Caspofungin,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2005, 140(3):552-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/16139017/pubmed\" id=\"16139017\" target=\"_blank\">",
"        16139017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hariprasad SM, Mieler WF, Holz ER, et al, &ldquo;Determination of Vitreous, Aqueous, and Plasma Concentration of Orally Administered Voriconazole in Humans,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2004, 122(1):42-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/14718293/pubmed\" id=\"14718293\" target=\"_blank\">",
"        14718293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbrecht R, Denning DW, Patterson TF, et al, \"Voriconazole Versus Amphotericin B for Primary Therapy of Invasive Aspergillosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(6):408-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/12167683/pubmed\" id=\"12167683\" target=\"_blank\">",
"        12167683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Pappas PG, Patterson TF, &ldquo;Fungal Infections Associated With Contaminated Methylprednisolone Injections: Preliminary Report,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012 [epub ahead pf print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/23083312/pubmed\" id=\"23083312\" target=\"_blank\">",
"        23083312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kullberg BJ, Sobel JD, Ruhnke M, et al, &ldquo;Voriconazole Versus a Regimen of Amphotericin B Followed by Fluconazole for Candidaemia in Non-Neutropenic Patients: A Randomised Non-Inferiority Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9495):1435-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/16243088/pubmed\" id=\"16243088\" target=\"_blank\">",
"        16243088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarthy KL, Playford EG, Looke DF, et al, &ldquo;Severe Photosensitivity Causing Multifocal Squamous Cell Carcinomas Secondary to Prolonged Voriconazole Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(5):e55-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/17278050/pubmed\" id=\"17278050\" target=\"_blank\">",
"        17278050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DD, Cowen EW, Nguyen JC, et al, &ldquo;Melanoma Associated With Long-Term Voriconazole Therapy: A New Manifestation of Chronic Photosensitivity,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2010, 146(3): E1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/20083676/pubmed\" id=\"20083676\" target=\"_blank\">",
"        20083676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Cancer-Related Infections,&rdquo; Version 1.2008. Available at file://www.nccn.org/professionals/physician_gls/PDF/infections.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, &ldquo;Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Pappas P, Winston DJ et al, \"Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(4):225-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/38/17002/abstract-text/11807146/pubmed\" id=\"11807146\" target=\"_blank\">",
"        11807146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zonios DI, Gea-Banacloche J, Childs R et al, \"Hallucinations During Voriconazole Use,\" Abstract  M-1172; 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September, 2007.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10118 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-218.28.111.102-3C51B1EE61-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17002=[""].join("\n");
var outline_f16_38_17002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855140\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234787\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234806\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234788\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234789\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234790\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234759\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234761\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234828\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234760\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6156604\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14694838\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234820\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234764\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234749\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234753\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234780\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234755\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234765\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234794\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234766\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234767\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324109\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234757\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234768\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234763\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/39/33397?source=related_link\">",
"      Voriconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=related_link\">",
"      Voriconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_38_17003="AD DDx";
var content_f16_38_17003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of severe atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary skin conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin barrier dysfunction: Netherton syndrome, ichthyoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory skin conditions: psoriasis, contact dermatitis (irritant or allergic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary immunodeficiencies and treatment complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe combined immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wiskott-Aldrich syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyper IgE syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary metabolic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mineral or vitamin deficiencies: zinc (acrodermatitis enteropathica), pyridoxine and niacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin infections: HIV-associated, impetigo, seborrheic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancies: cutaneous T cell lymphoma, Letterer-Siwe disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17003=[""].join("\n");
var outline_f16_38_17003=null;
var title_f16_38_17004="DDx Foot ankle pain athlete B";
var content_f16_38_17004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of foot and ankle pain in the young athlete (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Medial",
"ankle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor hallucis longus injuries",
"       </td>",
"       <td>",
"        Extreme plantar flexion",
"       </td>",
"       <td>",
"        FHL tendon (behind the medial malleolus); may radiate",
"to the medial arch",
"       </td>",
"       <td>",
"        AP, lateral, and mortise views of the ankle; lateral",
"ankle in full equinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Flexor digitorum longus injuries",
"       </td>",
"       <td>",
"        Excessive pronation",
"       </td>",
"       <td rowspan=\"2\">",
"        Medial plantar surface of FDL tendon",
"       </td>",
"       <td rowspan=\"2\">",
"        Not necessary for diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased effort of plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Os tibiale externum",
"       </td>",
"       <td>",
"        Direct pressure",
"       </td>",
"       <td rowspan=\"3\">",
"        Navicular tuberosity",
"       </td>",
"       <td rowspan=\"3\">",
"        AP, lateral, and oblique views of the foot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eversion ankle injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tibialis posterior tendon dysfunction",
"       </td>",
"       <td>",
"        Increased stress along TPT (eg, dancers, skaters,",
"running sports)",
"       </td>",
"       <td>",
"        Along TPT, usually distal to the medial malleolus",
"       </td>",
"       <td>",
"        AP, lateral foot; MRI depending upon stage of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S1 radiculopathy",
"       </td>",
"       <td>",
"        Disc herniation",
"       </td>",
"       <td>",
"        Posterior leg and foot",
"       </td>",
"       <td>",
"        Consider MRI spine (after EMG/NCS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tarsal tunnel syndrome",
"       </td>",
"       <td>",
"        S/P fracture or dislocation of talus, calcaneus, or",
"medial malleolus",
"       </td>",
"       <td>",
"        Plantar foot; distal foot toes; heel",
"       </td>",
"       <td>",
"        Consider MRI ankle (after EMG/NCS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FHL: flexor hallucis longus; AP: anteroposterior; FDL: flexor digitorum longus; TPT: tibialis posterior tendon; MRI: magnetic resonance imaging; EMG: electomyography; NCS: nerve conduction studies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17004=[""].join("\n");
var outline_f16_38_17004=null;
var title_f16_38_17005="TNM staging renal pelvis";
var content_f16_38_17005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for tumors of the renal pelvis and ureter",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ta",
"       </td>",
"       <td colspan=\"3\">",
"        Papillary noninvasive carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        Carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades subepithelial connective tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades the muscularis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         Renal pelvis only:",
"        </strong>",
"        Tumor invades beyond muscularis into peripelvic fat or the renal parenchyma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Ureter only:",
"        </strong>",
"        Tumor invades beyond muscularis into periureteric fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades adjacent organs, or through the kidney into the perinephric fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a single lymph node, 2 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a lymph node, more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MI",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0a",
"       </td>",
"       <td>",
"        Ta",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0is",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Stage IV",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Laterality does not affect the N classification.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17005=[""].join("\n");
var outline_f16_38_17005=null;
var title_f16_38_17006="Cyclic changes cx secretions";
var content_f16_38_17006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of cervical secretion variations during a menstrual cycle",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"10\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"9\">",
"        Fertile",
"       </td>",
"       <td class=\"subtitle1_single\" colspan=\"12\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"right\" colspan=\"2\">",
"        <strong>",
"         Cycle day",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;1",
"       </td>",
"       <td>",
"        &nbsp;2",
"       </td>",
"       <td>",
"        &nbsp;3",
"       </td>",
"       <td>",
"        &nbsp;4",
"       </td>",
"       <td>",
"        &nbsp;5",
"       </td>",
"       <td>",
"        &nbsp;6",
"       </td>",
"       <td>",
"        &nbsp;7",
"       </td>",
"       <td>",
"        &nbsp;8",
"       </td>",
"       <td>",
"        &nbsp;9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"right\" colspan=\"2\">",
"        <strong>",
"         Date",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <p>",
"         <strong>",
"          Cervical secretions",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          (Feel, look and touch)",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wet, slippery, transparent or stretchy",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thick, cloudy or sticky",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry, no secretions seen or felt",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Period",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_left\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Unprotected intercourse should be avoided during menses, on preovulatory days following days with intercourse, on all days with wet, slippery, transparent or stretchy secretions, and for four days past the last day with wet secretions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: The Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17006=[""].join("\n");
var outline_f16_38_17006=null;
var title_f16_38_17007="Number of heart transplants reported by year";
var content_f16_38_17007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Number of heart transplants reported by year",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 465px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stehlik J, Edwards LB, Kucheryavaya MS, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report&mdash;2011. J Heart Lung Transplant 2011; 30:1078. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_38_17007=[""].join("\n");
var outline_f16_38_17007=null;
